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 Traditional approaches in the pharmaceutical industry center around the development of 
small molecule therapeutics that bind to and inhibit overactive protein function. This has been 
transformational in the treatment of diseases resulting from an excess of protein function, however, 
thousands of diseases are alternatively caused by a deficiency of protein function and thus remain 
incurable. A major subset of these are characterized by mutations in critical ion channels and 
transporters, such as microcytic anemias, cystic fibrosis, and cardiovascular diseases. Deficiencies 
of these ion transporting proteins diminish ion flux in distinct sites and directions. Noting the many 
features that make small molecules advantageous as drugs, we asked can small molecules that 
imperfectly replicate the function of these missing proteins be sufficient to restore physiology in 
protein-deficient organisms.  
 Since the networks of active and passive ion transporting proteins remain active, we 
hypothesized an imperfect small molecule ion transporter could restore site- and direction-
selective transport by leveraging ion gradients that selectively buildup in ion-transport protein 
deficiencies, thereby restoring physiology to the protein deficient organism. Iron is a critical 
cofactor in all forms of life, yet its excess is paradoxically toxic. Organisms have thus developed 
sophisticated homeostatic networks of iron-transport proteins and their regulators to maintain iron 
at levels sufficient for normal iron-dependent physiological processes without causing 
ferritoxicity. Acquired or congenital deficiencies of proteins involved in iron transport, 
homeostasis, or metabolism often impede the movement of iron into, within, and/or out of cells 
and are associated with more than 25 Mendelian diseases. We therefore asked whether a small 
molecule iron transporter could leverage transmembrane gradients of the labile iron pool that 
selectively build up in such situations to restore the movement of iron into, within, and/or out of 
cells and thereby enable its use in endogenous iron-dependent physiological processes. 
 We first used iron-deficient yeast as a discovery platform to find a small molecule 
candidate. In a modified functional complementation assay, the small molecule natural product, 
hinokitiol, restored growth to yeast missing the iron transporting complex Fet3Ftr1. Hinokitiol 
promoted iron uptake, and concomitantly restored cell growth back to wild-type levels. In contrast 
to water soluble iron chelators, hinokitiol:iron complexes are lipid soluble, and readily diffuse 
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through lipid membranes. Extensive biophysical studies suggest this growth restoration can be 
attributed to the capacity for hinokitiol to promote the transmembrane transport of iron. 
 Encouraged by these results, we next tested the capacity for hinokitiol to promote gut iron 
absorption and/or hemoglobinization in cells and animals missing three different iron-transport 
proteins by promoting iron mobilization and utilization. Hinokitiol restored the uptake and 
transepithelial transport of iron into and across Caco-2 gut epithelia missing the apical iron 
importer DMT1. It also promoted the efflux of iron out of endosomes into the cytosol in DMT1-
deficient erythroblasts, thereby restoring proper differentiation and hemoglobinization. Hinokitiol 
restored hemoglobinization in mitoferrin-deficient erythroblasts by mobilizing iron into the 
mitochondrial matrix from the intermembrane space. Treatment with this natural product also 
enabled the movement of iron out of J774 macrophages deficient in ferroportin. The same 
compound promotes gut iron absorption in DMT1-deficient rats and ferroportin-deficient mice, as 
well as hemoglobinization in DMT1- and mitoferrin-deficient zebrafish. 
 These findings illuminate a general mechanistic framework for small-molecule mediated 
site- and direction-selective restoration of iron transport. Quantification of labile iron levels using 
iron-sensitive fluorophores demonstrated a site-selective build-up of iron gradients are selectively 
formed in iron-transport protein deficiencies upstream of the membrane that normally hosts the 
missing protein. This enables a metallophore to leverage these gradients to promote the site- and 
direction-selective movement of iron into, within, and/or out of cells. Further, hinokitiol is 
functionally integrated into the endogenous homeostatic network of protein transporters, storage 
proteins, and their regulators to allow for the absorption of iron while preventing iron overload. 
Collectively, these results suggest that small molecules that partially mimic the function of missing 
protein transporters of iron, and possibly other ions, may have potential in treating human diseases. 
This approach may be effective in treating the millions of patients possessing acquired or genetic 
deficiencies of ferroportin, such as is the case with anemia of inflammation associated with 
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THE PROSPECT OF MOLECULAR PROSTHETICS 
 The use of small molecules that replicate missing protein function represents a 
transformational approach to treat pathogenic diseases that result from a deficiency of protein 
function. An increasing repertoire of natural products and small molecules continue to be 
discovered or developed to mimic protein function, such as ionophores, molecular motors, and 
biomimetic catalysts. Until recently, however, it was relatively unknown whether small molecule 
surrogates for missing proteins could be sufficient to prevent disease manifestations and restore 
normal physiological processes, akin to a prosthesis on the molecular scale. This chapter evaluates 
the breadth of diseases that result from genetic mutations of critical proteins or regulators, and 
further explores the potential for small molecules to mimic the function of these missing proteins. 
Finally, this chapter discusses the use of an imperfect small molecule surrogate to restore growth 
to yeast missing a potassium ion-transport protein, and possibly in other diseases. 
 Work presented in this chapter was performed with the aid of colleague Dr. Alex Cioffi. 
Portions of this chapter have been adapted from Cioffi, A.G.; Hou, J.; Grillo, A.S.; Diaz, K.A.; 
Burke M.D., Restored physiology in protein-deficient yeast by a small molecule channel, J. Am. 
Chem. Soc. 2015, 137, 10096-10099.  
 
1.1 DEFICIENCIES OF PROTEIN FUNCTION IN HUMAN DISEASE 
 
 Many diseases that result from an overactivity of protein function are effectively treated 
with a small molecule that disrupts the function of the aberrant protein. This has been 
transformational in the treatment of many diseases ranging from chronic myelogenous leukemia 
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treated with imatinib and the ACE inhibitor lisinopril to reduce high blood pressure (Figure 1.1A, 
B).1,2 In stark contrast, thousands of diseases, such as microcytic anemia, cystic fibrosis, 
hemochromatosis, and Huntington’s disease, result from a congenital or acquired deficiency of 
protein function, and thus cannot be effectively treated with a small molecule inhibitor.  
 The majority of these diseases result from random point mutations, frameshift mutations, 
or deletions of critical genes, which often leads to the inactivity, partial dysfunction, degradation, 
or hypomorphicity of the mutant protein.3-6 Furthermore, increasing evidence suggests a growing 
number of disease phenotypes result from the simultaneous dysfunction of multiple proteins such 
as those of synergistic heterozygosity, digenic diseases, and somatic mutations.4 The World Health 
Organization (WHO) estimates that there are approximately 30,000 human diseases worldwide, 
and recognized that ~5,000 diseases are caused by genetic loss-of-function mutations.7,8 While 
more than 30% of all diseases have effective treatments, only ~5% of Mendelian disorders are 
currently treatable.6-9  
Figure 1.1 Small molecule inhibitors of protein function. (A) In the classic paradigm of pharmacology, small 
molecules bind to and inhibit protein function. An excellent example of this is in the BCR-ABL inhibitor imatinib 
used to treat chronic myelogenous leukemia. (B) Lisinopril is used as an effective ACE inhibitor to decrease high 
blood pressure. These small molecule inhibitors bind to their respective proteins with high affinity, turning them off. 
 3 
 Several classes of functional deficiencies underlie these currently incurable human 
diseases. For example, the metabolic disorder phenylketonuria (PKU) is characterized by a 
mutation in phenylalanine hydroxylase (PAH) causing the aberrant accumulation of phenylalanine 
from the diet.10 A mutation in the gene encoding the structural protein dystrophin causes 
mitochondrial bursting leading to muscular dystrophy.11 Mutations in the β-globin subunit of 
Hemoglobin A leads to ineffective oxygen acquisition and is recognized as Sickle Cell Anemia. 
Polymorphs of the transcriptional regulator HTT cause the neuropathy Huntington’s disease.12,13 
Additionally, a major subset of these functional deficiencies centers on proteins that are normally 
responsible for the movement of targeted ions across lipid membranes in targeted directions. These 
channelopathies are caused by deficiencies of critical ion transport proteins.14-17 The archetypical 
ion channel is the potassium-selective channel KcsA, whose structure was determined in 1998 by 
MacKinnon earning him the Nobel Prize.18,19 The focus herein will center on deficiencies of 
proteins involved in ion transport, storage, or secretion due to its prevalence in human disease. 
 
1.2 MENDELIAN DISEASES OF ION HOMEOSTASIS 
 Congenital or acquired deficiencies of proteins involved in the movement of ions across 
lipid membranes are responsible for hundreds of diseases, making them a primary contributor to 
the rapidly increasing list of Mendelian diseases. Deficiencies of passive ion-transport proteins 
cause many human diseases, including anemias, arrhythmias, and neurological, skeletal muscle, 
cardiac, endocrine, and renal disorders.20-23 The first discovered and perhaps most famous 
channelopathy, cystic fibrosis, can be caused by one of dozens of genetic mutations in the cystic 
fibrosis transmembrane regulator (CFTR), an anion channel found on the apical membrane of lung 
epithelia.21,24,25 Cystic fibrosis is recognized as the most common fatal genetic disease affecting 
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more than 70,000 young people worldwide. Additionally, many neuropathies are caused by genetic 
disruptions in ion movement due to their role in synaptic neurotransmission.17 For example, recent 
research has recognized that loss-of-function mutations in the gene encoding the ATP-sensitive 
potassium channel Kir4.1 are associated with diseases such as epilepsy, ataxia, EAST syndrome, 
and multiple sclerosis.26 Congenital or acquired deficiencies of the iron efflux protein ferroportin-
1 (FPN1) cause anemic disorders such as hereditary hemochromatosis type IV and the anemia of 
chronic inflammation that affects millions of patients with rheumatoid arthritis, IBD, ulcerative 
colitis, and systemic lupus erythematosus (Figure 1.2).27-31 
 More than two billion people worldwide are affected by micronutrient deficiencies, with 
more than one billion being deficient in divalent metals (Figure 1.3A). Metals are ubiquitously 
used in biological systems to perform the vast array of diverse catalytic reactions necessary for 
life. It is estimated that >50% of all catalytic enzymes require a metal cofactor, with each enzyme 
Figure 1.2 Pathophysiology of anemia of chronic inflammation. Acquired FPN1 deficiencies play a critical role in 
the occurrence of anemia in patients suffering from autoimmune disorders such as IBD, ulcerative colitis, and 
rheumatoid arthritis. Induction of inflammation increases levels of IL-6, which stimulates the production of the 
systemic iron regulatory peptide hepcidin in hepatocytes. The circulating hepcidin is then recognized by FPN1 and 
promotes its proteasomal degradation. This decreases the absorption and recycling of iron, causing severe anemia. 
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selecting the metal whose reactivity is precisely tuned for the needs of the reaction. As a result, 
humans often do not meet the daily nutritional requirements for many of these metals. Analysis of 
a recent report released by the WHO revealed that of the top 10 ion nutritional deficiencies, 7 of 
these are metal ions, with nearly 50% of cases being attributed to deficiencies of transition metals 
(Figure 1.3A).32,33 The most prevalent of these, iron deficiency anemia, is one of the leading 
contributors to premature death in young children in third world countries, and has drastic 
irreversible consequences in their development and cognitive functions (Figure 1.3B).32,33  
 Iron, as an ion, and in the forms of iron-sulfur [Fe-S] clusters and heme, is an essential 
cofactor for reduction/oxidation (redox) reactions, whereby it mediates electron transfer.34 Iron 
plays a role in many diverse cellular processes, such as dopamine synthesis,35 oxygen transport,36,37 
mitochondrial respiration,34 xenobiotic metabolism,38 and maintenance of circadian rhythm.39 
Conversely, an excess of labile iron causes significant oxidative damage and toxicity through 
reactive oxygen species (ROS) generation.20,40-42 No known mechanisms of iron excretion exist, 
and thus regulation of iron absorption and recycling is critical to maintain the delicate balance 
between the utilization of iron and preventing its toxicity (Figure 1.4).20,43 Iron absorption, both 
through non-heme and heme dietary sources, occurs in the brush-border of duodenal enterocytes 
Figure 1.3 Prevalence of anemia worldwide. (A) Nutritional deficiencies of ions, especially metals, affect billions 
of people worldwide. Iron deficiency is a leading cause of micronutrient deficiencies in the United States. (B) 
Prevalence of anemia in pre-school aged children worldwide. Scale represents prevalence of anemia in these children 
for each country. Graph taken from a report by the micronutrient malnutrition unit at the World Health Organization. 
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before its release in the blood for hemoglobin production through the transferrin cycle (Figure 
1.4).20,43 Recycling of iron from senescent red blood cells in reticuloendothelial macrophages is 
efficient, resulting in a biological half-life of iron of ~12 years. Dozens of proteins have been 
discovered in recent years which participate in the transport, metabolism, and/or regulation of iron 
acquisition.  
 Mutations in many of these proteins can result in a range of anemias or hemochromatosis 
disorders, with more than 25 congenital diseases associated with deficiencies of proteins involved 
in the transport of iron (Table 1.1).20,30,42-53 Three overarching categories can be used to describe 
these diseases: i) mutations in iron transport proteins, ii) mutations in proteins involved in iron 
transport, and iii) secondary disorders that lead to irregular iron levels. These diseases, notably 
hereditary hemochromatosis, microcytic anemia, Huntington’s disease, ataxia, and 
protoporphyrias affect >2 million people in the US alone. In fact, hereditary hemochromatosis is 
recognized as the most prevalent congenital disorder worldwide, albeit rarely fatal.49,54,55 
Figure 1.4 Body iron stores and the transferrin cycle. No known mechanisms of regulating iron excretion exist, 
and thus iron homeostasis is exquisitely maintained. Absorption of dietary iron occurs in the duodenum of the small 
intestines into the blood. The serum iron is then associated with apotransferrin. Transferrin is recognized for 
endocytosis in differentiating erythroblasts during erythropoiesis, and is incorporated into hemoglobin in RBCs. The 
iron in senescent RBCs is recycled in reticuloendothelial macrophages, and re-utilized. 
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Treatments to increase the absorption of iron, and possibly other ions, have tremendous potential 
in treating human disease and are a major focus of many current research programs. However, due 
Table 1.1. Disorders of iron absorption, homeostasis, and metabolism. Noninclusive list of diseases that are 
associated with defective iron absorption, homeostasis, and metabolism. These diseases can broadly be separated into 
three categories: (i) Diseases of defective iron absorption, (ii) Diseases of iron-related proteins associated with 
aberrant tissue iron levels, and (iii) Secondary disorders associated with aberrant iron levels. From refs 20, 30, 42-53. 
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to the difficulty to treat these diseases using traditional medicine, new approaches are needed. 
 
1.3 POTENTIAL TREATMENTS FOR DISEASES CAUSED BY PROTEIN DEFICIENCIES 
 The use of gene therapy with CRISPR-Cas9 gene editing suggests that genetic alteration 
may prove to be a viable strategy in the future.56-59 For example, researchers in a Chinese study in 
2015 targeted the gene responsible for β-thalassemia in human embryos, however, the embryos 
were abnormal and nonviable due to low HDR efficiency and off-target mutations.60 
Encouragingly, a recent landmark study successfully corrected mutations in the MYBPC3 gene 
responsible for hypertrophic cardiomyopathy without loss of genetic integrity.61 Additionally, 
some diseases have been treated by directly replacing the missing protein, such as the use of insulin 
to treat diabetes, human growth hormone to treat growth failure, and recombinant enzymes to treat 
lysosomal storage diseases.6,62,63 Finally, some small molecules, such as correctors and 
potentiators, have been developed to increase the function of mutant proteins when the mutant 
protein is present but inactive.64,65 For example, ivacaftor is a clinically approved small molecule 
that potentiates the activity of CFTR with a specific mutation (G551D) that causes a gating defect 
and is present in 2-4% of patients with cystic fibrosis.66-68 
 Despite tremendous progress in these areas, few FDA-approved treatments have been 
realized, with many failing in large scale clinical trials due to low specificity or effectiveness in 
genetically diverse patient populations. Small molecules that attempt to “correct” the function of 
mutated proteins are often ineffective, as they require an inducible macromolecule of a specific 
genotype that can be corrected. Difficulties in targeting a specific location or tissue with synthetic 
protein makes directly replacing the missing protein difficult and is often only applicable to 
systemically circulating proteins; more than 90% of FDA-approved drugs are to treat blood or 
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metabolic disorders. For example, replacing a membrane-embedded protein located in 
mitochondrial membranes cannot presently be accomplished. Achieving selective genetic 
modification as well as targeting specific tissues or cell types is immensely challenging with gene 
therapies, with limited success outside of human embryos. In addition, a disease phenotype could 
be attributed to hundreds of different genotypes, each requiring personalized development making 
them time-consuming and costly. Noting these challenges, we alternatively hypothesized small 
molecules that can autonomously replicate protein function could provide a solution to these 
longstanding problems. 
 Small molecules possess many qualities that make them ideal as drug candidates. 
Specifically, relative to biological macromolecules, small molecules are often more evasive of the 
immune system, metabolically stable, cell permeable, orally bioavailable, and generally cost-
effective. These features suggest a small molecule approach to address diseases caused by protein 
deficiencies could be highly influential. In this vein, some small molecules can activate proteins, 
including ligands for endogenous receptors, chaperones, and disruptors of quaternary structures. 
All of these approaches, however, require a macromolecular target. With the goal of overcoming 
this substantial barrier, it is intriguing to consider the possibility that small molecules might also 
possess untapped potential to replicate the functions of deficient proteins, thereby operating as 
prostheses on the molecular scale. 
 
1.4 MECHANISMS OF ROBUSTNESS SUGGEST IMPRECTION IS ENOUGH 
 If effective treatments for these diseases require that a small molecule perfectly replicates 
the function of a missing protein, it is challenging to envision this approach being successful. For 
example, proteins responsible for ion uptake are highly regulated, often inwardly rectified, and 
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exhibit inherent selectivity for certain ions.18 Due to intrinsic mechanisms of robustness,69-72 
however, it is hypothesized that an imperfect mimic may be sufficient to restore normal 
physiology. 
 Robustness refers to an organism’s excess of capacity to perform and/or compensate for 
many of the functions required for physiology. It arises from a variety of molecular mechanism 
including functional redundancy, enzyme degeneracy, feedback control, localization, 
compartmentalization, and exquisite regulation.69,72 As a result, the loss of a protein often does not 
result in an observable phenotype.71 In fact, a large-scale study through the 1000 Genomes Project 
Consortium by the Broad Institute in 2010 concluded that on average, each person has ~250 loss-
of-function variants which lead to a deficiency of protein function.73 It is approximated that 100 
of these mutations have been implicated to cause human diseases, yet these patients exhibit no 
disease phenotype.73 This phenomenon, known as reduced or incomplete penetrance, can be 
attributed to the underlying causes discussed above.  
 In the cases of a pathogenic deficiency of a critical protein, however, the functional 
capacity of an organism drops below the threshold required for normal physiology, resulting in an 
observable abnormality such as petite phenotypes in cells or a disease state in humans (Figure 
1.5A). Importantly, the concept of robustness implies that in such cases, albeit insufficient for 
normal physiology, the level of functional capacity is high (Figure 1.5A). This analysis leads to 
the hypothesis that a small molecule that can only partially mimic the function of a missing protein 
could enable the threshold for physiology to be surmounted, and thus the underlying phenotype 
could be restored. 
 The concept of robustness can be exceptionally contextualized in the selectivity of proteins 
for certain ions over others. Site- and direction-selective transmembrane ion transport is achieved 
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in living systems through the concerted functions of active ion-transport proteins that generate 
localized electrochemical gradients and the passive ion-transport proteins that use them (Figure 
1.5B).18,20 Many of these passive ion-transport proteins are imperfectly selective.18,20 However, the 
relative abundance of different ions contributes to increased selectivity in living systems.18,74 For 
example, protein chloride channels are largely unselective with respect to chloride versus bromide 
and iodide, but the low natural abundance of the latter halogens favors chloride selectivity in vivo.74  
 Differential ion accessibility further enhances the in vivo selectivity observed for many 
imperfect ion-transport proteins.75-77 Many metal binding proteins are inherently more selective 
for copper over other divalent metals.43,78,79 Nigel Robinson, a leader in studying metal ion 
accessibility, recently described that these metal homeostatic pathways maintain the availability 
of these ions in the inverse order of the stabilities of their metal-ligand complexes.80 For example, 
to overcome the inherent selectivity of ligands with copper over iron, networks of high affinity 
metalloproteins limit the availability of copper in cells.77 Specifically, the cytosolic labile copper 
pool is 10 orders of magnitude smaller than that of iron. This is attributed to robust networks of 
Figure 1.5 Robustness of living systems in ion transport. (A) The concept of robustness suggests that in the case 
of a protein deficiency, the functional capacity of an organism to promote physiology remains high. This leads to the 
hypothesis that a small molecule that imperfectly replicates the function of a missing protein may be sufficient to 
restore physiology. (B) In the case of a deficiency of an ion transporter, the protein pumps remain active. This led us 
to hypothesize that a build-up of ions may occur upstream of the membrane that normally hosts the missing protein. 
A small molecule that can transport these ions may be sufficient to restore site- and direction-selective ion movement. 
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transporters, chaperones, storage proteins, efflux proteins, and regulators that bind divalent copper 
with exceptional affinities and selectivities. One such example is the transcriptional activator 
Mac1, which is essential in regulating yeast copper homeostasis, and binds copper with a 
dissociation constant (Kd) of 9.7 x 10
-20 M.77  
 Furthermore, in the case of a deficiency of a critical ion transport protein, it is important to 
note that the dynamic network of active and passive transport proteins remains active. Because the 
corresponding active ion-transport proteins typically remain functional, there may be a buildup of 
ion gradients upstream of the membranes that normally host these missing proteins (Figure 1.5B). 
Noting the capacity for these robust networks to achieve ion-selective transport despite the 
unselective nature of many ion transport proteins, we hypothesized that small molecules that 
imperfectly mimic the function of ion transport could collaborate with endogenous pumps and 
channels by leveraging such gradients to restore transmembrane ion flux in a site- and direction-
selective manner, thereby preventing manifestation of the disease phenotype (Figure 1.5B). 
 
1.5 SMALL MOLECULES THAT CAN PROMOTE PROTEIN-LIKE FUNCTIONS 
 Synthetic anion receptor chemistry efforts over the past decade have focused on the 
discovery and/or design of small molecules that can mimic the function of ion-transport proteins, 
known as ionophores, with great success.81-85 Multiple lipid soluble natural products such as 
valinomycin, lasalocid, monensin, beauvericin, nigericin, and nonactin, have been known to carry 
potassium, sodium, calcium, or other cations across lipid bilayers, however, few natural products 
can achieve selective anion transport (Figure 1.6A).86 One of the most famous of these is 
prodigiosin, the tris-pyrrolic natural product which has been the center of extensive research for 
nearly 30 years due to its therapeutic properties including its antiproliferative, antifungal, 
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antibacterial, antimalarial, and anticarcinogenic properties (Figure 1.6B).82,83,87-89 While the 
primary mechanism of action is currently debated, recent research supports that the capacity for 
prodigiosin and its derivatives to promote chloride/proton symport correlates with their toxicity in 
lung cancer GLC4 cells. Crystal structures, isothermal titration calorimetry, liposomal and cellular 
studies, as well as computational studies support that in its protonated form prodigiosin can 
strongly bind chloride and ferry it across lipid membranes.88,89  
Figure 1.6 Small molecules that promote transmembrane ion transport. (A) Noninclusive list of natural products 
and synthetic small molecules that can transport cations. (B) Anion-selective ionophores have garnered special 
interests due to the putative importance of chloride deficiencies in many human diseases, including CF. (C) Some 
small molecules have been reported to promote the transport of divalent and trivalent metals. (D) The archetype for a 
small molecule that forms ion channels, AmB, is highly conductive to many cations and anions. 
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 Learning from these studies, Gale, Davis, Quesada, and others have developed numerous 
classes of synthetic ionophores that can transport chloride, bicarbonate, nitrate, or other anions.81-
85,87 Early efforts focused on supramolecular assemblies of tren-based thioureas which were 
designed to facilitate several hydrogen bond interactions with chloride, thereby promoting Cl-
/HCO3
- exchange across POPC liposomes.82 Simpler analogues were later developed in the hopes 
to produce transporters with enhanced pharmacological properties in living systems. These 
included cholapods, small fluorinated thioureas, cyanoguanidines, squaramides, isophthalamides, 
ortho-phenylenediamines, and others (Figure 1.6B).82 Follow-up studies in liposomes, cells, and 
computational studies discovered that there is a loose connection between the anion binding 
affinity and transport activity, however, the lipophilicity was found to play a key role.90-92 Multiple 
QSAR studies demonstrated that a lipophilic balance is required to effectively transport chloride 
across lipid bilayers. Derivatives that were too hydrophilic were not lipid permeable, however, 
highly lipophilic derivatives did not acquire the water-soluble anions. Further, inverse correlations 
between the size of ionophore and chloride transport rates were observed.82,92 
 In addition, there are hints throughout the literature that some small molecules may 
transport divalent metals across lipid bilayers (Figure 1.6C).93-97 These small molecules, often 
discovered while studying iron chelators for iron overload, strongly bind to multiple metals to 
putatively form lipophilic complexes. These include quercetin, zincophorin, zinc pyrathione, 
dithiocarbamate, and other small molecules. However, these reports do not definitely demonstrate 
autonomous metal transport, and often require excessively high concentrations of metal. 
 In contrast to the success in developing numerous ion carriers that ferry ions across 
membranes, few synthetic small molecules, such as the Gokel peptide SCMTR,98,99 Yang 
channel,100,101 and GL-172,102,103 have been established that can form high conductance ion 
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channels in cells or differentiated gut epithelia. However, nature has provided the archetype for a 
small molecule that forms ion channels. The macrolide natural product amphotericin B (AmB), 
has been known for nearly 50 years to form ion channels across lipid membranes (Figure 1.7A, 
B).104-106 AmB is permeable to chloride, potassium, sodium, bicarbonate, and other ions with little 
inherent selectivity.107 Molecular modeling studies predict that AmB self-assembles with 
ergosterol to span the lipid bilayer in a single- or double-barrel stave model (Figure 1.7A, B).108,109 
The hydrophobic polyene region is believed to interact with the fatty acid backbone, while the 
polyol region creates an aqueous pore to allow ion transport.   
 Despite the promising results demonstrating a multitude of small molecules can mimic ion 
transport function, it remained unknown whether an imperfect small molecule surrogate can 
replace a missing protein, acting as a prosthesis on the molecular scale. The biological activity and 
mechanistic understanding of these ionophores are only beginning to be explored.83,110 
Unfortunately, much of these efforts center on the cytotoxicity of ionophores and synthetic ion 
channels by disrupting membrane potentials at high concentrations. However, we asked if 
treatment with any of these putative molecular prosthetics could restore healthy physiology in 
systems missing ion-transport proteins. Thus, our initial efforts focused on answering this 
longstanding question in yeast, a simplified model for eukaryotic physiology and disease.111 
Figure 1.7 Amphotericin self-aggregates to form ion channels across lipid bilayers when complexed with 
ergosterol. (A) AmB forms a complex with membrane-embedded ergosterol or other sterols. (B) This AmB-ergosterol 
complex self-aggregates to form single ion channels to allow for transmembrane iron transport. Computational models 
predict that 8 amphotericin molecules form an aqueous pore in a single (left) or double (right) barrel stave. 
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1.6 RESTORED GROWTH IN POTASSIUM-DEFICIENT YEAST WITH AMPHOTERICIN B 
 As previously mentioned, deficiencies of proteins involved in transmembrane potassium 
transport are pathophysiologically responsible for neurological disorders such as multiple 
sclerosis. The ion channel-forming natural product AmB was identified as a small molecule that 
allowed us to ask whether an imperfect small molecule surrogate for a missing potassium transport 
protein could be sufficient to restore normal physiology. AmB can permeabilize yeast cells to 
potassium and other ions, and previous results from our lab suggested the channel activity of AmB 
might be separated from its cytocidal activity by simply adding this compound at low 
concentrations.112-114 In collaboration with colleague Dr. Alex Cioffi, we thus tested the hypothesis 
that AmB could restore cell growth in potassium transporter-deficient yeast with a modified 
functional complementation experiment (Figure 1.8A).111 Consistent with prior reports, growth 
was observed when wild-type Saccharomyces cerevisiae were streaked onto agar plates containing 
normal concentrations of potassium (10 mM) and no growth was observed for the potassium 
transporter-deficient strain (trk1Δtrk2Δ) under the same conditions (Figure 1.8B). Strikingly, the 
addition of a low concentration of AmB (125 nM) vigorously restored growth of the trk1Δtrk2Δ 
mutant (Figure 1.8B). 
 A series of additional experiments confirmed the observed restoration of cell growth is 
caused by the small molecule-based ion channel activity. A disc diffusion assay and liquid broth 
dilution assays revealed the predicted dependence of this growth rescue on the concentration of 
AmB (Figure 1.8C, D). To directly probe the importance of the ion channel activity of AmB, we 
also tested the single atom-deficient variant C35deOAmB, which does not form ion channels. This 
derivative failed to restore growth in trk1Δtrk2Δ cells at any tested concentration (Figure 1.8D). 
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We also monitored the uptake of radioactive 86Rb+ as a reporter of transmembrane potassium 
movement.115 86Rb+ uptake was observed in wild-type yeast but not in the trk1Δtrk2Δ mutant 
(Figure 1.8E). In contrast, 86Rb+ uptake was restored when trk1Δtrk2Δ cells were treated with 
AmB (Figure 1.8E).  
 Thus, imperfect small molecule mimics of missing protein ion transporters can restore 
physiology in yeast. A common channels and pumps architecture is responsible for the directional 
movement of ions in organisms ranging from yeast to humans, suggesting that this phenomenon 
may also be effective in restoring physiological processes in more complex organisms, or even 
Figure 1.8 Amphotericin restores growth to potassium-deficient yeast. (A) AmB was used to test whether 
treatment with a small molecule that forms ion channels could restore growth to potassium-deficient yeast missing 
the potassium transporter Trk1 and Trk2 (trk1Δtrk2Δ yeast). (B) Wild type yeast grow on agar plates, while the 
trk1Δtrk2Δ yeast do not. Addition of AmB (125 nM) to the identical agar plates restored growth. (C) Disc diffusion 
assay of trk1Δtrk2Δ yeast streaked onto agar plates. A disc impregnated with AmB was then added. A zone of 
functional complementation is observed around the AmB-impregnated disc. (D) Liquid broth dilution assay supports 
AmB restores growth, while the channel inactive derivative C35deOAmB does not. (E) AmB treatment restores the 
influx of 86Rb+ as a surrogate for K+. 
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animals. Further, this approach may have a significant impact in the treatment of currently 
incurable human diseases. 
 
1.7 METHODS 
Yeast culture conditions 
 All growth rescue experiments were performed using the same normal concentration of 
potassium (10 mM) for both wild type S. cerevisiae (ATCC 9763) and trk1∆trk2∆ S. cerevisiae 
(SGY 1528). This yeast peptone adenine dextrose (YPAD) growth media consisted of 10 g/L yeast 
extract, 20 g/L peptone, 20 g/L dextrose, 0.015 g/L adenine hemisulfate salt (final potassium 
concentration = 10 mM), and the media was adjusted to pH 5.0 using citric acid. For culturing on 
solid media, 20 g/L agar was added to this same mixture. After autoclave sterilization, dextrose 
was subsequently added as a sterile 40% w/v solution in water (dextrose solutions were filter-
sterilized using a 0.22 µm filter). As previously described,116 to culture trk1∆trk2∆ prior to 
performing these experiments, additional potassium was added in the form of potassium chloride 
(100 mM KCl) to the same (YPAD) growth media (“permissive conditions”). To ensure the same 
conditions for both strains, wild type yeast were also cultured prior to performing these 
experiments under the same permissive conditions. Overnight liquid cultures were incubated at 30 
°C on a rotary shaker (200 rpm). Wild type stock cultures were maintained on solid YPAD media 
at 4 °C, and trk1∆trk2∆ stock cultures were maintained on solid YPAD media under permissive 





Growth rescue assay on solid media  
 These growth rescue experiments were performed using solid media prepared as described 
above containing normal concentrations of potassium (10 mM). For solid media containing AmB 
(AK Scientific), the same media was allowed to cool for 15 minutes before addition of AmB as a 
solution in DMSO to provide a final concentration of 125 nM AmB. Cultured yeast diluted to an 
OD600 of 0.1 were streaked onto these plates, and plates were examined for growth after 24-48 
hours of incubation.  
 
Disc diffusion assay 
 Wild-type and trk1Δtrk2Δ yeast were streaked onto YPAD-agar plates as described above. 
Discs containing either DMSO vehicle or AmB (10 µL of a 4 mg/mL solution) were added. The 
agar plates were allowed to grow for 48 hours as described above before imaging. A normal media 
concentration of potassium (10 mM) was used for all experiments. 
 
Broth microdilution assay 
 The protocol was adapted from the minimum inhibitory concentration assay described in 
the Clinical and Laboratory Standards Institute document M27-A2117 with the following 
modifications: After culturing as described above, wild type or trk1∆trk2∆ yeast were transferred 
to normal potassium (10 mM) YPAD liquid media adjusted to pH 5.0 using citric acid containing 
DMSO vehicle or the indicated concentration of the indicated small molecule (40X dilution in 




86Rb+ uptake assay 
 The procedure for 86Rb+ uptake was adapted from Mulet and coworkers.118 Yeast were 
cultured overnight as described above. After centrifugation, the supernatant was poured off, and 
the cells were resuspended in sterile water. This wash was repeated two more times. The cells were 
then resuspended in 40 mL of the potassium starvation/uptake buffer (50 mM succinic acid, 2% 
glucose, adjusted to pH 5.5 with Tris). The same buffer was used for all experiments for both 
trk1∆trk2∆ and wild type yeast. After 3-hour incubation in the potassium starvation buffer, cells 
were centrifuged and washed twice with sterile water. Cells were resuspended in 1 mL of the 
potassium starvation/uptake buffer. Cell concentration was determined using an INCYTO 
Neubauer disposable hemocytometer, and wild type S. cerevisiae and trk1Δtrk2Δ cells were 
diluted to the same cell density (3x107 cells/mL). 700 µL of the yeast suspension was added to a 
1.5 mL Eppendorf tube. After a 5 minute preincubation in the potassium starvation/uptake 
medium, trk1∆trk2∆ yeast were then treated with DMSO solutions of AmB or C35deOAmB (final 
concentration 3 µM). 86RbCl (1.1 µCi) was then added to the reaction mixtures. Reaction mixtures 
were vortexed to ensure a homogeneous solution. At the indicated times, the uptake reaction was 
stopped by taking a 100 µL aliquot from the reaction mixture and diluting with 10 mL of ice-cold 
20 mM MgCl2. Cells were then collected via vacuum filtration through a 0.45-µm-pore-size 
nitrocellulose filter (Millipore HAWP). Cells were washed with two 15 mL aliquots of 20 mM ice-
cold MgCl2. Moist filters were transferred to plastic vials for measuring radioactivity. 
Radioactivity was monitored using a Perkin Elmer Wizard2 automatic gamma counter. Results are 
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THE DISCOVERY OF A SMALL MOLECULE THAT BINDS AND TRANSPORTS IRON 
 
 In this chapter, the discovery of a small molecule metallophore, hinokitiol, that restores 
growth to iron-deficient yeast will be discussed. An extensive biophysical characterization of the 
iron binding, transport, electrochemistry, and metal selectivity of hinokitiol is also explored. These 
studies support that a small molecule that autonomously binds and transports iron can restore iron-
dependent physiological processes, and is thus an excellent candidate for further studies in 
mammalian cells and animals.  
 Parts of the work presented in this chapter were performed with aid from colleagues Dr. 
Alex Cioffi (metal transport selectivity), Anna SantaMaria (yeast sustainability and iron 
competition studies), Bruno Nicolau (electrochemistry), or undergraduates Dillon Svoboda, Chris 
Nardone, James Fan, John Hong, or Jake Anderson (biophysical experiments). Portions of this 
chapter have been adapted from Grillo et al., Restored iron transport by a small molecule promotes 
absorption and hemoglobinization in animals, Science 2017, 356, 608-616 and Cioffi, A.G.; Hou, 
J.; Grillo, A.S.; Diaz, K.A.; Burke M.D., Restored physiology in protein-deficient yeast by a small 
molecule channel, J. Am. Chem. Soc. 2015, 137, 10096-10099. 
 
2.1 A SMALL MOLECULE THAT RESTORES GROWTH TO IRON-DEFICIENT YEAST 
 
 As discussed in Chapter 1, iron homeostasis is maintained by dynamic networks of active 
and passive iron-transport proteins and their regulators that permit essential use while minimizing 
toxicity of this redox-active metal. Deficiencies or dysfunction of proteins involved in iron 
transport, homeostasis, or metabolism often impede the movement of iron into, within, and/or out 
of cells and are associated with more than 25 Mendelian diseases (see Chapter 1).1-6 We asked 
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whether a small molecule iron transporter could leverage transmembrane gradients of the labile 
iron pool4 that selectively build up in such situations to restore the movement of iron into, within, 
and/or out of cells and thereby enable its use in endogenous iron-dependent physiological 
processes. 
 Noting the prospect for small molecules that imperfectly mimic the function of missing 
proteins to treat iron-related disorders, we sought to discover a small molecule candidate that can 
autonomously transport iron across lipid bilayers, and thus restore iron-dependent physiological 
processes.7 Previous reports suggest that high doses of hydrophilic iron chelators, such as 
deferoxamine (DFO), deferiprone (DFP), and pyridoxal isonicotinoyl hydrazone (PIH), as well as 
more lipophilic derivatives, such as salicylaldehyde isonicotinoyl hydrazone (SIH), may bind and 
relocate excess iron.8-10 However, the corresponding complexes of many of these chelators show 
limited membrane permeation and may require the action of colocalized proteins to achieve iron 
Figure 2.1 Siderophore uptake in biology. (A) Siderophores are secreted molecules from bacteria or fungi that bind 
environmental iron before being recognized by siderophore uptake proteins and taken into the cell. (B) Three different 
classes of siderophores. 
 28 
mobilization.11, 12 For example, siderophores are small molecules and peptides utilized by bacteria 
and fungi to scavenge environmental iron with exceptional affinities, which are then recognized 
by siderophore uptake proteins and subsequently degraded to load iron inside the cell (Figure 2.1A, 
B).13-16 As these uptake pathways are not ubiquitous in mammals, we alternatively sought to 
identify a lipophilic small molecule that can autonomously perform transmembrane iron transport 
to promote physiology in cells and animals missing iron transport proteins that are normally 
responsible for the movement of iron in different sites and directions.7 
 S. cerevisiae represent an excellent model for studying eukaryotic physiology as they are 
widely studied, grow quickly, are highly homologous to mammalian organisms, their genome is 
fully sequenced and tractable, and genetic deletions often lead to dramatic physiological 
consequences such as a loss of growth phenotype.17, 18 We thus acquired a strain of S. cerevisiae 
missing the active high affinity iron transporting complex Fet3Ftr1 (fet3Δftr1Δ),13, 16 normally 
located on the plasma membrane, to discover a small molecule candidate. In contrast to wild type 
yeast, fet3Δftr1Δ yeast exhibit reduced iron levels, and thus cannot grow on normal low-iron (10 
µM FeCl3) synthetic dextrose (SD) media. We then asked whether treatment with a small molecule 
can restore growth to these mutant yeast (Figure 2.2A).  
 Using a modified functional complementation assay,19 we streaked fet3Δftr1Δ yeast onto 
SD-agar plates, and impregnated a disc with a range of ~30 candidate compounds known or 
predicted to bind iron. The hydrophilic iron chelators deferiprone, PIH, and SIH did not restore 
growth to any measurable degree. In contrast, the tropolone natural product, hinokitiol (Hino, 
2.1),20 isolated from the extracts of red cedar trees, vigorously restored growth to these mutant 
yeast (Figure 2.2B, C). This natural product has previously been characterized as a potent chelator 
of iron and other metals that exerts a range of other biological activities. A zone of functional 
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complementation was observed around the hinokitiol-impregnated disc (Figure 2.2C). No growth 
was observed proximal to the disc, presumably due to dose-dependent toxicity of this small 
molecule, however, at intermediary distances and hinokitiol concentrations, robust yeast cell 
growth was observed, which faded as hinokitiol diffused radially from the disc. Hinokitiol restored 
growth to iron transporter-deficient yeast under both fermentative (SD media) and respiratory (SG 
media) media conditions (Figure 2.2D), indicating the availability of iron for metabolic processes 
that require high levels of this redox active metal. Hinokitiol similarly restored growth to a strain 
of iron-deficient yeast missing the Fet3Ftr1 complex and all known siderophore uptake proteins 
(fet3Δarn1-4Δ, Figure 2.2E),16 supporting that this small molecule functions independently of 
these iron chelate-recognizing proteins. 
Figure 2.2 Discovery of a small molecule that restores yeast growth. (A) Simplified schematic of restored growth 
in fet3Δftr1Δ yeast with a small molecule that transports iron. (B) Chemical structures of hinokitiol and the inactive 
derivative C2deOHino. (C) A zone of functional complementation was observed around hinokitiol-impregnated disc 
on SD-agar plates streaked with fet3Δftr1Δ yeast. (D) A growth deficiency was observed for fet3Δftr1Δ yeast (ΔΔ) 
relative to wild-type (wt). Hinokitiol restores growth under both fermentable and non-fermentable media. (E) 
Hinokitiol restores growth to iron-deficient yeast missing all known siderophore uptake proteins (fet3Δarn1-4Δ, ΔΔ). 
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 Having discovered a small molecule candidate, we asked whether hinokitiol restored 
fet3Δftr1Δ yeast cell growth to wild type levels. In a liquid broth dilution assay, hinokitiol restores 
growth across a wide range of concentrations, with maximal rescue observed at ~10 µM, using the 
optical density at 600 nm (OD600) as a readout for cell growth (Figure 2.3A). Importantly, 
hinokitiol restores fet3Δftr1Δ cell growth back to wild type levels (Figure 2.3B). The doubling 
time of hinokitiol-rescued fet3Δftr1 yeast (189 ± 22.1 mins) was insignificant to that of wild-type 
yeast (153 ± 11.6 mins) (Figure 2.3C). This growth restoration was sustained for >100 days upon 
repeated streaking of hinokitiol-rescued fet3Δftr1Δ yeast onto SD-agar plates containing hinokitiol 
(Figure 2.3D). Removal of hinokitiol at any point during this experiment ablated the growth 
restoration effect, suggesting continued reliance on hinokitiol for cell growth. 
 A single atom-deficient derivative that does not bind or transport iron was synthesized 
which served as a negative control. The C-2 oxygen atom was removed after triflation of hinokitiol 
and hydrogenolysis to provide >100 grams of a mixture of C-2 deoxy hinokitiol (C2deOHino, 2.2, 
also known as nezukone, Figure 2.2B) and C-7 deoxy hinokitiol (C7deOHino) which were purified 
by preparative HPLC. Hinokitiol dose-dependently restored yeast growth with a relatively large 
therapeutic window ranging from 1-15 µM before the minimum inhibitory concentration (MIC) 
of 25 µM, while C2deOHino was unable to restore growth at any tested concentration (Figure 
Figure 2.3 Hinokitiol restores growth to fet3Δftr1Δ yeast. (A) Hinokitiol restores growth over a range of 
concentrations, while C2deOHino does not. (B) Hinokitiol restores growth to wild type levels with (C) similar 
doubling times. (D) Hinokitiol-promoted restoration of fet3Δftr1Δ yeast cell growth can be sustained for >100 days. 
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2.3A). This growth restoration is also dependent on the amount of iron in the media. In the absence 
of added iron (III), hinokitiol cannot restore fet3Δftr1Δ cell growth. As iron is increased to normal 
levels (10 µM), the extent of cell growth increases until it reaches wild-type levels (Figure 2.4A). 
As the environmental iron is further increased, the MIC increases thus broadening the therapeutic 
window (Figure 2.4B). Radioactive 55Fe uptake into yeast was monitored over several hours. Wild 
type yeast readily uptake 55Fe, while the fet3Δftr1Δ cells in the absence or presence of C2deOHino 
do not. Hinokitiol addition restored the influx of 55Fe into fet3Δftr1Δ yeast (Figure 2.4C). 
 
2.2 CHARACTERIZATION OF IRON BINDING WITH HINOKITIOL 
 Several biophysical experiments were performed to better understand the capacity for 
hinokitiol to bind and transport ferrous and ferric iron across lipid membranes. This natural product 
rapidly binds iron to form a hinokitiol:iron complex. Upon addition of ferrous or ferric chloride to 
an aqueous solution of hinokitiol, an immediate change in color was observed as well as significant 
changes in the UV-Vis spectrum, with a new peak being observed at ~420 nm (Figure 2.5A, B). 
No changes in the UV-Vis spectrum were observed upon treatment of C2deOHino with iron 
(Figure 2.5C). While future efforts focus on determining the transport-active complex through SS-
NMR studies with gallium (III), this new peak is characteristic of a 3:1 complex of a α-hydroxy 
Figure 2.4 Restored growth is iron-dependent. (A) In the absence of iron, hinokitiol does not restore growth to 
wild-type levels. As the environmental iron is increased, the extent of hinokitiol-promoted yeast cell growth is 
increased. (B) As iron is further increased, the window of growth restoration is widened over a larger range of 
hinokitiol concentrations. (C) Hinokitiol increased 55Fe influx into fet3Δftr1Δ yeast, while C2deOHino did not. 
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ketone with iron. Further, speciation studies are consistent with a 3:1 Hino:FeIII complex in 
aqueous buffer. Upon titration of iron (III) with hinokitiol (Figure 2.5D), an increase in the 
absorption of hinokitiol at 420 nm was observed until 3:1 Hino:FeIII, upon which no further 
changes were observed (Figure 2.5E). Additionally, a redshift of the λmax from 242 nm to 250 nm 
was observed until 3:1 Hino:Fe stoichiometry (Figure 2.5F). Consistent with this, addition of ferric 
nitrate to hinokitiol in ethanol led to the precipitation of pseudo-octahedral Fe(Hino)3 complexes 
as characterized by CHN analysis and single crystal X-ray crystallography (Figure 2.5G, H). The 
same Fe(Hino)3 complex was predominantly formed when using either 1, 2, 3, or 5 equivalents of 
hinokitiol. 
 We sought to determine the affinity of hinokitiol for iron (II) and iron (III). Due to the low 
solubility of the Fe(Hino)3 complex in aqueous buffer, we were unable to absolutely determine the 
association constants through potentiometric or other traditional methods. We thus approximated 
the association constants for ferrous and ferric iron through binding competition assays using well-
established iron chelators with known binding affinities. To determine the binding affinity of 
Figure 2.5 Hinokitiol binds iron to form a 3:1 Hino:Fe complex. (A) UV-Vis spectrum changes upon treatment of 
hinokitiol with ferric iron and (B) ferrous iron, while (C) C2deOHino does not bind ferric iron. (D) Titration of 
hinokitiol (50 µM) with increasing equivalents of iron (III). (E and F) Analysis of changes in UV-Vis spectrum upon 
hinokitiol titration with iron supports the formation of a 3:1 Hino:Fe complex. (G and H) Two distinct C1-symmetric 
octahedral complexes of tris(hinacolato) iron(III) were observed by x-ray crystallography. 
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hinokitiol with iron (II), we observed the disappearance of the peak at λmax = 562 nm corresponding 
to Fe(ferrozine)3 upon titration of increasing equivalents of hinokitiol (Figure 2.6A, B). Hinokitiol 
strongly binds ferrous iron with an association constant (Ka) of 5.1 x 10
15, which is ~2-5 times 
higher than the binding affinities of maltol, EDTA, and the FDA approved iron chelator 
Table 2.1 Binding affinities and electrochemical characteristics of iron chelators. Binding affinities and redox 
potentials of hinokitiol and other chelators were determined through competition assays and cyclic voltammetry, 
respectively. Hinokitiol binds iron (II) and iron (III) stronger than many other iron chelators, including deferiprone. 
The iron:hinokitiol complex is soluble in non-polar solvents as determined by its octanol-water partition coefficient. 
KA units are M-1 assuming a 1:1 chelator:iron ratio. 
Figure 2.6 Hinokitiol strongly binds ferrous and ferric iron. (A and B) UV-Vis spectra of ferrozine bound to iron 
(II) with increasing doses of the competitive chelator hinokitiol. High [Hino] remove iron from ferrozine. Hinokitiol 
strongly binds ferrous iron relative to deferiprone as determined by the EC50 values obtained from a ferrozine 
competition assay. (C and D) UV-Vis spectra of hinokitiol bound to iron (III) with increasing doses of the competitive 
chelator EDTA. High doses of EDTA largely remove iron from hinokitiol. Hinokitiol strongly binds ferric iron relative 
to deferiprone as determined by the EC50 values obtained from an EDTA competition study. (E) Transferrin (100 µM) 
saturated with iron is not denatured after extraction with ethyl acetate. (F and G) Hinokitiol removes iron from (F) 
transferrin (1 nM) and (G) ferritin (2.5 ng ferritin/mL) in a dose-dependent fashion using 55Fe as a radiotracer. (H) 
Increased absorbance of the peak at 387 nm for hinokitiol increases with increasing pH. A clear isobestic point is 
observed (365 nm), indicating speciation between the protonated and deprotonated forms of hinokitiol. 
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deferiprone (Table 2.1).21-24 Analyzing the disappearance of the Fe(Hino)3 peak at 420 nm upon 
titration with increasing equivalents of EDTA, the association constant for ferric iron was 
determined to be 5.8 x 1025, which is ~50 times higher than deferiprone (Figure 2.6C, D and Table 
2.1). Thus, hinokitiol strongly binds both ferrous and ferric iron, presumably due to the increased 
orbital overlap caused by the 7-membered ring and enhanced electron density at oxygen. 
 Consistent with its high binding affinity, hinokitiol can remove iron from chelators that 
compose the labile iron pool (LIP). Labile iron is the cytosolic and serum chelateable iron that is 
weakly bound to small molecules or proteins such as citrate and phosphates. The LIP, while 
estimated to be only ~1-10 µM, is primarily responsible for the recycling and utilization of iron 
into heme and iron binding proteins.4, 25 Upon addition of hinokitiol to ferric iron-citrate in aqueous 
buffer, transfer of iron from citrate to hinokitiol was observed by UV-Vis analysis (Figure 2.5A). 
In buffered solution, competition experiments indicate that hinokitiol can also remove iron from 
the iron-binding proteins transferrin and ferritin, but only when hinokitiol is used in >1,000-fold 
excess relative to transferrin and >1,000,000-fold excess relative to ferritin (Figure 2.6E-G). 
 As hinokitiol strongly binds both ferric and ferrous iron, we asked whether this binding is 
reversible. Both the iron-binding anionic and the neutral states of hinokitiol are expected to be 
accessible under physiological conditions, as hinokitiol has a pKa of 7.33 (Figure 2.6H). To test 
the reversible nature of the iron binding by hinokitiol, we pre-formed a complex of a non-
Figure 2.7 Hinokitiol reversibly binds iron. (A) To determine the reversibility of hinokitiol-iron binding, a non-
radioactive 56Fe-iron complex was formed. Then radioactive 55Fe was added, and the (B) rate of equilibration was 
determined. 
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radioactive isotope of iron (56Fe) with hinokitiol in aqueous solution, and then spiked the solution 
with one equivalent of radioactive 55FeCl3. We then observed the rate of equilibration between 
56Fe and 55Fe to form a 1:1 mixture of 55Fe-Hino and 56Fe-Hino complexes (Figure 2.7A). 56Fe 
bound to hinokitiol readily exchanged with 55Fe in solution, with >20% exchange observed within 
10 minutes (Figure 2.7B). Thus, the binding of iron by hinokitiol under physiological conditions 
is expected to be highly dynamic, which may allow for the facile release of iron from hinokitiol 
complexes to high affinity iron-binding chaperones or metalloproteins and its subsequent use in 
iron-related physiological processes. 
 
Figure 2.8 Growth restoration to fet3Δftr1Δ yeast correlates with the lipophilicity of an iron complex. (A) In 
contrast to water soluble iron chelators, the iron-hinokitiol complex partitions into non-polar solvents. (B) 
Quantification of iron levels in organic layer with or without hinokitiol. (C) Octanol-water partition coefficients of 
various iron chelators bound to iron. (D) Other lipophilic α-hydroxy ketones restore fet3Δftr1Δ cell growth, while 
hydrophilic ones and transporters of other ions do not. 
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2.3 CHARACTERIZATION OF IRON TRANSPORT WITH HINOKITIOL 
 Understanding the capacity for hinokitiol to bind and release both ferrous and ferric iron, 
we asked whether this small molecule can autonomously promote the transport of iron across lipid 
bilayers, thereby mimicking the function of iron transport proteins. X-ray crystallography of 
tris(hinacolato) iron (III) revealed a pair of C1-symmetric complexes, each composed of a 
lipophilic outer shell encasing a hydrophilic and iron-binding central core (Figure 2.5G and H). 
Consistent with this, hinokitiol:iron complexes predominantly partition into nonpolar solvents 
rather than water, unlike water-soluble iron chelators (Figure 2.8A).9 For example, >95% of 
hinokitiol:iron complexes partition into octanol rather than water, whereas deferiprone:iron 
complexes exhibit >95% partitioning into water. This is consistent with quantitative extraction of 
hinokitiol:iron complexes from the aqueous to the organic layer, as determined by ICP-MS 
analysis (Figure 2.8B). Growth restoration of fet3Δftr1Δ yeast was similarly observed with other 
lipophilic α-hydroxy ketones, but not with hydrophilic α-hydroxy ketones nor small molecules that 
transport other ions (Figure 2.8C, D).  
 Based on these results and extensive literature precedent with chloride ion carriers 
discussed in Chapter 1,26-28 we hypothesized a lipophilic balance is necessary to enable physiology 
restoration. Iron chelators that are too polar may not be membrane permeable, but too lipophilic 
derivatives may have low effective concentrations in the cellular milieu to access water-soluble 
iron complexes. To preliminarily test this, we synthesized a series of tropolone derivatives 
possessing a range of lipophilicites. The α-, β-, and γ-bromo tropolones protected as the 
corresponding methyl ether were synthesized as previously reported.29-32 Using frontier cross-
coupling methodology currently under development in our lab, we performed many sp2-sp3 Suzuki 
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cross couplings with unactivated primary boronic acids and 7-bromotropolone methyl ether 2.3 
using Pd[P(o-tolyl)3]2 catalyst and Ag2O base (Scheme 2.1).  
 Gratifyingly, these alkyl derivatives possessed a range of lipophilicities as determined by 
their Rf on TLC using 2:1 Hex:EtOAc as eluent (Figure 2.9A), and similarities in their 
1H NMR 
and 13C NMR chemical shifts suggest these derivatives exhibit similar electronic characteristics 
(Supporting Figure 2.14). Consistent with the necessity for lipophilic balance, tropolone 
derivatives substituted with α-methyl (2.16), α-ethyl (2.17), and α-propyl (2.18) groups vigorously 
restored fet3Δftr1Δ yeast cell growth which rapidly diminished as the tail length increased (Figure 
2.9B-D). Comparison of the relative lipophilicities with the OD600 of yeast suspensions treated 
with the iron chelators hinokitiol, tropolone, 2.16-2.20, and 2.25 indicated a clear parabolic trend 
(Figure 2.9C). Intriguingly, these derivatives possessed similar toxicity profiles, suggesting the 
toxicity and growth restoration effects may be separated (Figure 2.9B). These results indicate the 
Scheme 2.1 Synthesis of α-tropolone derivatives through the sp3-sp2 coupling of bromotropolone 2.3 with 
alkylboronic acids. These tropolone derivatives with increasing tail lengths populate a range of lipophilicities. 
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lipophilicity of the small molecule may play a major role in the growth restoration effects. As 
hinokitiol is readily available on large scale and displays good toxicity profiles in mammals,33, 34 
we chose it for further studies over synthesized derivatives. 
 We next tested the capacity for hinokitiol to autonomously transport iron across lipid 
bilayers. We loaded model POPC liposomes with iron (II) or iron (III) using an ascorbate or citrate 
buffer, respectively, and removed the extracellular iron by size-exclusion chromatography. The 
extraliposomal buffer contained ascorbate and ferrozine, such that any extraliposomal iron would 
be reduced to iron (II) and bound by the iron (II) chelator ferrozine, forming a purple colored 
solution. We then quantified the rate of iron efflux from these liposomes by observing the 
absorption of Fe(ferrozine)3 by UV-Vis spectroscopy. Hinokitiol rapidly transports both ferrous 
and ferric iron across these model lipid membranes, while C2deOHino and water-soluble chelators 
Figure 2.9 Lipophilic derivatives restore growth to yeast. (A) Increasing the carbon chain length on the α-position 
increases the lipophilicity. (B) OD600 of fet3Δftr1Δ yeast treated with hinokitiol derivatives after 48 hours. (C) A clear 
parabolic trend was observed when comparing the relative lipophilicity and fet3Δftr1Δ growth upon treatment with 5 
µM small molecule. Similar results were obtained with 10 µM treatment. This suggests a lipophilic balance is required 
to restore yeast cell growth. (D) Derivatives restore growth to fet3Δftr1Δ yeast streaked onto SD-agar plates. 
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deferiprone and PIH do not (Figure 2.10A, B). Hinokitiol sub-stoichiometrically transported iron 
in these studies, with ~25 turnovers being observed in one hour. The rate of transport 
proportionally increased with the concentration of hinokitiol for both ferrous and ferric iron at low 
concentrations (Figure 2.10C and D). Collectively, these results suggest the capacity for hinokitiol 
to repeatedly and reversibly bind, transport, and release iron. 
 
 
2.4 CHARACTERIZATION OF IRON REDOX POTENTIAL WITH HINOKITIOL 
 Iron, as an ion, and in the forms of iron-sulfur [Fe-S] clusters and heme, is an essential 
cofactor for reduction/oxidation (redox) reactions, whereby it mediates electron transfer.35 This 
plays a role in many diverse cellular processes, such as dopamine synthesis,36 oxygen transport,37 
mitochondrial respiration,38 xenobiotic metabolism,39 and maintenance of circadian rhythm.40 
Conversely, an excess of labile iron causes significant oxidative damage and toxicity through 
reactive oxygen species (ROS) generation.41-46 This occurs through the Fenton reaction,41-43 in 
which H2O2 is reduced by Fe
II to create a hydroxyl radical, which further undergoes Haber-Weiss 
cycling with oxidation of H2O2 by Fe
III to form hydroperoxyl radicals (Scheme 2.2).41 These 
radicals then react with a number of polyunsaturated fatty acids, DNA, and proteins to cause 
significant lipid peroxidation and oxidative damage (Scheme 2.2).44 ROS and free radicals have 
been implicated to play a role in numerous disorders, including ageing, asthma, Alzheimer’s, 
Figure 2.10 Hinokitiol autonomously promotes transmembrane iron transport in liposomes. (A and B) 
Hinokitiol promotes the efflux of (A) ferrous and (B) ferric iron from POPC liposomes. (C and D) Increased rates of 
iron transport were observed with increasing hinokitiol concentrations. 
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arthritis, atherosclerosis, cancer, and the exacerbation of inflammation.45 Due to this inherent 
toxicity of iron, organisms have developed sophisticated regulatory mechanisms to sequester 
excess iron, allow for its essential use, and maintain systemic iron homeostasis.46 
 Noting the capacity for hinokitiol to bind and transport iron across lipid membranes, we 
sought to understand the changes in the iron reduction potential upon hinokitiol binding under 
physiologically relevant conditions. A large body of evidence supports that ferrous iron-selective 
chelators, such as bipyridyl, increase reactive oxygen species (ROS) in organisms, while ferric 
iron-selective chelators prevent ROS generation.47-49 Nitrogen based chelators, such as 2,2’-
bipyridine, are more selective for FeII and cause oxidative damage, while the FeIII selective chelator 
deferiprone decreases oxidative damage in animals.9, 48, 49 Analyzing the previously determined 
iron binding affinities with hinokitiol, we predicted iron-hinokitiol complexes would exhibit 
decreased reduction potentials, making it less likely to undergo redox processes.  
 To definitively test this, in collaboration with the Gewirth Lab (UIUC), we evaluated the 
iron redox potential through cyclic voltammetry (CV). Due to the low solubility of Fe(Hino)3 in 
aqueous buffer and the sensitivity of CV requiring millimolar concentrations of hinokitiol, we had 
to alternative use a 1:1 H2O:MeOH buffer. In this buffer, two different redox waves were observed 
for the hinokitiol-iron solution (Figure 2.11A). Diffusion-controlled linear behavior was observed 
Scheme 2.2 Haber-Weiss cycling from iron overload causes severe toxicity. 
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vs. the square root of scan rate for E1 (Figure 2.11B, C). The number of electrons obtained utilizing 
the Randles-Sevcik equation50 were 1.1 for the electrochemical reduction process and 0.9 for the 
oxidation process suggesting this redox pair is the one electron reduction of the FeIII(Hino)3 
complex. Non-linear behavior was observed for E2, consistent with a surface-confined 
electrodeposition process at more negative potentials (Figure 2.11D, E). This process is not likely 
pertinent to the electrochemical characterization of iron-hinokitiol complexes in biological 
Table 2.2 Redox potentials of different iron complexes in relation to NADP+. The redox potentials were obtained 
by CV for a number of different iron:chelator complexes. CVs were obtained with a 100 mV/s scan rate with a Hg 
electrode. Ag/AgCl reference, and a graphite auxiliary using a 0.1 M Tris buffer in 1:1 MeOH:H2O at pH=7.2 using 
500 µM small molecule and 100 µM Fe(NO3)3. 
Table 2.3 Standard redox potentials of hinokitiol:iron complexes at different pHs and hinokitiol concentrations. 
The redox potential of the redox wave corresponding to the one electron redox process (E01) was determined at various 
pHs. CVs were obtained with a 100 mV/s scan rate with a Hg electrode, Ag/AgCl reference, and graphite auxiliary 
using a 0.1 M Tris buffer in 1:1 MeOH:H2O and 100 µM Fe(NO3)3. pH was adjusted by titration with H2SO4 or KOH 
after addition of iron and hinokitiol. 
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Figure 2.11 Electrochemical characterization of hinokitiol-bound iron. (A) Cyclic voltammograms (CVs) of iron 
and an iron-hinokitiol complex. Two different redox waves are present in the voltammogram for hinokitiol. (B and 
C) CVs obtained at different scan rates under identical conditions for E1 support a 1-electron redox process. (D and 
E) CVs obtained at different scan rates under identical conditions for E2 support surface-confined electrodeposition. 
(F) Decreasing the concentration of MeOH decreased E01. (G) Extrapolation of the obtained E01 vs. MeOH 
concentration estimates the redox potential of Fe(Hino)3 in aqueous solutions to be as low as -361 mV vs. NHE. (H) 
In a strongly reducing ascorbate (62.5 mM) buffer, iron (III) is instantaneously reduced to iron (II) as determined by 
the absorbance of a ferrozine-FeII complex at 562 nm. Preformed FeIII(Hino)3 significantly attenuated the rate of 
reduction, however, iron (II) was primarily present after one hour using the same ascorbate buffer. (I) Quantification 
of the rate of iron (III) reduction over time in the same strongly reducing ascorbate buffer. (J) Effect of pH on the 
redox potential of Fe(Hino)3. (K) The Fe(Hino)3 redox potential decreases with increasing pH. (L) Effect of the 
Hino:Fe ratio on E01. 
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systems, and was not investigated further. In this 1:1 MeOH:H2O buffer, the redox potential of 
hinokitiol-bound iron is -211 mV (Table 2.1 and 2.2).51-54 Using varying ratios of water and 
methanol, we estimated the redox potential of Fe(Hino)3 in aqueous systems to be as low as -361 
mV compared with a redox potential of +770 mV for aqueous iron (Figure 2.11F, G and Table 
2.2). It would then be expected that ferrous iron bound to hinokitiol would rapidly oxidize. 
Consistent with this, addition of hinokitiol to a solution of iron (II) in a non-reducing environment 
led to the rapid oxidation of iron (II) to iron (III), likely through inner sphere electron transfer with 
the electron-rich tropolone core.  
 The cytosol is a slightly reducing environment primarily due to the high concentrations of 
NADPH needed to promote anabolic metabolism. In the absence of iron chelators, cytosolic iron 
(III) is rapidly reduced to iron (II), which is its most common oxidation state in biological systems. 
Compared to the high redox potential of NADP+ (108 mV), the reduction of hinokitiol-bound iron  
(III) becomes disfavorable, with an estimated ΔG = +21.6 kcal/mol if a stoichiometric process. In 
a highly reducing environment, however, the rate of reduction of iron (III) was drastically 
decreased in the presence of hinokitiol, but it was still nearly quantitative in less than 2 hours 
(Figure 2.11H, I). Moreover, the redox potential increased with decreasing pH and decreasing 
hinokitiol concentrations (Figure 2.11J-L and Table 2.3), possibly due to increased speciation to 
the 2:1 or 1:1 hinokitiol:iron complexes at more acidic pH and with fewer equivalents of hinokitiol. 
Collectively, these data suggest that both ferric and ferrous iron should be readily accessible in the 
presence of hinokitiol and that ROS generation should be subdued under physiological conditions. 
They further suggest hinokitiol may have potential in preventing oxidative damage in many iron-
overload disorders, such as hemochromatosis, as well as other diseases exacerbated by metal-
dependent oxidative damage and inflammation.55-62 
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2.5 CHARACTERIZATION OF METAL SELECTIVITY WITH HINOKITIOL 
 The cellular milieu is composed of a dynamic environment of diverse metals, nutrients, 
and biomolecules whose acquisition must be precisely controlled to maintain normal homeostasis. 
This is especially evident in metal ion homeostasis, in which nearly 50% of all catalytic enzymes 
utilize a metal cofactor to promote reactivity.63 These enzymes commonly bind their metal partner 
through interactions with a limited number of residues, including histidine, aspartate, cysteine, 
serine, and asparagine amongst others. The fundamental principles governing these metal-ligand 
interactions dictate the stability and specificity of their metal-protein complexes.64-66 These include 
the donor atom preference underlying the principles of Hard and Soft Acids and Bases, the steric 
strain of chelates, preorganization with an intended metal, and the preferred coordination geometry 
based on the Ligand Field Stabilization Energy.66-68 It is often the case that some metals, such as 
CuII and ZnII, bind proteins more favorable than the intended metal by forming thermodynamically 
more favorable metal-protein complexes.63, 65 
Table 2.4 Selectivity of hinokitiol binding and transport. Hinokitiol binds and transports many other divalent 
metals, as determined by ICP-MS analysis of organic-soluble hinokitiol:metal complexes after extraction and by 
determination of the rates of metal efflux from liposomes. The selectivity for binding and transport in biological 
systems is likely high for iron due to the high metallomic abundance of labile iron over other metals inside of cells. 
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 The Irving-Williams series ranks relative complex stabilities of the first-row transition 
metals.68 This takes into account multiple atomic properties, such as the polarizability, ionic radius, 
number of d electrons, and the ligand field stabilization energy of each metal. From this series, it 
is predicted that Cu2+ forms more favorable complexes with proteins over Mn2+ or Zn2+. This 
presents a significant challenge for organisms to achieve correct protein metalation in imperfectly 
selective metalloproteins.63 The metallomic abundance of each metal plays a role to attain 
specificity and selectivity for an intended metal; cells alter the ion accessibility at the locations at 
which metal-protein binding takes places.16, 69, 70 Cells maintain the labile concentrations of each 
metal in the inverse order of the relative stability of their metal-ligand complexes.63 The estimated 
concentrations of each labile metal are shown in Table 2.4, in which the available cytosolic 
concentration of iron is 10,000,000,000-fold greater than that of copper.16 This is attributed to 
robust networks of chaperones, transporters, efflux proteins, storage proteins, and regulators that 
bind Cu2+ with exceptional affinities and selectivities. For example, the transcriptional activator 
Mac1, which is essential in regulating yeast copper homeostasis, binds copper with a dissociation 
constant (Kd) of 9.7 x 10
-20 M.16  
 Hinokitiol is a well-known chelator of iron and many other metals, including AgI, PdII, 
AlIII, ZrIV, and MoVI, and possesses a range of biological activities that have been attributed to its 
metal binding capacity.71-77 We thus sought to understand the inherent metal ion binding and 
transport selectivity of hinokitiol.  Addition of excess hinokitiol to aqueous solutions of either 
FeCl2, MnCl2, CoCl2, NiCl2, ZnCl2, or CuCl2 led to immediate color changes, indicating 
complexation with hinokitiol (Figure 2.12A). This is consistent with quantitative extraction of FeII, 
MnII, CoII, NiII, ZnII, and CuII into 1:1 Hexane:EtOAc in the presence of hinokitiol, while each 
metal partitioned into water in the absence of hinokitiol as determined by ICP-MS analysis (Figure 
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2.12B). Next, we performed competition experiments using equimolar amounts of these metals 
and hinokitiol. The relative binding selectivity was then determined through extraction of metal-
hinokitiol complexes into 1:1 Hexane:EtOAc and quantification by ICP-MS. Hinokitiol bound 10-
times more CuII than FeII, which exhibited high selectivity for these metals over other divalent 
metals tested (Figure 2.12C and Table 2.4). 
 The transport selectivity of this metallophore for divalent metals was determined using a 
modified liposome assay adapted from Mackenzie and coworkers.78 POPC liposomes were loaded 
with either FeII, MnII, CoII, NiII, ZnII, or CuII. The extraliposomal metal was removed by size 
exclusion chromatography, and the metal-sensitive fluorescent turn-off probe PhenGreen was 
added to the liposomal suspension. After liposomal efflux of the metal, PhenGreen fluorescence 
at 520 nm is quenched upon binding of the divalent metal to the phenanthroline motif (Figure 
2.13A).78 The rate of fluorescence quenching for each metal was then quantified using OriginPro. 
From these studies, it was concluded that hinokitiol transported CuII 80-times faster than FeII 
(Table 2.4) Interestingly, hinokitiol did not transport MnII to any observable degree in both 
liposomes and HEK293T cells. Further, the selectivity for transport closely tracked the Irving-
Figure 2.12 Binding selectivity of hinokitiol with divalent metals. (A) Hinokitiol binds multiple divalent metals to 
form lipophilic complexes that partition into organic solvents. (B) ICP-MS analysis of metal content in aqueous and 
organic layers before and after organic extraction. (C) Metal content in organic layer after extraction upon competitive 
binding of hinokitiol with divalent metals. 
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Williams Series,68 with a transport selectivity of Mn2+ << Fe2+ < Co2+ ~ Ni2+ < Cu2+ > Zn2+ (Figure 
2.13B-H). 
 Although hinokitiol is a broad-spectrum metallophore capable of binding and transporting 
multiple divalent metals, the low accessibility of copper likely leads to high iron selectivity in vivo. 
To test this, we quantified total intracellular metal content in wild-type and fet3Δftr1Δ yeast in the 
presence or absence of hinokitiol by ICP-MS. Consistent with previous results,79, 80 untreated 
fet3Δftr1Δ yeast exhibited reduced iron and manganese levels, with no changes observed in zinc 
Figure 2.13 Metal selectivity of hinokitiol for divalent metals. (A) PhenGreen was used to observe the efflux of 
divalent metals. PhenGreen fluorescence is quenched upon metal binding. (B) Selectivity of hinokitiol for transporting 
various divalent metals using t1/2 calculated from OriginPro. (C-H) Rate of PhenGreen fluorescence quenching after 
hinokitiol (blue) or DMSO (black) addition and metal efflux. (I) Treatment of fet3Δftr1Δ yeast with hinokitiol 
increased iron levels, but did not increase levels of other divalent metals.  
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or copper relative to wild-type yeast. Addition of hinokitiol to fet3Δftr1Δ yeast, however, 
increased intracellular iron levels. Importantly, the total cellular levels of copper, manganese, 
cobalt, nickel, zinc, magnesium, sodium, and potassium remained unchanged (Figure 2.13I). This 
remarkable tolerance for imperfection may be attributed to the many high affinity metal 
transporters, efflux proteins, chaperones, and regulators that maintain metal homeostasis. These 
results further support the hypothesis that the inherent robustness81 of living systems enables an 
imperfect small molecule mimic of missing proteins to restore normal physiology in protein-
deficient organisms. Finally, these robustness mechanisms may allow for an imperfect iron 
transporting small molecule to restore iron-dependent physiological processes in more complex 
organisms, and even animals. 
 
2.6 METHODS 
Cell lines and growth conditions 
 Wild type (DEY1457) and isogenic fet3Δftr1Δ S. cerevisiae were obtained from D. 
Kosman.82 Wild type (YPH499) and isogenic fet3Δarn1-4Δ S. cerevisiae were obtained from C. 
Philpott.15 Yeast were maintained on standard YPD media containing 10 g/L yeast extract, 20 g/L 
peptone, and 20 g/L dextrose without (liquid media) or with (solid media) 20 g/L agar. Unless 
otherwise indicated, growth-restoration assays in yeast used a low iron SD media consisting of 
1.91 g/L iron-free YNB-FeCl3 (ForMedium CYN 1201), 0.79 g/L Complete Supplement Mixture 
(Sunrise Science Products 1001-010), 5 g/L ammonium sulfate (Sigma A4418), 20 g/L dextrose, 
10 µM FeCl3 (Sigma 451649), and 10 µM hinokitiol (β-Thujaplicin, Sigma 469521) in 50 mM 
MES/Tris buffer at pH=7.0 without (liquid media) or with (solid media) 20 g/L agar. Dextrose, 
hinokitiol, and FeCl3 were added after autoclave sterilization from a filter-sterilized 40% w/v 
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dextrose solution in water, from a freshly prepared sterile 10 mM hinokitiol stock in DMSO, and 
from a freshly prepared 10 mM FeCl3 stock in sterile water, respectively. Non-fermentable growth 




 All data depicts the means or weighted mean ± SEM with a minimum of 3 biological 
replicates unless otherwise noted. Statistical analysis represents P values obtained from student t-
test or one- or two-way analysis of variance (ANOVA) with post-hoc TUKEY test where 
appropriate. NS, not significant; * P < 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001 unless 
otherwise noted. 
 
Growth rescue of iron-deficient yeast with small molecules on agar plates 
 Growth rescue in yeast was performed similar to previously reported19 on low iron SD-
agar plates in 50 mM MES/Tris buffer at pH=7.0 containing 2% agarose gel, 10 µM FeCl3, and 10 
µM hinokitiol (from 40X stock in DMSO). Wild type and fet3Δftr1Δ or fet3Δarn1-4Δ controls 
treated with vehicle (DMSO) were performed under identical conditions using the same low iron 
SD media containing 10 µM FeCl3 in the absence of hinokitiol. Yeast were grown overnight in 
YPD media and diluted to an optical density at 600 nM (OD600) of 1.0 in low iron SD media before 
10-fold serial dilution and inoculation of these yeast suspensions (10 µL per dot) onto the low iron 
SD-agar plates described above containing either DMSO vehicle or hinokitiol (10 µM from 40X 
DMSO stock).  
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 For disc diffusion assays, yeast were grown overnight in YPD media and diluted to an 
OD600 = 0.1 in low iron SD media and streaked onto low iron SD-agar plates containing 10 µM 
FeCl3. Disc diffusion assays were performed using ≥10 mM stock solutions (in DMSO) of 
hinokitiol, tropolone (Sigma T89702), α-dolabrin (Specs Compound Handling AN-
584/43416897), maltol (Sigma H43407), deferiprone (DFP, Sigma 379409), pyridoxal 
isonicotinoyl hydrazone (PIH, Santa Cruz sc-204192), salicylaldehyde isonicotinoyl hydrazone 
(SIH, see synthesis and characterization below), comenic acid (COMA, kindly donated by Obiter 
Research, LLC), amphotericin B (AK Scientific L970), nonactin (Sigma N2286), calcimycin 
(Sigma C7522), prodigiosin (Santa Cruz sc-202298), or synthesized derivative (10 µL per paper 
disc) on low iron SD-agar plates containing 10 µM FeCl3 streaked with the appropriate yeast strain 
(from OD600 = 0.1 in low iron SD media). Growth restoration under non-fermentable conditions 
was performed using 3% glycerol instead of 2% dextrose. Images were taken 48-72 hours after 
inoculation and incubation at 30 °C unless otherwise noted. 
 
Growth rescue of fet3Δftr1Δ yeast with small molecules in liquid media 
 Growth rescue in yeast was performed similar to previously reported19 using 10 µM 
hinokitiol in low iron SD liquid media containing 10 µM FeCl3 in a 96-well plate unless otherwise 
noted. Wild type and fet3Δftr1Δ controls treated with vehicle (DMSO) were performed under 
identical conditions using the same low iron SD media containing 10 µM FeCl3 in the absence of 
hinokitiol. Yeast were grown overnight in YPD media and diluted at an OD600 of 0.1 in SD media, 
diluted 10-fold, and incubated at 30 °C with continuous shaking (200 rpm). The OD600 was 
obtained 24-48 hours after inoculation unless otherwise noted.  
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 Small molecule dose-response with hinokitiol, C2-deoxy hinokitiol (C2deOHino), and 
synthesized derivatives (see syntheses below) was determined by addition of the small molecule 
(40X stock solution in DMSO) to give the indicated final concentrations.  
 Iron dose-response studies were performed in the same low iron SD media without FeCl3 
containing 10 µM hinokitiol (from a 40X stock solution in DMSO). FeCl3 (40X stock solution in 
water) was added to the give the indicated final concentrations up to 10 µM FeCl3.  
 For dose-dependent hinokitiol-promoted rescue at increasing dosages of FeCl3, SD media 
was made containing either 10, 25, 50, or 100 µM FeCl3 from a 10 mM FeCl3 stock before adding 
hinokitiol (40X stock solution in DMSO) to give the indicated final concentrations. 
 
Sustainability assay 
 Sustainable hinokitiol-promoted growth restoration of fet3Δftr1Δ yeast was performed 
similar to previously reported19 by inoculation of hinokitiol-rescued yeast from low iron SD-agar 
plates containing 10 µM hinokitiol and 10 µM FeCl3 into low iron SD liquid media containing 10 
µM hinokitiol and 10 µM FeCl3, then streaking of the yeast suspension (diluted to OD600 of 0.1) 
onto agar plates. This process was repeated for >100 days. Continued reliance of fet3Δftr1Δ yeast 
growth on hinokitiol was observed, as removal of hinokitiol from the SD-agar plates led to no 
fet3Δftr1Δ yeast cell growth. 
 
Doubling time of fet3Δftr1Δ yeast treated with hinokitiol 
 Doubling times of wild type and hinokitiol-rescued fet3Δftr1Δ yeast were determined 
similar to previously reported19 by tracking the OD600 every hour over 48 hours in the same low 
 52 
iron SD media containing 10 µM FeCl3 and DMSO or 10 µM hinokitiol (from 40X stock in 
DMSO) and applying the equation Td = (t2-t1) x [log(2)/log(q2/q1)] during exponential phase. 
 
55Fe3+ uptake assay in yeast 
 Iron (III) uptake into wild type and fet3Δftr1Δ yeast was adapted from Kosman and 
coworkers.83 Overnight yeast cultures were repeatedly centrifuged and rinsed with water. The cell 
pellet was resuspended in MilliQ water, and diluted in SD media without FeCl3. The cells were 
incubated at 30 °C for 3 hours, centrifuged and rinsed with water twice. The cells were then 
suspended to 3x107 cells/mL in SD media containing 50 mM sodium citrate and 2% glucose. 
Hinokitiol or C2deOHino (from 40X stocks in DMSO) was added to a final concentration of 100 
µM before 55FeCl3 (1.1 µCi) was added to the yeast suspensions. The suspension was continuously 
homogenized before aliquots were taken and diluted with 10 mL of room temperature water. Cells 
were then collected via vacuum filtration through a 0.45 µm nitrocellulose filter (Millipore 
HAWP), and rinsed with room temperature water (x5 of 100mL). The filters were then transferred 
to a scintillation vial containing 3 mL of scintillation cocktail for measuring radioactivity using a 
liquid scintillation counter. Hinokitiol showed a dose-dependent increase in 55Fe uptake from 5 to 
100 µM while C2deOHino showed no uptake up to 100 µM. 
 
Lipophilicity determination for small molecule iron chelates 
 Octanol-water partition coefficients were obtained as previously reported84, 85 with 100 µM 
small molecule and 33 µM FeCl3 (50 µM FeCl3 for PIH as it forms a 2:1 complex) using equal 
volumes of equilibrated pH=5 water and octanol. Concentrations of small molecule in water were 
determined via UV-Vis spectroscopy compared to known initial standards. 
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 Hexane-water partition was obtained similar to above with 500 µM small molecule and 50 
µM FeCl3 using equal volumes of 50 mM Mes-Tris buffer at pH=7.0 and hexanes. 
 
Determination of the pKa of hinokitiol 
 The pKa of hinokitiol was determined by spectrophotometric titration with varying pH. 
Hinokitiol (100 µM) was dissolved in a 0.1 M KCl solution in H2O and acidified to pH = 3.0 (using 
0.1 M HCl). The UV-Vis spectrum was repeatedly obtained upon sequential titration of 0.1 M 
KOH to obtain a range of pHs (3.0, 3.4, 3.9, 4.2, 4.6, 4.9, 6.0, 6.4, 7.0, 7.2, 7.6, 8.4, 9.3, 9.7, 10.4, 
10.9, 11.7, 12.0). A clear isobestic point was observed at 365 nm, and a new λmax was observed 
with decreasing pH at 387 nm. The pKa was then determined via plotting the Abs387 / Abs240 vs. 
pH and logistic fitting on OriginPro (R2 = 0.996) to calculate the point of inflection (pKa = 7.33). 
 
Determination of small molecule iron binding 
 Small molecule iron (III) binding was determined by UV-Vis spectroscopy of small 
molecules (30 µM) before and after addition of FeCl3 (10 µM) or iron (III) citrate (10 µM, Sigma 
F3388) in 10 mM MES/Tris buffer at pH=7.0. Iron (II) binding was determined by UV-Vis 
spectroscopy of small molecules (30 µM) and FeCl2 (10 µM) in a 25 mM MES/Tris buffer at 
pH=7.0 containing 62.5 mM sodium ascorbate.  
 
Titration of hinokitiol with iron (III) 
 An iron (III) titration study was performed by addition of 50 µM hinokitiol and increasing 
equivalents of FeCl3 (0, 1, 5, 10, 12.5, 15, 16.67, 17.5, 20, 25, 30, 35, 37.5, 40, and 50 µM) in 10 
mM MES/Tris buffer at pH=7.0. No precipitate was observed in all cases, and the solution changed 
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to a brown colored solution with increasing equivalents of iron (III). As the amount of iron was 
increased, the λmax shifted from ~240 to 250 nm and the absorbance at 420 nm increased up to ~3:1 
Hino:Fe. 
 
Determination of iron (II) and iron (III) binding affinity with small molecules 
 The association constants of hinokitiol, deferiprone, tropolone, maltol, and/or EDTA with 
iron (II) or iron (III) were determined through competition studies similar to previously reported.86 
Specifically, the association constant for iron (II) was determined by a ferrozine competition assay 
(KA of ferrozine = 3.65x10
15).21  FeCl2 (25 µM) was pre-mixed with ferrozine (75 µM) in a 25 
mM MES/Tris buffer at pH=7.0 containing 62.5 mM sodium ascorbate. Then increasing 
concentrations of small molecule (from 40X stocks in DMSO) were added to the indicated final 
concentrations. The solutions were allowed to equilibrate for 24 hours before reading of the 
absorbance at 562 nm. The association constants of hinokitiol, tropolone, and deferiprone for iron 
(III) was determined by an EDTA (KA = 1.7x10
24) competition assay,86 and a citrate (KA = 1x10
17) 
competition assay for maltol.87 Each chelator was mixed with FeCl3 in a 3:1 ratio in 50 mM 
MES/Tris buffer at pH=7.0 containing 0.1 M KCl to form the corresponding iron complex. The 
λmax of the peak corresponding to the 3:1 chelator:iron complex was determined (~400-500 nm) 
for each complex. Then this Fe(chelator)3 stock was added to a solution containing increasing 
concentrations of EDTA or citrate in 50 mM MES/Tris buffer at pH=7.0 containing 0.1 M KCl to 
give the indicated final concentrations of chelator (75 µM), FeCl3 (25 µM), and the competitive 
chelator. The system was allowed to equilibrate overnight, and the absorbance corresponding to 
the Fe(chelator)3 complex was determined. The EC50 values for each chelator were calculated by 
a nonlinear curve fit (Hill1) on OriginPro by plotting the absorbance vs. concentration of titrant, 
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and the KA for each complex was determined from the equation: KA, ligand = (KA, competitor * [EC50]) 
/ [ligand] where the ligand is the molecule originally bound to iron, and the competitor is the 
competing chelator. 
 
Removal of 55Fe from iron-binding proteins with hinokitiol 
 The capacity for hinokitiol to remove iron from transferrin was determined through a 55Fe 
assay adapted from Cerami and coworkers.10 55Fe was loaded onto transferrin (Tf) similar to 
previously described in PBS buffer.88 Increasing hinokitiol doses (from 1000X stocks in DMSO) 
were added to a solution of 55Fe2Tf (1 nM) in PBS buffer to give the final indicated concentrations. 
The solution was incubated at 37 °C for 3 hours. After incubation, any 55Fe bound to hinokitiol 
was isolated by extraction of iron:hinokitiol complexes with EtOAc. The radioactive levels in the 
organic layer were determined after dilution in scintillation cocktail. No extraction of 55Fe was 
observed in the absence of hinokitiol, and transferrin was not denatured from the extraction process 
as determined by UV-Vis spectroscopy of holo-transferrin before and after EtOAc extraction in 
PBS buffer.  
 Ferritin was loaded with 55Fe by incubation of wild type Caco-2 monolayers and isolation 
of ferritin through immunoprecipitation as described below. The immunoprecipitated ferritin was 
diluted to 2.5 ng ferritin/mL (determined by ELISA as described below) in 50 mM MES/Tris buffer 
at pH=7.0, and increasing concentrations of hinokitiol were added (from 1000X stock in DMSO) 
to give the final indicated concentrations. The suspension was mixed at room temperature for 2 
hours. After incubation, repeated centrifugations and rinses with PBS were performed to remove 
any 55Fe not bound to ferritin, and the radioactive levels remaining in the agar pellet were 
determined after dilution in scintillation cocktail and liquid scintillation counting.  
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Crystal structure of Fe(Hino)3 
 An x-ray quality crystal of synthesized Fe(Hino)3 was obtained from a recrystallization of 
Fe(Hino)3 (10 mg) in acetone (2 mL) and benzene (0.2 mL) in an uncapped 1 mL vial by allowing 
the solvent to slowly evaporate undisturbed overnight. X-Ray single crystal analysis was 
performed by the University of Illinois X-Ray facility. 
 
Determination of hinokitiol binding selectivity by ICP-MS 
 The binding selectivity for hinokitiol with multiple divalent metals was determined similar 
to previously described.14 Specifically, a 2 mM solution of hinokitiol in 10 mM MES/Tris buffer 
in 1:1 H2O:MeOH at pH=7.0 was mixed in equal volume with a solution containing 2 mM FeCl2, 
2 mM MnCl2, 2 mM CoCl2, 2 mM NiCl2, 2 mM ZnCl2, and 2 mM CuCl2 in a 10 mM MES/Tris 
buffer in 1:1 H2O:MeOH at pH=7.0 to give a final concentration of 1 mM for each divalent metal 
and hinokitiol. The colored solution was allowed to incubate for 4 hours at room temperature. The 
solution was diluted in buffer, and extracted (x3) using 1:1 Hexanes:Ethyl Acetate. The organic 
layer was collected, dried by MgSO4, and filtered. The solvent was removed in vacuo, digested 
with 70% HNO3, and metal content was determined by ICP-MS analysis through the University 
of Illinois SCS Microanalysis Facility.  
 Control experiments were performed similar to those described above but in the absence 
of hinokitiol. No metal was detected in the organic layer by ICP-MS. Control experiments were 
also performed similar to those described above but using 60 mM hinokitiol. Metal content after 
extraction was compared to the initial metal content in the aqueous solution before extraction, and 
it was determined that the metal:hinokitiol complexes are extracted into the organic layer.  
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Determination of iron efflux from liposomes using ferrozine 
 Iron (III) efflux from POPC liposomes was determined similar to previously reported.89 
POPC liposomes were prepared as similarly reported90 using 30 mM FeCl3, 62.5 mM citrate at 
pH=7.0 in 25 mM Mes/Tris buffer. External iron was removed by size exclusion chromatography 
using Sephadex G-50 and eluting with external buffer. External buffer consisted of 62.5 mM 
ascorbate at pH=7.0 in 25 mM Mes/Tris buffer. The liposomes were diluted to 1 mM phosphorus 
in this buffer. Ferrozine (Sigma 160601) was added (100X stock in external buffer) to a final 
concentration of 500 µM. Liposomal suspension was then transferred to a 96-well plate, and either 
DMSO or 5 µM hinokitiol, C2deOHino, deferiprone, or PIH (40X stock solution in DMSO) were 
added to initiate the experiment. The OD562 was determined every minute over the course of 2 
hours using a plate-reader with continuous shaking at 30 °C to detect the relative amounts of 
external ferrozine-iron chelate at the indicated times. After 2 hours, liposomes were lysed with 
Triton-X to give 100% iron efflux. Hinokitiol dose- and temperature-dependently promoted iron 
(III) efflux from POPC liposomes while C2deOHino showed no efflux up to 100 µM. 
 Iron (II) efflux was performed as described above, however, the internal buffer 
alternatively consisted of 30 mM FeSO4, 62.5 mM ascorbate at pH=7.0 in 25 mM Mes/Tris buffer 
and Triton-X lysis was performed after 1 hour. 
 The rates of iron efflux with increasing concentrations of intraliposomal iron and/or 
hinokitiol were determined as described above using the indicated concentration of iron and 
hinokitiol. For the varying concentrations of iron, hinokitiol (10 µM) was added to the POPC 
liposomes, and the change in absorbance at 562 nm was determined over 2 hours. For the varying 
concentrations of hinokitiol, 30 mM intraliposomal iron was used as described above. The 
concentration of iron outside of liposomes was determined using the extinction coefficient for 
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ferrozine-iron (27,900 M-1cm-1) (66). This was used to determine the amount of iron released from 
liposomes at the indicated times using the total volume for each experiment. Rates of iron efflux 
were determined after one hour of hinokitiol treatment. 
 
Determination of metal efflux from liposomes using PhenGreen 
 Hinokitiol-promoted release of different divalent metals from POPC liposomes was 
performed by tracking the quenching of PhenGreen (Fisher P14312) similar to previously 
reported.78, 91 Liposomes were prepared as described above with an internal buffer consisting of 
either 10 mM ascorbate in a 5 mM MES/Tris buffer at pH=7.0 (for Fe2+), 10 mM citrate in a 5 mM 
MES/Tris buffer at pH=7.0 (for Cu2+), or a 5 mM MES/Tris buffer at pH=7.0 (for Mn2+, Co2+, 
Ni2+, and Zn2+). In all cases, liposomes were prepared using 5 mM of either FeCl2, MnCl2, CoCl2, 
NiCl2, ZnCl2, or CuCl2 added to the internal buffer. The external buffer was a 5 mM MES/Tris 
buffer at pH=7.0 containing 10 µM PhenGreen (from 1000X stock in DMSO). The liposome 
suspension was diluted to 1 mM of phosphorus. The liposome suspension was transferred to a 96-
well plate, and either DMSO or 2 µM hinokitiol (from a 40X stock in DMSO) was added at t = 2 
min. The fluorescence was monitored with excitation at 500 nm and emission at 530 nm over 1 
hour. After one hour, the liposomes were lysed with Triton-X and the fluorescence was recorded. 
In all cases, quenching of fluorescence was observed in the DMSO-treated liposomes after lysis, 
which reached similar levels to that for hinokitiol-treated liposomes before lysis (except for Mn2+ 
where no efflux was observed in Hino-treated liposomes; fluorescence quenching was observed 
after lysis for Mn2+). The DMSO-treated and hinokitiol-treated liposomes had similar fluorescence 
quenching levels after lysis. The total amount of metal efflux was determined using standard 
curves of fluorescence quenching in external buffer with 10 µM PhenGreen and known 
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concentrations of each metal. The t1/2 values were calculated using an asymptotic fit in OriginPro. 
The t1/2 values indicate the time required to reach half of the maximum metal efflux for each metal. 
 
Determination of metal selectivity in yeast 
 The experiment observing the influx of iron into yeast was repeated (without 55Fe 
radiotracer) using wild type and fet3Δftr1Δ yeast at an OD600 = 0.50 in SD media (50 mM 
MES/Tris, pH=7.0) containing 100 µM FeCl3 and DMSO-control or hinokitiol (10 µM). After 2.5 
hours of incubation, cells were centrifuged at 5 °C, rinsed twice with cold 10 mM EDTA in 50 
mM Tris/HCl buffer (pH = 6.5), and once with metal-free water. Cells were then lyophilized for 
48 hours, and intracellular metal levels were quantified by ICP-MS. To do this, cells were initially 
digested with a 5:1 mixture of HNO3:HCl and were then subjected to an automated sequential 
microwave digestion in a CEM Discover SP-D microwave digester. The resulting clear solution 
was diluted in metal-free water, and elemental analysis was performed by ICP-MS (Perkin Elmer 
DRC-e). For most elements, two isotopes were analyzed, and the one with lesser interference and 
higher abundance was used for quantification. The isotopes consisted of 57Fe, 55Mn, 59Co, 58/60Ni, 
64/66Zn, and 63/65Cu. The RSD values were often < 2%, indicating adequate precision of the 
analysis.  
 
Exchangeability of ferric iron bound to hinokitiol 
 The reversible exchange of ferric iron bound to hinokitiol was determined similar to 
previously described.92 Non-radioactive FeCl3 (100 nM from a 1000X stock, referred to as 
56Fe) 
was added to hinokitiol (100 nM from a 1000X stock) in 10 mM MES/Tris buffer at pH=7.0. The 
solution was equilibrated for 1 hour at 37 °C, and then an equal amount of 55FeCl3 (100 nM) was 
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added. The solution was incubated at 37 °C, and at the indicated time points an aliquot was taken 
and added to water. The iron-hinokitiol complex was immediately separated from unbound iron 
through extraction with ethyl acetate and the radioactive counts were determined by scintillation 
counting. Less than 2% of iron was found in the ethyl acetate layer in the absence of hinokitiol. 
The percent equilibrium was then determined by normalizing the radioactive counts from the 
theoretical maximum 55Fe found in the hinokitiol complex (1:1 55Fe:56Fe at equilibrium). 
 
Electrochemical studies of hinokitiol and other chelators 
 Potentiostatic electrochemical methods were performed on a CH Instruments 
electrochemical workstation (model 760 C, Austin, TX) on a three-electrode cell. Hg working 
electrodes were fabricated by the electrodeposition of Hg on a Pt wire utilizing the procedure 
previously described by Barton et al..93 All experiments were reported versus a Ag/AgCl reference 
electrode and utilized a graphite auxiliary electrode. The electrolyte was sparged with UHP argon 
before measurements. A positive pressure of argon was maintained throughout the experiments. 
 Unless otherwise indicated, experiments used a 0.1 M Tris buffer in H2O or 1:1 
MeOH:H2O at pH=7.2 using HNO3 and KOH as titrant. Unless otherwise indicated, experiments 
used a 100 mV/s scan rate, 100 µM Fe(NO3)3, and 500 µM small molecule. All redox potentials 
are recorded versus a normal hydrogen electrode (NHE). 
 The estimated redox potential of Fe(Hino)n was determined through extrapolation of the 
best-fit line of the determined redox potentials of Fe(Hino)n as a function of the concentration of 




Rate of iron (III) reduction 
 The rate of iron (III) reduction in the absence or presence of hinokitiol was determined 
using ferrozine to quantify the concentration of iron (II) similar to previously described.52 
Specifically, iron (III) or Fe(Hino)3 was pre-mixed in a solution of H2O, and diluted into a 25 mM 
MES/Tris buffer at pH=7.0 containing 62.5 mM sodium ascorbate and ferrozine (3 mM) to a final 
concentration of 10 µM FeCl3 and 30 µM hinokitiol. The absorbance at 562 nm, corresponding to 
Fe(ferrozine)3, was determined at the indicated time points. The concentration of iron (II) was then 
calculated through the determined extinction coefficient of ferrozine-iron in this buffer (ε = 19,200 
M-1cm-1). 
 
2.7 SYNTHESIS AND CHARACTERIZATION OF SMALL MOLECULES 
Materials 
 Commercial reagents were purchased from Sigma-Aldrich and were used without further 
purification unless otherwise noted. Solvents were purified via passage through packed columns 
as described by Pangborn and coworkers.94 All water was deionized prior to use.  
 
General experimental procedures 
 Unless otherwise noted, reactions were performed in flame-dried round-bottomed or 
modified Schlenk flasks fitted with rubber septa under a positive pressure of argon. Organic 
solutions were concentrated via rotary evaporation under reduced pressure with a bath temperature 
of 20-35 °C unless otherwise noted. Reactions were monitored by analytical thin layer 
chromatography (TLC) using the indicated solvent on E. Merck silica gel 60 F254 plates (0.25 
mm). Compounds were visualized by exposure to a UV lamp (λ = 254 nm or 366 nm), and/or a 
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solution of KMnO4 stain, followed by heating using a Varitemp heat gun. Flash column 
chromatography was performed using Merck silica gel grade 9385 60Å (230-240 mesh). 
Preparative HPLC purification was performed using an Agilent 1260 Infinity series preparative 
HPLC with a SunFire 5 µm C18 column (Waters Corporation). 
 
Structural analysis  
 1H NMR, 13C NMR, and 19F NMR were recorded at 20 °C on Unity Inova 500NB, Varian 
XR500, Bruker CB500, or Unity 500 instruments. Chemical shifts (δ) are reported in parts per 
million (ppm) downfield from tetramethylsilane and referenced to residual protium in the NMR 
solvent (CHCl3, δ=7.26; DMSO-d6, δ=2.50). Data are reported as follows: chemical shift, 
multiplicity (s=singlet, d=doublet, t=triplet, m=multiplet, app=apparent), coupling constant (J) in 
Hertz (Hz), and integration. 13C NMR are referenced to carbon resonances in the NMR solvent 
(CDCl3, δ=77.16; DMSO-d6, δ=39.52). 
19F NMR are referenced to fluorine resonance in an 
external standard (CFCl3, δ=0.00) High resolution mass spectra (HRMS) were performed at the 
University of Illinois, School of Chemical Sciences Mass Spectrometry Laboratory. Elemental 
analysis was performed at the University of Illinois Microanalysis Laboratory. HPLC 
characterization was performed using an Agilent 1260 Infinity series analytical HPLC with a 5 µm 







Iron (III) hinokitiol complex 
 
 To a flame-dried 20-mL vial equipped with a stir bar was added iron (III) nitrate 
nonahydrate (819.8 mg, 2.03 mmol) followed by hinokitiol (1.0092 g, 6.15 mmol). Then ethanol 
(10 mL) was added. The reaction was vigorously stirred for 2 hours to give a purple colored 
suspension. The product was collected via filtration and recrystallized in acetone to yield the 
product as a purple solid (959.9 mg, 1.76 mmol, 86.7% yield). 
HRMS (ESI+) 
 Calculated for C30H34O6Fe (M+H)
+ : 546.1705 
 Observed    : 546.1703 
Elemental Analysis 
 Calculated [C]  : 66.06% Observed [C]  : 65.88% 
 Calculated [H]  :   6.10% Observed [H]  :   6.21% 






Triflation of hinokitiol 
 
 
 To an oven-dried 300 mL round-bottomed flask equipped with a stir bar was added 
hinokitiol (3.014 g, 18.27 mmol) followed by anhydrous CH2Cl2 (200 mL). The system was put 
under nitrogen, and freshly distilled lutidine (2.54 mL, 21.92 mmol) was added via syringe. The 
system was cooled to 0 °C in an ice/water bath before triflic anhydride (3.38 mL, 20.10 mmol) 
was added dropwise via syringe. The solution was stirred for 15 minutes at 0 °C, then allowed to 
warm to room temperature and stirred for an additional 3 hours. After completion, the reaction was 
quenched with a saturated aqueous NH4Cl solution. The product was extracted in CH2Cl2, washed 
with CuSO4, washed with brine, and dried over anhydrous MgSO4. The product was filtered and 
solvent removed by rotary evaporation. The product was then purified as an inseparable mixture 
of the C-2 and C-7 isomers by flash column chromatography (3:1 Hexane:EtOAc) to yield a 
slightly colored oil (4.819 g, 16.27 mmol, 88.6% yield as a 53:47 mixture of the C-2 and C-7 
isomers). 
TLC (1:1 Hex:EtOAc) 
 Rf = 0.68, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.34-7.24 (m, 5H), 7.14 (dt, J = 11.5, 0.7 Hz, 1H), 7.08 (dt, J = 8.6, 0.6 Hz, 1H), 6.99 
 (dd, J = 11.4, 9.4 Hz,  1H), 2.91-2.80 (app. m, 2H), 1.26 (d, J = 6.8 Hz, 6H), 1.26 (d, J = 
 6.8 Hz, 6H) 
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13C NMR (126 MHz, CDCl3) 
 δ 178.0, 177.7, 158.7, 155.9, 152.3, 139.0, 138.2, 137.9, 137.8, 131.9, 129.9, 129.3, 
 127.6, 38.8, 38.2, 22.9, 2.8 
19F NMR (470.2 MHz, CDCl3) 
 δ -74.76, -74.84 
HRMS (ESI+) 
 Calculated for C11H12F3O4S (M+H)
+ : 297.0408 
 Observed    : 297.0408 
 
Hydrogenolysis of hinokitiol-triflate 
 
 
 Sodium acetate (1.11 g, 13.4 mmol), the triflated hinokitiol (2.00 g, 6.76 mmol), 10 wt% 
palladium on carbon (71.8 mg) and methanol (75 mL) were added to a flame-dried 200 mL round-
bottomed flask containing a stir bar. The suspension was degassed with N2, then put under a H2 
atmosphere without bubbling H2 through the solution. The reaction was stirred and analyzed by 
TLC (Et2O) for 30 minutes. After completion, N2 was bubbled through the system, and the black 
suspension was filtered over celite. The methanol was removed by rotary evaporation, and the 
product was extracted in diethyl ether and washed with brine. After drying with anhydrous MgSO4, 
the solvent was removed by rotary evaporation to yield a slightly colored oil. The product was 
purified by preparative HPLC (283 nm, 20% MeCN in H2O) to yield C2-deoxyhinokitiol and C7-
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deoxyhinokitiol as clear oils (C2deOHino: 325 mg, 2.21 mmol, 32.4% yield; C7deOHino: 204 mg, 
1.38 mmol, 20.4% yield). 
TLC (Et2O) 
 Rf = 0.49, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ C2: 7.10-6.97 (m, 3H), 6.91 (ddd, J = 12.0, 2.6, 0.8 Hz, 1H), 6.81 (ddd, J = 8.7, 1.5, 0.7 
 Hz, 1H), 2.73 (heptet, J = 6.8 Hz, 1H), 1.19 (d, J = 6.9 Hz, 6H) 
 δ C7: 7.09-7.01 (m, 3H), 6.93-6.92 (m, 2H), 2.74 (heptet, J = 6.8 Hz, 1H), 1.21 (d, J = 
 6.9 Hz, 6H) 
13C NMR (126 MHz, CDCl3) 
 δ C2: 188.0, 156.2, 141.9, 140.1, 138.1, 137.2, 130.5, 38.1, 23.0 
 δ C7: 188.0, 157.4, 141.9, 138.7, 137.1, 136.1, 133.8, 38.4, 22.9 
HRMS (ESI+) 
 Calculated for C10H13O (M+H)
+   : 149.0966 
 Observed    : 149.0973 
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Synthesis of salicylaldehyde isonicotinoyl hydrazone 
 
 
 Isonicotinic hydrazide (198 mg, 1.4 mmol) was added to a flame-dried 7 mL vial 
containing a stir bar and EtOH (3 mL). Salicylaldehyde (175 mg, 1.4 mmol) was then added 
dropwise via syringe. The solution was stirred at 75 °C under N2 for 6 hours. The solution was 
cooled to 0 °C, and the solid was collected by vacuum filtration. The product was rinsed with cold 
EtOH, and recrystallized in EtOH to yield a white solid after vacuum filtration (237 mg, 1.0 mmol, 
69% yield, >95% pure). Characterization matched that to previously reported.95 
TLC (EtOAc) 
 Rf = 0.38, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, DMSO-d6) 
 δ 11.08 (s, 1H), 8.80 (dd, J = 4.5, 1.7 Hz, 2H), 8.68 (s, 1H), 7.85 (dd, J = 4.4, 1.7 Hz, 
 2H), 7.61 (dd, J = 7.7, 1.7 Hz, 1H), 7.32 (ddd, J = 8.2, 7.2, 1.7 Hz, 1H), 6.97-6.90 (m, 
 2H), -1.76 (s, 1H) 
13C NMR (126 MHz, DMSO-d6) 
 δ 161.4, 157.5, 150.4, 149.0, 140.0, 131.8, 129.3, 121.6, 119.5, 118.7, 116.5 
HRMS (ESI+) 
 Calculated for C13H12N3O2 (M+H)
+ : 242.0930 
 Observed    : 242.0924 
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Synthesis of tropolone methyl ether 
 
 To a flame-dried 500 mL round-bottomed flask equipped with a stir bar was added 
anhydrous K2CO3 (13.9 g, 100.7 mmol) followed by tropolone (4.06 g, 33.3 mmol) and 18-crown-
6 (0.99 g, 3.75 mmol) as solids. Then anhydrous acetonitrile (225 mL) was added followed by 
iodomethane (23.3 g, 164.2 mmol). The flak was sealed with a rubber septum and heated at 90 °C 
for 4 hours, upon which the thick, yellow colored suspension turned into a fine, white particulate 
suspension. After completion, the K2CO3 was removed by filtration over celite, rinsed with 
acetone, and the solvent was removed by rotary evaporation. The crude mixture was adsorbed onto 
celite, and purified by flash column chromatography (EtOAc) to yield the product as a colorless 
oil (4.391 g, 32.3 mmol, >98% pure, 97% yield). 
TLC (EtOAc) 
 Rf = 0.16, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.28-7.18 (m, 2H), 7.10 (ddd, J = 10.8, 9.8, 1.0 Hz, 1H), 6.91-6.84 (m, 1H), 6.77 (d, J = 
 9.9, 0.8 Hz, 1H), 3.94 (s, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 180.3, 165.2, 136.6, 136.6, 132.7, 127.8, 112.4, 56.2 
HRMS (ESI+) 
 Calculated for C8H9O2 (M+H)
+ : 137.0603 
 Observed    : 137.0603 
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Synthesis of α-bromotropolone methyl ether 2.3 
 
 To a flame-dried 250 mL round-bottomed flask equipped with a stir bar was added the 2-
methoxytropone (4.120 g, 30.2 mmol). It was then azeotroped with dichloromethane. Then carbon 
tetrachloride (125 mL) was added followed by freshly recrystallized N-bromosuccinimide (6.058 
g, 34.0 mmol). The reaction was then stirred at 80 °C and monitored by TLC (EtOAc). After 3 
hours, the flask was cooled, and the orange solution was transferred to a separatory funnel 
containing water. The crude product was extracted in dichloromethane, washed with sodium 
thiosulfate, washed with brine, and dried over anhydrous MgSO4. The product was then purified 
by flash column chromatography (2:1 Hex:EtOAc then 1:1 Hex:EtOAc) to yield the product as a 
slightly yellow solid (5.48 g, 25.6 mmol, 84% yield) and 4-bromo-7-methoxytropone (Rf = 0.58). 
TLC (EtOAc) 
 Rf = 0.41, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 8.19 (dd, J = 9.5, 1.0 Hz, 1H), 7.15 (ddd, J = 10.8, 9.9, 1.0 Hz, 1H), 6.79 (app. dt, J = 
 9.9, 0.7 Hz, 1H), 6.68 (ddd, J = 10.4, 9.5, 0.7 Hz, 1H), 3.96 (d, J = 0.8 Hz, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 174.1, 163.0, 140.0, 138.0, 133.0, 125.4, 112.4, 56.9 
HRMS (ESI+) 
 Calculated for C8H8BrO2 (M+H)
+ : 214.9708 
 Observed    : 214.9717 
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General Procedure for the Synthesis of Tropolone Derivatives from 2.3 and alkyl boronic acids 
 
 Unless otherwise noted, the following coupling and deprotection sequences were 
performed to make a series of α-substituted tropolone derivatives. 
 
Coupling of 2.3 and alkyl boronic acids to form 2.4-2.15 
 In the glove-box, to a flame-dried 3 mL I-Chem vial equipped with a stir bar was added 
bromide 2.3 (21.5 mg, 0.1 mmol), silver (I) oxide (69.5 mg, 0.3 mmol), Pd[P(o-tol)3]2 (7.2 mg, 
0.01 mmol), and the corresponding boronic acid (0.3 mmol) as solids. Then anhydrous dioxane 
(250 µL) was added. The vial was capped, removed from the glove-box, and heated at 70 °C for 
16 hours. After cooling, the reaction was diluted with EtOAc (1 mL), filtered over a small plug of 
silica gel, and rinsed with EtOAc. The solvent was then removed by rotary evaporation, and the 
product purified by flash column chromatography (gradient from 100% Hex to 100% EtOAc) to 
yield the product as a colorless solid or oil. 
 
Deprotection of cross-coupled product to form 2.16-2.27 
 In a 1.5 mL I-Chem vial equipped with a stir bar was added the protected tropolone. Then 
33% HBr in AcOH (0.5 mL) was added via syringe. The vial was capped, and heated at 90 °C for 
3 hours, upon which it formed a brown colored solution. The vial was allowed to cool to room 
temperature, and was transferred to a 7 mL vial. Water (2 mL) was added followed by saturated 
NaOH (1 mL). The aqueous suspension was stirred for 10 minutes, and was then acidified with 
 71 
HCl. The product was then extracted with ethyl acetate (x3), and dried over anhydrous MgSO4. 
The solvent was removed, and the product purified by flash column chromatography (gradient 
from 100% Hex to 50% Hex in EtOAc) to yield a colorless solid or oil. 
 
Synthesis of Methyl Substituted Derivative 2.16 
 
 The cross-coupling of 2.3 was performed as described above with methyl boronic acid to 
yield product 2.4 (64% yield). 
TLC (EtOAc) 
 Rf = 0.30, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.42 (dd, J = 8.8, 1.1 Hz, 1H), 6.99 (t, J = 10.3 Hz, 1H), 6.79 (dd, J = 10.7, 8.9 Hz, 1H), 
 6.74 (d, J = 9.7 Hz, 1H), 3.92 (s, 3H), 2.36 (s, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 180.0, 164.5, 146.6, 136.1, 130.8, 127.2, 112.4, 56.4, 23.7 
HRMS (ESI+) 
 Calculated for C9H11O2 (M+H)
+ : 151.0759 





 The deprotection of 2.4 was performed as described above to yield product 2.16 (5% yield). 
TLC (3:1 Hex:EtOAc) 
 Rf = 0.12, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.98 (d, J = 10.5 Hz, 1H), 7.48-7.42 (m, 2H), 6.75 (t, J = 10.4 Hz, 1H), 2.48 (s, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 140.9, 140.2, 29.9 
HRMS (ESI+) 
 Calculated for C8H9O2 (M+H)
+ : 137.0603 
 Observed    : 137.0604 
 
Synthesis of Ethyl Substituted Derivative 2.17 
 
 The cross-coupling of 2.3 was performed as described above with ethyl boronic acid to 
yield product 2.5 (51% yield). 
TLC (EtOAc) 
 Rf = 0.38, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.35 (dd, J = 8.9, 1.1 Hz, 1H), 6.98 (dd, J = 10.0, 0.8 Hz, 1H), 6.82 (dd, J = 10.6, 9.0 Hz, 
 1H), 6.71 (d, J = 9.7 Hz, 1H), 3.91 (s, 3H), 2.78 (q, J = 7.4 Hz, 2H), 1.19 (t, J = 7.5 Hz, 
 3H) 
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13C NMR (126 MHz, CDCl3) 
 δ 179.7, 163.9, 151.7, 135.1, 130.7, 127.3, 112.1, 56.4, 29.5, 13.7 
HRMS (ESI+) 
 Calculated for C10H13O2 (M+H)
+ : 165.0916 
 Observed    : 165.0919 
 
 The deprotection of 2.5 was performed as described above to yield product 2.17 (17% 
yield). 
TLC (3:1 Hex:EtOAc) 
 Rf = 0.27, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.49 (dd, J = 10.0, 0.9 Hz, 1H), 7.39-7.28 (m, 2H), 7.01 (td, J = 9.8, 1.2 Hz, 1H), 2.87 (q, 
 J = 7.5 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 172.2, 168.6, 143.1, 139.0, 136.0, 127.7, 121.7, 28.7, 13.7 
HRMS (ESI+) 
 Calculated for C9H11O2 (M+H)
+ : 151.0759 







Synthesis of Propyl Substituted Derivative 2.18 
 
 The cross-coupling of 2.3 was performed as described above with propyl boronic acid to 
yield product 2.6 (89% yield). 
TLC (EtOAc) 
 Rf = 0.45, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.34 (dd, J = 8.9, 1.0 Hz, 1H), 6.96 (ddd, J = 10.7, 9.6, 1.1 Hz, 1H), 6.80 (ddd, J = 10.7, 
 8.9, 0.8 Hz, 1H), 6.70 (dd, J = 9.6, 0.8 Hz, 1H), 3.90 (s, 3H), 2.73 (t, J = 7.5 Hz, 2H), 1.60 
 (hextet, J = 7.3 Hz, 2H), 0.91 (t, J = 7.3 Hz, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 179.7, 163.9, 150.2, 135.9, 130.7, 127.2, 112.1, 56.4, 38.5, 22.3, 14.2  
HRMS (ESI+) 
 Calculated for C11H15O2 (M+H)
+ : 179.1072 
 Observed    : 179.1072 
 
 The deprotection of 2.6 was performed as described above to yield product 2.18 (79% 
yield). 
TLC (3:1 Hex:EtOAc) 
 Rf = 0.44, visualized by UV (254 nm) and KMnO4 stain 
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1H NMR (500 MHz, CDCl3) 
 δ 7.47 (d, J = 10.0 Hz, 1H), 7.36 (dd, J = 10.6, 3.5 Hz, 1H), 7.30 (t, J = 10.0 Hz, 1H), 6.99 
 (t, J = 10.2 Hz, 1H), 2.82 (t, J = 7.6 Hz, 2H), 1.67 (hextet, J = 7.7 Hz, 2H), 1.00 (t, J = 7.4 
 Hz, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 171.9, 169.0, 141.3, 139.9, 136.2, 127.6, 122.2, 37.5, 22.5, 14.2 
HRMS (ESI+) 
 Calculated for C10H13O2 (M+H)
+ : 165.0916 
 Observed    : 165.0921 
 
Synthesis of Butyl Substituted Derivative 2.19 
 
 The cross-coupling of 2.3 was performed as described above with butyl boronic acid to 
yield product 2.7 (71% yield). 
TLC (EtOAc) 
 Rf = 0.48, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.35 (dd, J = 8.9, 0.9 Hz, 1H), 6.96 (ddd, J = 10.6, 9.5, 1.1 Hz, 1H), 6.79 (ddd, J = 10.6, 
 8.9, 0.8 Hz, 1H), 6.70 (ddd, J = 9.8, 1.1, 0.8 Hz, 1H), 3.91 (s, 3H), 2.75 (t, J = 7.5 Hz, 2H), 
 1.60-1.50 (m, 2H), 1.36 (hextet, J = 7.3 Hz, 2H), 0.91 (t, J = 7.3 Hz, 3H) 
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13C NMR (126 MHz, CDCl3) 
 δ 179.7, 163.9, 150.5, 135.8, 130.7, 127.2, 112.1, 56.4, 36.2, 31.3, 22.9, 14.1 
HRMS (ESI+) 
 Calculated for C12H17O2 (M+H)
+ : 193.1229 
 Observed    : 193.1226 
 
 The deprotection of 2.7 was performed as described above to yield product 2.19 (43% 
yield). 
TLC (3:1 Hex:EtOAc) 
 Rf = 0.46, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.47 (d, J = 10.0 Hz, 1H), 7.36 (dd, J = 10.3, 2.6 Hz, 1H), 7.30 (t, J = 9.9 Hz, 1H), 6.99 
 (t, J = 9.8 Hz, 1H), 2.84 (t, J = 7.7 Hz, 2H), 1.61 (quintet, J = 7.6 Hz, 2H), 1.41 (hextet, J 
 = 7.6 Hz, 2H), 0.95 (t, J = 7.3 Hz, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 171.9, 168.9, 141.6, 139.8, 136.1, 127.6, 122.1, 35.3, 31.5, 22.9, 14.1 
HRMS (ESI+) 
 Calculated for C11H15O2 (M+H)
+ : 179.1072 






Synthesis of Pentyl Substituted Derivative 2.20 
 
 The cross-coupling of 2.3 was performed as described above with pentyl boronic acid to 
yield product 2.8 (85% yield). 
TLC (EtOAc) 
 Rf = 0.54, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.35 (dd, J = 9.0 Hz, 1H), 6.97 (dd, J = 10.0, 1.0 Hz, 1H), 6.80 (dd, J = 9.3, 1.2 Hz, 1H), 
 6.71 (dd, J = 9.7, 0.9 Hz, 1H), 3.90 (s, 3H), 2.74 (t, J = 7.5 Hz, 2H), 1.60-1.52 (m, 2H), 
 1.39-1.23 (m, 4H), 0.87 (t, J = 7.4 Hz, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 179.6, 163.9, 150.5, 135.9, 130.7, 127.2, 112.2, 56.4, 36.5, 31.9, 28.8, 22.6, 14.1 
HRMS (ESI+) 
 Calculated for C13H19O2 (M+H)
+ : 207.1385 
 Observed    : 207.1375 
 
 The deprotection of 2.8 was performed as described above to yield product 2.20 (51% 
yield). 
TLC (3:1 Hex:EtOAc) 
 Rf = 0.51, visualized by UV (254 nm) and KMnO4 stain 
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1H NMR (500 MHz, CDCl3) 
 δ 7.47 (dd, J = 10.1, 1.0 Hz, 1H), 7.36 (dd, J = 10.4, 1.1 Hz, 1H), 7.29 (ddd, J = 10.5, 10.0, 
 1.0 Hz, 1H), 6.99 (td, J = 9.8, 1.1 Hz, 1H), 2.83 (t, J = 7.8 Hz, 2H), 1.63 (quintet, J = 7.2 
 Hz, 2H), 1.43-1.29 (m, 4H), 0.90 (t, J = 7.1 Hz, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 171.9, 169.0, 141.6, 139.8, 136.1, 127.6, 122.1, 35.5, 32.0, 29.0, 22.7, 14.2 
HRMS (ESI+) 
 Calculated for C12H17O2 (M+H)
+ : 193.1229 
 Observed    : 193.1233 
 
Synthesis of Hexyl Substituted Derivative 2.21 
 
 The cross-coupling of 2.3 was performed as described above with hexyl boronic acid to 
yield product 2.9 (82% yield). 
TLC (EtOAc) 
 Rf = 0.56, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.34 (d, J = 8.9 Hz, 1H), 6.96 (t, J = 10.1 Hz, 1H), 6.79 (dd, J = 10.6, 8.9 Hz, 1H), 6.70 
 (d, J = 9.7 Hz, 1H), 3.90 (s, 3H), 2.73 (q, J = 7.5 Hz, 2H), 1.55 (quintet, J = 7.4 Hz, 2H), 
 1.42-1.20 (m, 6H), 0.85 (t, J = 7.4 Hz, 3H) 
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13C NMR (126 MHz, CDCl3) 
 δ 179.6, 163.9, 150.5, 135.8, 130.7, 127.2, 112.1, 56.3, 36.5, 31.8, 29.4, 29.1, 22.7, 14.2 
HRMS (ESI+) 
 Calculated for C14H21O2 (M+H)
+ : 221.1542 
 Observed    : 221.1538 
 
 The deprotection of 2.9 was performed as described above to yield product 2.21 (61% 
yield). 
TLC (3:1 Hex:EtOAc) 
 Rf = 0.55, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.47 (d, J = 9.9 Hz, 1H), 7.35 (d, J = 10.5 Hz, 1H), 7.29 (t, J = 10.0 Hz, 1H), 6.98 
 (t, J = 9.7 Hz, 1H), 2.83 (t, J = 7.9 Hz, 2H), 1.62 (quintet, J = 7.5 Hz, 2H), 1.42-1.23 (m, 
 6H), 0.88 (t, J = 7.4 Hz, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 171.8, 169.0, 141.6, 139.7, 136.1, 127.6, 122.1, 35.6, 31.8, 29.5, 29.3, 22.7, 14.2 
HRMS (ESI+) 
 Calculated for C13H19O2 (M+H)
+ : 207.1385 






Synthesis of Octyl Substituted Derivative 2.22 
 
 The cross-coupling of 2.3 was performed as described above with octyl boronic acid to 
yield product 2.10 (70% yield). 
TLC (EtOAc) 
 Rf = 0.59, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.35 (d, J = 8.9 Hz, 1H), 6.97 (t, J = 10.1 Hz, 1H), 6.80 (dd, J = 10.1, 9.2 Hz, 1H), 6.71 
 (d, J = 9.7 Hz, 1H), 3.90 (s, 3H), 2.74 (t, J = 7.4 Hz, 2H), 1.56 (quintet, J = 7.8 Hz, 2H), 
 1.42-1.16 (m, 10H), 0.86 (t, J = 7.5 Hz, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 179.6, 163.9, 163.9, 150.6, 135.8, 130.7, 127.2, 112.2, 56.4, 36.6, 32.0, 29.8, 29.6, 29.4, 
 29.2, 22.8, 14.2 
HRMS (ESI+) 
 Calculated for C16H25O2 (M+H)
+ : 249.1855 
 Observed    : 249.1857 
 
 The deprotection of 2.10 was performed as described above to yield product 2.22 (54% 
yield). 
TLC (3:1 Hex:EtOAc) 
 Rf = 0.55, visualized by UV (254 nm) and KMnO4 stain 
 81 
1H NMR (500 MHz, CDCl3) 
 δ 7.47 (d, J = 10.0 Hz, 1H), 7.36 (d, J = 9.9 Hz, 1H), 7.30 (dd, J = 9.7, 1.2 Hz, 1H), 6.99 
 (t, J = 9.6 Hz, 1H), 2.83 (t, J = 7.8 Hz, 2H), 1.62 (quintet, J = 7.4 Hz, 2H), 1.43-1.18 (m, 
 10H), 0.87 (t, J = 7.2 Hz, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 171.8, 169.0, 141.6, 139.8, 136.1, 127.7, 122.2, 35.6, 32.0, 29.8, 29.6, 29.4, 29.3, 22.8, 
 14.2  
HRMS (ESI+) 
 Calculated for C15H23O2 (M+H)
+ : 235.1698 
 Observed    : 235.1702 
 
Synthesis of Decyl Substituted Derivative 2.23 
 
 The cross-coupling of 2.3 was performed as described above with decyl boronic acid to 
yield product 2.11 (72% yield). 
TLC (EtOAc) 
 Rf = 0.60, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.35 (d, J = 8.9 Hz, 1H), 6.97 (t, J = 10.0 Hz, 1H), 6.80 (dd, J = 10.6, 8.9 Hz, 1H), 6.71 
 (d, J = 9.7 Hz, 1H), 3.91 (s, 3H), 2.74 (t, J = 7.5 Hz, 2H), 1.55 (quintet, J = 7.7 Hz, 2H), 
 1.39-1.15 (m, 14H), 0.86 (t, J = 6.9 Hz, 3H) 
 82 
13C NMR (126 MHz, CDCl3) 
 δ 179.7, 163.9, 150.6, 135.9, 130.7, 127.2, 112.2, 56.4, 36.6, 32.0, 29.8, 29.7, 29.7, 29.6, 
 29.4, 29.2, 22.8, 14.2 
HRMS (ESI+) 
 Calculated for C18H29O2 (M+H)
+ : 277.2168 
 Observed    : 277.2163 
 
 The deprotection of 2.11 was performed as described above to yield product 2.23 (42% 
yield). 
TLC (3:1 Hex:EtOAc) 
 Rf = 0.56, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.47 (d, J = 10.0 Hz, 1H), 7.36 (dd, J = 6.5 Hz, 1H), 7.30 (t, J = 10.0 Hz, 1H), 6.99 (t, J 
 = 9.8 Hz, 1H), 2.83 (t, J = 7.8 Hz, 2H), 1.62 (quintet, J = 7.3 Hz, 2H), 1.44-1.18 (m, 14H), 
 0.88 (t, J = 6.9 Hz, 3H) 
13C NMR (126 MHz, CDCl3) 
 δ 171.8, 169.0, 141.6, 139.8, 136.1, 127.6, 122.2, 35.6, 32.0, 29.8, 29.8, 29.7, 29.6, 29.5, 
 29.3, 22.8, 14.3 
HRMS (ESI+) 
 Calculated for C17H27O2 (M+H)
+ : 263.2011 




Synthesis of Isobutyl Substituted Derivative 2.24 
 
 The cross-coupling of 2.3 was performed as described above with isobutyl boronic acid to 
yield product 2.12 (47% yield). 
TLC (EtOAc) 
 Rf = 0.55, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.31 (dd, J = 8.9, 1.0 Hz, 1H), 6.97 (ddd, J = 10.6, 9.6, 1.0 Hz, 1H), 6.79 (ddd, J = 10.6, 
 8.8, 0.7 Hz, 1H), 6.70 (d, J = 9.6 Hz, 1H), 3.91 (s, 3H), 2.63 (d, J = 7.0 Hz, 2H), 1.99 
 (nonet, J = 6.7 Hz, 1H), 0.90 (d, J = 6.7 Hz, 6H) 
13C NMR (126 MHz, CDCl3) 
 δ 179.8, 163.9, 149.3, 136.7, 130.8, 127.0, 112.1, 56.4, 45.8, 27.8, 22.8 
HRMS (ESI+) 
 Calculated for C12H17O2 (M+H)
+ : 193.1229 
 Observed    : 193.1227 
 
 The deprotection of 2.12 was performed as described above to yield product 2.24 (42% 
yield). 
TLC (3:1 Hex:EtOAc) 




 Calculated for C12H17O2 (M+H)
+ : 193.1229 
 Observed    : 193.1235 
 
Synthesis of Cyclopropyl Substituted Derivative 2.25 
 
 The cross-coupling of 2.3 was performed as described above with cyclopropyl boronic acid 
to yield product 2.13 (73% yield). 
TLC (EtOAc) 
 Rf = 0.36, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 6.95 (dd, J = 9.6, 0.7 Hz, 1H), 6.92 (dd, J = 8.2, 1.3 Hz, 1H), 6.78 (ddd, J = 10.1, 9.1, 0.8 
 Hz, 1H), 6.71 (d, J = 9.6 Hz, 1H), 3.91 (s, 3H), 2.55 (app. tt, J = 8.5, 5.6 Hz, 1H), 1.07-
 0.99 (m, 2H), 0.68-0.58 (m, 2H) 
13C NMR (126 MHz, CDCl3) 
 δ 180.5, 163.2, 151.0, 130.9, 130.2, 127.0, 112.3, 56.4, 15.2, 9.4 
HRMS (ESI+) 
 Calculated for C11H13O2 (M+H)
+ : 177.0916 
 Observed    : 177.0914 
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 The deprotection of 2.13 was performed as described above to yield product 2.25 (32% 
yield). 
TLC (3:1 Hex:EtOAc) 
 Rf = 0.06, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.71 (d, J = 9.8 Hz, 1H), 7.41-7.32 (m, 2H), 7.12 (ddd, J = 9.8, 8.8, 2.2 Hz, 1H), 4.92 
 (dd, J = 7.5, 5.4 Hz, 1H), 1.90-1.78 (m, 2H), 1.00 (t, J = 7.4 Hz, 2H) 
13C NMR (126 MHz, CDCl3) 
 δ 174.1, 167.0, 144.1, 137.4, 136.8, 128.1, 119.6, 75.7, 29.6, 10.7 
HRMS (ESI+) 
 Calculated for C10H11O2 (M+H)
+ : 163.0759 
 Observed    : 163.0764 
 
Synthesis of Isopropyl Substituted Derivative 2.14 
 
 The cross-coupling of 2.3 was performed similarly to described above with isopropyl 
boronic acid to yield product 2.14 (34% yield). The reaction used catalyst Pd2dba3 (0.005 mmol), 
Ag2O (0.15 mmol), and P(o-Bn)3 (0.01 mmol) in dioxane (0.2 mL) at 55 °C for 36 hours. 
TLC (EtOAc) 
 Rf = 0.56, visualized by UV (254 nm) and KMnO4 stain 
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1H NMR (500 MHz, CDCl3) 
 δ 7.30 (dd, J = 9.0, 1.1 Hz, 1H), 6.97 (t, J = 9.8 Hz, 1H), 6.87 (t, J = 9.2 Hz, 1H), 6.71 (d, 
 J = 9.5 Hz, 1H), 3.92 (s, 3H), 3.67 (heptet, J = 6.8 Hz, 1H), 1.20 (d, J = 6.9 Hz, 6H)  
13C NMR (126 MHz, CDCl3) 
 δ 179.8, 164.1, 155.7, 132.9, 130.6, 127.4, 112.0, 56.5, 30.6, 22.8 
HRMS (ESI+) 
 Calculated for C11H15O2 (M+H)
+ : 179.1072 
 Observed    : 179.1073 
 
Synthesis of Tolyl Substituted Derivative 2.27 
 
 The cross-coupling of 2.3 was performed as described above with tolyl boronic acid to 
yield product 2.15 (70% yield). 
TLC (EtOAc) 
 Rf = 0.49, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.45 (dd, J = 9.2, 4.4 Hz, 1H), 7.37 (d, J = 8.1 Hz, 2H), 7.20 (d, J = 8.1 Hz, 2H), 7.01 
 (ddd, J = 9.5, 5.1, 0.8 Hz, 1H), 6.87 (ddd, J = 10.3, 5.2, 0.8 Hz, 1H), 6.73 (dd, J = 9.7, 4.5 
 Hz, 1H), 3.94 (s, 3H), 2.37 (s, 3H) 
13C NMR (126 MHz, CDCl3) 




 Calculated for C15H15O2 (M+H)
+ : 227.1072 
 Observed    : 227.1068 
 
 The deprotection of 2.15 was performed as described above to yield product 2.27 (89% 
yield). 
TLC (3:1 Hex:EtOAc) 
 Rf = 0.20, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ 7.58 (dd, J = 10.2, 1.0 Hz, 1H), 7.45-7.38 (m, 3H), 7.37 (ddd, J = 10.5, 9.3, 1.0 Hz, 1H), 
 7.27 (d, J = 7.9 Hz, 2H), 7.08 (ddd, J = 10.5, 9.4, 1.3 Hz, 1H), 2.41 (s, 3H)  
13C NMR (126 MHz, CDCl3) 
 δ 170.9, 170.9, 140.7, 138.7, 138.4, 137.0, 136.8, 129.3, 129.1, 127.5, 122.5, 21.4 
HRMS (ESI+) 
 Calculated for C14H13O2 (M+H)
+ : 213.0916 
 Observed    : 213.0922 
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RESTORED IRON ABSORPTION AND HEMOGLOBINIZATION IN CELLS AND ANIMALS 
 Discovering a small molecule candidate that restores growth to iron-deficient yeast, we 
asked whether hinokitiol can restore the site- and direction-selective transport of iron in more 
complex systems, and even whole organisms. This chapter discusses the capacity for hinokitiol to 
restore iron absorption in gut epithelia monolayers and in animals missing either DMT1 or 
ferroportin-1, and hemoglobinization in developing erythroids or animals missing either DMT1 or 
mitoferrin-1. These results suggest that an imperfect small molecule mimic for missing iron 
transport proteins is sufficient to restore iron-dependent physiological processes in complex 
organisms by restoring the movement of iron into, within, and/or out of cells.  
 Portions of the work presented in this chapter was performed with the aid of colleagues Dr. 
Alex Cioffi (Caco-2 transfection), and/or undergraduates Chris Nardone and James Fan (Caco-2 
transport). Execution of the Belgrade rat studies was performed with collaborators Archita Menon 
and Murui Han from Jonghan Kim’s Lab at Northeastern. Flatiron mouse studies were performed 
by collaborators Young Ah Seo and Marianne Wessling-Resnick at Harvard Medical School. 
Zebrafish studies were performed by collaborators Dr. Yvette Yien, Nick Huston, and Martin 
Kafina from Barry Paw’s Lab at Harvard Medical School. Portions of this chapter have been 
adapted from Grillo et al., Restored iron transport by a small molecule promotes absorption and 
hemoglobinization in animals, Science, 2017, 356, 608-616 and Yien et al., Target of 
erythropoietin, Fam210b, regulates erythroid hemoglobinization, submitted. 
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3.1 DEFICIENCIES OF PROTEIN FUNCTION IN IRON-RELATED DISEASES 
 Site- and direction-selective transmembrane iron transport is achieved in mammalian 
systems through the concerted functions of active ion-transport proteins that generate localized 
electrochemical gradients and the passive ion-transport proteins that use them (Figure 3.1).1 For 
example, sodium-potassium ATPase (Na+/K+ATPase) uses the energy from ATP hydrolysis to 
pump sodium outside the cell, which is then used to create a favorable proton gradient in the gut 
through the sodium-hydrogen exchanger 1 (NHE1) before duodenal non-heme iron absorption 
occurs. Deficiencies of these passive ion-transport proteins cause many diseases, including 
anemias, neurodegenerative disorders, and hemochromatosis.2 Because the corresponding active 
ion-transport proteins typically remain functional, there may be a buildup of ion gradients 
upstream of the membranes that normally host these missing proteins (Figure 3.1). Noting the 
capacity for these robust networks to achieve ion-selective transport despite the unselective nature 
of many ion-transport proteins,1,3 we hypothesized small molecules capable of autonomously 
Figure 3.1 A build-up of iron gradients may selectively occur in iron-transport protein deficiencies. 
 94 
performing ion transport could leverage such gradients to restore transmembrane ion flux in a site- 
and direction-selective manner (Figure 3.1).4 
 Iron homeostasis, in particular, is maintained by dynamic networks of active and passive 
iron-transport proteins, chaperones, and their regulators that permit essential use while minimizing 
toxicity of this redox-active metal.3 No known regulatory mechanisms of iron excretion exist,5 and 
system iron levels are thus primarily controlled through rigorous regulation of dietary iron 
absorption.3,5 Deficiencies or dysfunction of proteins involved in iron transport, homeostasis, or 
metabolism often impede the movement of iron into, within, and/or out of cells and are associated 
with more than 25 Mendelian diseases.2,5-7 We asked whether a small molecule iron transporter 
could leverage transmembrane gradients of the labile iron pool3 that selectively build up in such 
situations to restore the movement of iron into, within, and/or out of cells and thereby enable its 
use in endogenous iron-dependent physiological processes (Figure 3.2).  
Figure 3.2 Hinokitiol may leverage built-up gradients to restore the site- and direction-selective transport of 
iron into, within, and/or out of cells missing diverse iron-transport proteins. 
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 We specifically chose to study three disease-relevant iron-transporter deficiencies that 
disrupt iron movement in different directions, cellular locations, and tissues.3,5 Deficiencies of 
divalent metal transporter 1 (DMT1, also known as NRAMP2, DCT1, or SLC11A2) normally 
located in the luminal membrane of the microvilli in proximal duodenal villous enterocytes, 
reduces the gut absorption of dietary non-heme iron (Figure 3.3A).3 DMT1 is also located on the 
endosomal membrane of developing red blood cell (RBC) progenitors, where it plays an essential 
role in hemoglobinization through endosomal iron release, and increasing evidence suggests it 
plays a critical role in the uptake of iron into mitochondria (Figure 3.3B).5 A deficiency of DMT1 
causes severe hypochromic, microcytic anemia by precluding gut iron absorption, 
Figure 3.3 Simplified schematics for role of iron transport proteins in humans. (A) Dietary non-heme iron 
absorption occurs in duodenal enterocytes. This process is highly regulated to prevent iron overload, with iron-
dependent regulation (via IRP and HIF2α) of the iron uptake protein DMT1, the iron storage protein ferritin, and the 
iron efflux protein FPN1. (B) Transferrin-mediated endocytosis in red blood cell progenitors leads to the uptake of 
iron in endosomes, which is released via DMT1 for utilization in mitochondria for iron incorporation into heme. (C) 
MFRN1 is responsible for bringing in iron into the mitochondrial matrix through the inner mitochondrial membrane. 
(D) FPN1 promotes the efflux of iron from macrophages into the blood to recycle iron from senescent red blood cells. 
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hemoglobinization, and RBC differentiation. Mitoferrin (MFRN1, also known as SLC25A37) 
deficiencies in the inner mitochondrial membrane impair iron import into the mitochondrial matrix 
thus preventing hemoglobinization during erythropoiesis and causing hypochromic anemia 
(Figure 3.3C).8,9 Ferroportin (FPN1, also known as IREG1, MTP1, or SLC40A1) deficiencies 
cause hemochromatosis type IV by reducing iron efflux into the blood from gut epithelium, and 
from reticuloendothelial macrophages responsible for the recycling of iron from senescent RBCs 
(Figure 3.3A, D).10-12 We thus asked whether hinokitiol could promote iron movement into, within, 
and/or out of cells and animals deficient in DMT1, MFRN1, or FPN1 and thereby restore gut iron 
absorption and hemoglobinization. 
 
3.2 RESTORED IRON TRANSPORT IN DMT1-DEFICIENT CACO-2 GUT EPITHELIA 
 We first studied iron uptake and transepithelial transport in differentiated DMT1-deficient 
Caco-2 gut epithelia monolayers.13,14 These originated from human colorectal adenocarcinoma 
cells and undergo spontaneous enterocytic polarization and differentiation into epithelia 
monolayers. Caco-2 cells are widely used as the leading model for the study of differentiated 
human enterocytes in the small intestines and to predict the absorption of drugs and nutrients in 
the gut, making them an excellent model to first test our hypothesis that hinokitiol can restore the 
absorption of dietary iron.15-17 DMT1-deficient Caco-2 gut epithelia cell lines were established 
through stable short hairpin RNA (shRNA) transfection using lipofectamine and G418 selection. 
These cells exhibited reduced levels of Dmt1 mRNA and DMT1 protein by qRT-PCR and western 
blotting analysis, respectively (Figure 3.4A-C). 
  Cells were simultaneously grown to produce polarized and fully differentiated gut epithelia 
monolayers. Relative to wild-type controls, DMT1-deficient monolayers exhibited reduced iron 
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uptake into cells and ~90% reduced transepithelial iron transport to the basolateral fluid after apical 
addition of 55FeCl3 radiotracer (Figure 3.5A, B). Apical addition of hinokitiol (500 nM) restored 
both uptake and transport in time frames commensurate with dwell times in the gut, while the 
inactive derivative C2deOHino had no observable effects (Figure 3.5A-C). Hinokitiol-promoted 
iron transport occurs at both low and high iron concentrations. Mammals commonly acquire ~5-
10% of their daily intake of dietary iron. This was observed in normal gut epithelia, while DMT1-
deficient epithelia exhibited reduced levels. Hinokitiol treatment restored absorption back to 
normal levels (Figure 3.5D). Further, hinokitiol did not disrupt monolayer integrity by TEER 
analysis, caused no observable toxicity, and did not affect basal DMT1 expression (Figure 3.4B, 
C and Figure 3.5E). Hinokitiol-mediated transport occurred across a range of pHs found 
throughout the duodenum and increased with decreasing pH (Figure 3.5F).   
 While hinokitiol promoted uptake and transport over a wide range of concentrations, 
C2deOHino and subtoxic concentrations of the water-soluble iron chelators deferiprone, 
deferoxamine, PIH, and SIH did not promote both uptake and transport (Figure 3.5G, H). High 
concentrations of these more hydrophilic iron chelators instead decreased iron uptake into DMT1-
deficient monolayers. In permeability assays using analytical HPLC, hinokitiol is estimated to be 
moderately to highly membrane permeable with an A→B (apical to basolateral) apparent 
Figure 3.4 Development of DMT1-deficient Caco-2 monolayers. (A-C) A polyclonal DMT1 cell line established 
by shRNA transfection exhibits reduced (A) Dmt1 mRNA by qRT-PCR (normalized to actin) and (B and C) DMT1 
protein by western blotting after differentiation into polarized monolayers. Hinokitiol treatment did not effect DMT1 
protein levels. 
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permeability coefficient (Papp) of 18.00 ± 1.15 and a B→A Papp of 12.10 ± 1.17 s
-1cm-2. Consistent 
with this reversible permeability, basolateral addition of hinokitiol restores normal transport of 
apical 55Fe to the basolateral fluid of DMT1-deficient monolayers. 
Figure 3.5 Restored iron uptake and transport in DMT1-deficient Caco-2 monolayers. (A-C) Apical addition of 
hinokitiol (500 nM) restores (A) iron uptake into and (B) transepithelial iron transport across DMT1-deficient Caco-
2 monolayers on (C) time frames commensurate with dwell times in the gut. (D) Hinokitiol restores relative iron 
transport. (E) Hinokitiol treatment did not affect the monolayer integrity as determined by the transepithelial electric 
resistance. (F) Hinokitiol promotes transport across a range of pHs. (G and H) In contrast to hinokitiol, the iron 
chelators deferiprone, PIH, SIH, and deferoxamine (DFO) do not simultaneously restore (G) uptake into or (H) 
transcellular transport across DMT1-deficient Caco-2 monolayers. While a slight increase in transport was observed 
in SIH treated cells, reduced uptake was observed, consistent with paracellular, and not transcellular, iron transport. 
Concentrations used for each small molecule were 0, 0.01, 0.1, 1, and 10 µM. 
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3.3 RESTORED HEMOGLOBINIZATION IN DMT1-DEFICIENT MEL CELLS 
 Humans are composed of 3-5 grams of iron, making it the most abundant transition metal 
in the body.18,19 Almost 70% of this iron is used by erythroid cells to synthesize hemoglobin during 
erythropoiesis (Figure 3.6).20 During erythroid progenitor differentiation, iron is mainly obtained 
through the transferrin receptor (TfR)-mediated pathway (Figure 3.6).3 After duodenal iron 
absorption of dietary iron, through which humans acquires ~1-2 mg daily, each apotransferrin 
molecule binds two Fe3+ ions in the plasma (Figure 3.6). Holo-transferrin then interacts with TfR 
on the cell surface of erythroid progenitors in the bone marrow. This complex is internalized via 
clathrin-mediated endocytosis. In late endosomes,21 DMT1 is critical in the maturation of these 
RBC progenitors through the efflux of ferrous iron after V-ATPase-mediated acidification and 
STEAP3 promoted reduction of iron (II) (Figure 3.3B).5 After cytosolic release from the late 
endosome, iron is then shuttled into the intermembrane space by promiscuous ion-transport 
proteins, and is finally imported into the mitochondrial matrix via mitoferrin-1 (MFRN1) where it 
Figure 3.6 Body iron stores and the transferrin cycle. No known mechanisms of regulating iron excretion exist, 
and thus iron homeostasis is exquisitely maintained. Absorption of dietary iron occurs in the duodenum. Serum iron 
associates with apotransferrin, is recognized for endocytosis in erythroblasts during erythropoiesis, and is incorporated 
into hemoglobin in RBCs. The iron in senescent RBCs is recycled in reticuloendothelial macrophages, and re-utilized. 
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is utilized in heme synthesis (Figure 3.3C) and incorporated into hemoglobin in RBCs (Figure 
3.6). 
 DMT1-deficient erythroblasts cannot differentiate properly, leading to reduced 
hemoglobin expression, decreased RBC counts, and other pathophysiological markers in animal 
models and patients with the disease.22-25 Previous results suggested the small molecule iron 
chelators PIH, deferiprone, and 2,2’-dipyridyl could cause iron redistribution in mouse, rat, and/or 
human erythrocyte progenitors, however, these studies required extraordinarily high 
concentrations of iron (often ≥ 100 µM).26-28 Additionally, we demonstrated in Chapter 2 that these 
compounds were relatively incapable of restoring fet3Δftr1Δ yeast cell growth and transepithelial 
iron transport and thus were not further explored. Nevertheless, these studies led us to hypothesize 
that hinokitiol could similarly restore iron distribution, and as a result normal physiology, in a 
model for erythroid maturation. 
 In collaboration with the Kim Group (Northeastern), we first repeated these studies in 
isolated primary reticulocytes from DMT1-deficient Belgrade (b/b) and healthy (+/b) rats after 
phenylhydrazine treatment to induce reticulocytosis. Incubation of b/b and +/b reticulocytes in 
plasma isolated from healthy rats and spiked with 59Fe-transferrin was used to assess the capacity 
for hinokitiol to promote proper iron utilization. Consistent with transferrin-mediated uptake, total 
cellular levels of 59Fe uptake did not change upon hinokitiol treatment after one hour. Strikingly, 
Figure 3.7 Restored incorporation of iron into heme in DMT1-deficient primary murine reticulocytes ex vivo. 
Hinokitiol treatment (black bars) increased 59Fe incorporation into heme in DMT1-deficient reticulocytes isolated 
from Belgrade (b/b) rats carrying a G185R genetic mutation in DMT1 and exhibiting microcytic anemia, while 
C2deOHino (white bars) did not. N=4-8 rats. 
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hinokitiol (1 µM) increased 59Fe incorporation into heme ex vivo in a dose-dependent fashion after 
heme extraction and gamma counting at concentrations that do not cause hemolysis (Figure 3.7). 
Higher concentrations of hinokitiol (≥ 100 µM) led to hemolysis of these RBCs. C2deOHino, 
which cannot bind or transport iron, did not produce this effect. 
 To gain a better fundamental understanding of this phenomenon, we tested for DMSO-
induced differentiation and hemoglobinization in DS19 murine erythroleukemia (MEL) cells and 
shRNA transfected DMT1-deficient MEL cells in the absence or presence of hinokitiol. MEL cells 
have been used as a leading model to study adult erythroblast differentiation and synchronously 
differentiate into erythrocytes after induction with 2% DMSO over three days leading to increased 
iron uptake and globin expression.29,30 We thus developed three different polyclonal DMT1-
deficient cell lines and non-targeting controls through stable shRNA transfection and selection 
with G418 over 2 weeks. DMT1 deficiencies were validated through qRT-PCR, western blotting, 
and phenotypic assays (Figure 3.8A-C). Decreased levels of DMT1 protein in Clone 3 (shDMT1 
3) was determined to be a result of a growth defect leading to reduced rates of differentiation, and 
not due to effective gene silencing of DMT1. 
 The non-targeting control MEL cell lines differentiated normally after induction with 2% 
DMSO for 72 hours as indicated by the characteristic pink color of hemoglobin in cell pellets and 
Figure 3.8 Generation of DMT1-deficient MEL cells through shRNA transfection. (A-C) DMT1-silencing by 
shRNA transfection of DS19 MEL cells led to the development of three distinct polyclonal cell lines (shDMT1 1, 2, 
and 4) that exhibited reduced (A) Dmt1 mRNA levels by qRT-PCR and (B, C) DMT1 protein levels by western 
blotting. 
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brown staining of hemoglobinized cells after o-dianisidine treatment (Figure 3.9A-D). 
Differentiation was further quantified by analysis of stained and unstained cells with ImageJ  
(Figure 3.10A). Reduced hemoglobinization was observed in DMT1-deficient cells. Three days of 
hinokitiol treatment (1 µM) in the presence of iron-citrate (10 µM) restored proper differentiation 
and the production of hemoglobin without observable toxicity in a time- and dose-dependent 
fashion, whereas C2deOHino had no effect (Figure 3.10B-D). As expected, no differentiation was 
Figure 3.9 Restored differentiation in DMT1-deficient MEL cells. (A) After induction with 2% DMSO and 
incubation for 3 days, cell pellets from shControl and hinokitiol (1 µM) treated DMT-deficient MEL cells appear 
pink, characteristic of hemoglobin, whereas DMT1-deficient cell pellets do not. (B) Dianisidine is used as a stain for 
hemoglobinized cells, in which heme and H2O2 oxidize dianisidine to form a dark orange/brown stained cell. (C and 
D) Hinokitiol (1 µM) visually restores differentiation as evidenced by staining of hemoglobinized cells brown with 
o-dianisidine. Wild-type and hinokitiol-treated DMT1-deficient cells appear smaller and stop growing as terminal 
differentiation occurs. 
Figure 3.10 Quantification of restored differentiation in DMT1-deficient MEL cells. (A-C) ImageJ quantification 
of MEL cells stained brown with dianisidine. (D) Three days of hinokitiol (1 µM) treatment to induced shDMT1 MEL 
cells did not decrease MEL cell counts. (E) No differentiation was observed in hinokitiol (1 µM) treated MEL cells 
without DMSO induction. 
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observed in the absence of DMSO, with or without hinokitiol treatment (Figure 3.10E). Hinokitiol 
treatment restored proper cell morphology, with smaller cells being observed in both wild-type 
and hinokitiol-treated DMT1-deficient MEL cells differentiating to become RBC progenitors. 
 As a further readout of differentiation, 55Fe uptake and incorporation into heme was 
determined. After DMSO induction of control cells, an increase in 55Fe uptake was observed 72 
hpi while the DMT1-deficient cells in the presence and absence of C2deOHino did not produce 
this effect (Figure 3.11A). However, upon addition of hinokitiol, restoration of 55Fe uptake was 
observed (Figure 3.11A). 55Fe-heme was isolated through organic extraction and quantified. The 
DMT1-deficient cells were unable to incorporate 55Fe into heme relative to control cells, however, 
hinokitiol restored the capacity for 55Fe-heme incorporation (Figure 3.11B). Western blotting of 
globin protein and quantification of hemoglobin UV absorption at 414 nm indicated hinokitiol 
Figure 3.11 Restored hemoglobinization in DMT1-deficient MEL cells. (A) 55Fe uptake into hinokitiol-rescued 
DMT1-deficient MEL cells is restored. (B) Hinokitiol (1 µM) treatment restores the incorporation of 55Fe into heme 
in DMT1-deficient MEL cells. (C) Hinokitiol treatment increased globin production after DMSO induction. (D) 
Increased levels of hemoglobin were observed by quantifying the UV-vis absorbance of hemoglobin at 414 nm. 
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treatment restored normal globin synthesis, consistent with proper differentiation of these DMT1-
deficient MEL cells (Figure 3.11C, D). 
 
3.4 RESTORED PHYSIOLOGY IN MFRN1- AND FPN1-DEFICIENT CELLS 
 Having observed hinokitiol-mediated transport of iron into and within DMT1-deficient 
cells, we asked whether the same small molecule could also substitute for other iron-transport 
proteins to promote the transport of iron into mitochondria and out of cells. MFRN1 in the inner 
mitochondrial membrane imports iron into the mitochondrial matrix for hemoglobinization.3,8 
MFRN1-deficient MEL cells developed through CRISPR-Cas9-mediated knockout exhibited 
reduced hemoglobinization by o-dianisidine staining, 55Fe uptake, and 55Fe incorporation into 
heme after DMSO induction (Figure 3.12A-D). Hinokitiol (1 µM) restored hemoglobinization, 
whereas C2deOHino had no effect, suggesting hinokitiol-mediated mitochondrial delivery of iron 
(Figure 3.12A-D).  
 During erythropoiesis, an ensemble of proteins involved in porphyrin biosynthesis and iron 
transport work in concert both inside and outside of mitochondria to correctly incorporate iron into 
a porphyrin to make heme.20 Protoporphyrin IX, which becomes heme after iron incorporation, is 
Figure 3.12 Restored hemoglobinization in MFRN1-deficient MEL cells. (A) Two MFRN1 KD monoclonal cell 
lines were developed through CRISPR-Cas9 gene editing. (B) Hinokitiol (1 µM) treatment for 3 days to DMSO 
induced MFRN1-deficient MEL cells restored differentiation as indicated by positive staining of hemoglobinized cells 
with o-dianisidine. (C and D) Hinokitiol treatment restored both 55Fe (C) uptake and (D) incorporation into heme. 
 105 
synthesized in many steps that occur both inside and outside of the mitochondrial matrix. In 
addition to the proteins involved in biosynthesis, many proteins, such as TMEM14C,31 are 
involved in the transport of these porphyrin precursors across mitochondrial membranes. 
TMEM14C promotes the uptake of protoporphyrinogen IX into the mitochondrial matrix, which 
is oxidized to protoporphyrin IX (PPIX) and complexes with ferrous iron via ferrochelatase (FCH) 
to form heme (Figure 3.13A).31 A deficiency of TMEM14C precludes the synthesis of 
protoporphyin IX and leads to the accumulation of porphyrin precursors and decreased 
differentiation in MEL cells, while the network of iron transport proteins remains functional. Many 
proteins remain unknown, and the determination of the role of newly discovered proteins involved 
in erythropoiesis is often difficult as it is challenging to differentiate those involved in porphyrin 
biosynthesis and iron transport using traditional biochemical or genetic techniques. We 
Figure 3.13 The use of hinokitiol as a chemical probe. (A) Several proteins are required during erythropoiesis. For 
example, PPgenIX is taken into the mitochondrial matrix by TMEM14C, upon which it is simultaneously oxidized 
by protoporphyrin III-oxidase (PPOX), upon which iron that is transported by MFRN1 is incorporated by 
ferrochelatase (FECH). (B-D) As expected, hinokitiol treatment to DMSO-induced TMEM14CΔ MEL cells was 
unable to restore (B) dianisidine staining, (C) 55Fe uptake and (D) 55Fe-heme incorporation. (E) Hinokitiol (1 µM) 
restored hemoglobinization in FAM210B-deficient MEL cells, indicating that it plays a critical role in iron transport. 
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hypothesized hinokitiol may be a useful probe to distinguish between defects in porphyrin 
biosynthesis or iron transport, as it can only correct defects in iron transport.  
 To first test this, we attempted to restore hemoglobinization to cells alternatively deficient 
in a protein involved in porphyrin biosynthesis (TMEM14CΔ).31 As expected, hinokitiol was 
unable to restore hemoglobinization, 55Fe uptake, or 55Fe-heme incorporation into this cells over a 
wide range of concentrations (Figure 3.13B-D). We thus used hinokitiol as a chemical probe to 
help determine the previously unknown role of FAM210B in terminal erythropoiesis. Fam210b-/- 
MEL cells developed through shRNA transfection were functionally complemented by 3 days of 
hinokitiol treatment, while C2deOHino had no effect (Figure 3.13E). These initial results 
demonstrated that the primary role of FAM210B in the developing erythroid is to facilitate 
mitochondrial delivery of iron. Extensive additional studies by the Paw Lab at Harvard Medical 
School strongly supported that FAM210B is not an iron transport protein per se, but it mediates 
mitochondrial iron import and heme synthesis by facilitating co-localization of MFRN1 and the 
Figure 3.14 Hinokitiol restores iron transport in FPN1-deficient Caco-2 monolayers. (A and B) Incubation with 
quercetin to wild-type Caco-2 monolayers for 18 hours decreased FPN1 levels. (C) Hinokitiol (1 µM) treatment 
restored the transport of iron across FPN1-deficient Caco-2 monolayers (D) without affecting iron uptake in a (E) 
time-dependent fashion. (F) Hinokitiol did not disrupt Caco-2 monolayer integrity. 
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terminal heme-synthesis enzymes protoporphyin III-oxidase (PPOX) and ferrochelatase (FECH) 
(Figure 3.13A).32 
 We finally tested the capacity for hinokitiol to promote the movement of iron out of cells 
in FPN1 deficiencies. Deficiencies of this iron transporter reduces iron efflux across the basolateral 
membrane of gut epithelia and from reticuloendothelial macrophages that recycle iron from 
senescent erythrocytes (Figure 3.2A, D).11,33-35 FPN1 deficiencies are responsible for the genetic 
disease hemochromatosis type IV, which leads to hypoferremia with macrophage iron loading.36 
Quercetin37 and hepcidin35 were used to transiently decrease FPN1 levels in differentiated Caco-2 
epithelia monolayers and J774 macrophages, respectively (Figure 3.14A, B and Figure 3.15A, B). 
Basolateral addition of hinokitiol (1 µM) and 55Fe radiotracer restored transepithelial iron transport 
across FPN1-deficient Caco-2 monolayers without affecting iron uptake or disrupting monolayer 
integrity (Figure 3.14C-F). Hinokitiol also time- and dose-dependently restored iron release from 
FPN1-deficient J774 macrophages without observable toxicity (Figure 3.15C-E). 
 
3.5 RESTORED GUT IRON ABSORPTION AND HEMOGLOBINIZATION IN ANIMALS 
 We were thus encouraged to ask whether hinokitiol could restore gut iron absorption and 
hemoglobinization in animal models of these iron transporter deficiencies. DMT1- and FPN1-
deficiencies in duodenal enterocytes reduce rates of iron absorption in the gut by disrupting apical 
Figure 3.15 Restored iron release from J774 macrophages. (A and B) Hepcidin was used to knockdown FPN1 in 
J774 macrophages. (C) Hinokitiol (5 µM) treatment promoted the release of 55Fe from FPN1-deficient J774 
macrophages in a (D) time- and (E) dose-dependent manner without observable toxicity. 
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iron uptake into cells and basolateral efflux into the blood, respectively.3,5,10,38-40 In collaboration 
with the Kim (Northeastern) and Wessling-Resnick (Harvard) labs, we tested gut iron absorption 
in DMT1-deficient Belgrade (b/b) rats5 and FPN1-deficient Flatiron (ffe/+) mice33,38-40 upon 
administration of a single dose of 59Fe and 1.5 mg/kg hinokitiol via oral gavage. Higher doses of 
hinokitiol are reported to be non-toxic in rats upon chronic oral administration for two years.41,42 
Figure 3.16 Restored gut iron absorption in DMT1-deficient rats. (A) Hinokitiol (1.5 mg/kg) via oral gavage 
restores the absorption of 59Fe into the blood of Belgrade (b/b) rats after one hour. (B) Time course of 59Fe absorption. 
(C) Biodistribution of 59Fe in rats after treatment with vehicle, hinokitiol (1.5 mg/kg), or C2deOHino (1.5 mg/kg) for 
four hours. 
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Similar to the reduced iron absorption previously reported in b/b rats,22 a two-fold reduction in 
59Fe absorption was observed in C2deOHino-treated b/b rats relative to sibling controls (+/+ or 
+/b) after one hour (Figure 3.16A). Treatment of b/b rats with hinokitiol increased 59Fe absorption 
back to control levels after one hour (Figure 3.16A, B). We further evaluated the biodistribution 
of 59Fe in these b/b rats after four hours of hinokitiol treatment via oral gavage (Figure 3.16C). 
These rats unexpectedly die due to sudden kidney failure or anemia,22 however, hinokitiol 
encouragingly increased iron levels in the kidney and femur. Consistent with our previous results,40 
ffe/+ mice also absorbed iron at low rates (Figure 3.17A-C). Hinokitiol increased 59Fe absorption 
in ffe/+ mice after both one and two hours (Figure 3.17A-C).  
 We have previously shown restoration of hemoglobinization in Mfrn1-deficient zebrafish, 
via ectopic expression of Mfrn1 protein with complementary RNA.8 Danio rerio is well 
established as a powerful model organism in the study of hematopoiesis,43-46 and was employed to 
alternatively test whether chronic treatment with a small molecule iron transporter could restore 
hemoglobinization in DMT1- and Mfrn1-deficiencies.8,47 We first performed morpholino-
mediated transient knockdown of DMT1 in a Tg(globinLCR:eGFP) zebrafish strain expressing 
GFP-tagged RBCs.48 Injection of a designed anti-sense morpholino targeting the exon 4/intron 4 
junction of premature Dmt1 mRNA in fertilized zebrafish embryos reduced steady-state Dmt1 
Figure 3.17 Restored gut iron absorption in FPN1-deficient mice. (A and B) Hinokitiol (1.5 mg/kg) via oral gavage 
increased the absorption of 59Fe into the blood of FPN1-deficient flatiron (ffe/+) mice after (A) one and (B) two hours 
relative to vehicle-treated mice. (C) Time course of the absorption of 59Fe in FPN1-deficient mice. 
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levels and decreased the number of GFP-positive erythroids by FACS analysis (Figure 3.18A, B). 
Addition of hinokitiol to the water twenty-four hours post fertilization (hpf) and incubation for an 
additional two days reversed the anemia by promoting hemoglobinization and the production of 
RBCs in these DMT1-deficient morphant zebrafish without observable toxicity, whereas 
C2deOHino had no effect (Figure 3.18B).  
 We further tested whether hinokitiol could similarly restore hemoglobinization in 
genetically mutated Chardonnay  (cdyte216) zebrafish, which contain a nonsense mutation leading 
to truncated DMT1 and thereby exhibit severe hypochromic, microcytic anemia.47 A heterozygous 
cross of +/cdy fish led to a Mendelian distribution of ~75% healthy (+/+ and +/cdy) and ~25% 
anemic (cdy/cdy) embryos in each clutch after o-dianisidine staining 72 hpf (Figure 3.18C, D). 
Figure 3.18 Restored hemoglobinization in DMT1-deficient zebrafish embryos. (A) Injection of a morpholino 
targeting the exon/intron 4 junction of Dmt1 reduced steady state levels of mRNA. (B) Hinokitiol (1 µM) treatment 
via the water of DMT1-deficient morphants increased the production of red blood cells as determined by the number 
of GFP+ cells by FACS analysis. (C) Schematic for the heterozygous cross of chardonnay zebrafish. (D) Hinokitiol 
(1 µM) treatment via the water of a heterozygous cross of chardonnay zebra fish reduced the number of anemic fish 
as determined by dianisidine staining. (E) As expected, hinokitiol could not promote hemoglobinization in zebra fish 
embryos from a heterozygous cross of sauternes (+/sau) fish, deficient in an enzyme involved in porphyrin 
biosynthesis (Alas2). 
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Hinokitiol treatment 24 hpf for two days increased the number of fish exhibiting high hemoglobin 
levels, whereas C2deOHino had no effect. As expected, hinokitiol did not rescue sauternes 
(sautb223) zebrafish deficient in the initial enzyme involved in porphyrin biosynthesis (Alas2),49 
indicating the specificity of rescue to defects in iron transport (Figure 3.18E). 
 We also tested hemoglobinization in Mfrn1-deficient morphant Tg(globinLCR:eGFP) 
zebrafish.8,48 Forty-eight hours of hinokitiol treatment again restored hemoglobinization and the 
number of GFP-positive erythrocytes in these morphants (Figure 3.19A). Finally, we tested 
whether hinokitiol could restore hemoglobinization in genetically mutated Frascati (frstq223) 
zebrafish,8 which contain a missense mutation leading to an inactive Mfrn1 mitochondrial protein 
Figure 3.19 Restored hemoglobinization in MFRN1-deficient zebrafish. (A) MFRN1-deficient morphant embryos 
exhibited reduced red blood cell production. Hinokitiol (1 µM) treatment via the water restored the production of red 
blood cells, reversing the anemic disease phenotype. (B) Hinokitiol similarly reversed anemia in zebrafish embryos 
from a heterozygous cross of frascati zebrafish. (C) Genotyping of embryos resulting from a heterozygous cross of 
frascati zebra fish. (D) Wild type and heterozygous embryos produce many hemoglobinized cells by dianisidine 
staining (brown color), while MFRN1-deficient frs/frs zebra fish do not. Hinokitiol treatment restored positive 
dianisidine staining, and therefore hemoglobinization, to these genotyped mutant zebra fish. 
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and profound anemia during embryogenesis. Hinokitiol treatment of embryos collected from a 
heterozygous cross of +/frs fish rescued the anemic phenotype (Figure 3.19B). Genotyped healthy 
larvae (+/+ and +/frs) exhibit brown staining with o-dianisidine, whereas untreated frs/frs fish do 
not (Figure 3.19C, D). Hinokitiol treatment restored brown staining to frs/frs fish.  
 In this chapter, we have demonstrated the capacity for hinokitiol to restore absorption 
and/or hemoglobinization in cells and animals missing one of three different iron transport proteins 
normally responsible for the movement of iron in different directions and locations. This suggests 
an underlying mechanistic phenomenon is enabling the site- and direction-selective transport of 
iron by a small molecule that passively transports iron. 
 
3.6 METHODS 
Cell lines and growth conditions 
 Human Caco-2 cells (HTB-37) and mouse macrophages (J774A.1) were obtained from 
ATCC and cultured with DMEM (Gibco 10313-021) containing 10% HI FBS (Gibco 16000-036), 
4 mM glutamine (Lonza BE17-605E), 100 µg/mL PEN-STREP (Lonza DE17-602E), and 1% 
MEM NEAA (Fisher 11140-050). Transfected Caco-2 cell lines were maintained on this media 
containing 800 mg/L G418 (Santa Cruz sc-29065B). Friend mouse erythroleukemia cells (MEL, 
DS19 subclone) were obtained from Arthur Skoultchi (Albert Einstein College of Medicine, 
Bronx, NY) and cultured with DMEM containing 10% HI FBS, 2 mM glutamine, 100 µg/mL 
PEN-STREP, and 1% MEM NEAA. Transfected shControl and shDMT1 MEL cell lines were 
maintained on this media containing 1 g/L G418. 
 Caco-2 cells (passage 18-50) were grown in T75 flasks to ≥90% confluency before 
trypsinization with 0.25% trypsin-EDTA (Fisher 25200-056) and passaging at 10:1 dilution in 
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Caco-2 media without (wild type) or with G418 (transfected). Monolayers were grown by seeding 
Caco-2 cells (passage 20-50) onto 0.4 µm PET cell culture inserts (Fisher 08-771) in 6-well 
companion plates (Fisher 08-771-24) at 2x105 cells/well and allowed to fully differentiate for 21-
28 days before experiments were performed with changing of media every 3-4 days. 
 MEL cells were grown in suspension in T25 flasks until ~1x106 cells/mL and re-seeding 
into a new T25 flask at 1x105 cells/mL in MEL Complete media with or without G418. Every 
month of culturing, new backstocks of MEL cells were used. 
 J774 cells (passage 20-80) were grown in T25 flasks to ≥90% confluency before scraping 
and re-seeding at 5:1 dilution in J774 Complete media. Media was changed every 1-2 days. 
 
Animals and animal care 
 The studies performed were in strict accordance with the guidance and recommendations 
outlined in the Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health.  
 The protocols used for studies in healthy (+/+) and Flatiron (ffe/+) mice were approved 
by the Harvard Medical Animal Care and Use Committee. Breeding, diets, and genotyping of 
flatiron mice were performed as previously described.38  
 All zebrafish experiments were performed in accordance with the Institutional Animal Care 
and Use Committee regulations. The following wild type AB strains and zebrafish mutant strains 
were used: frascati (frstq223),8 chardonnay (cdyte216),47 and sauternes (sautb223).49 
 The protocols for studies in Belgrade (+/+, +/b, or b/b) rats were approved by the Division 
of Laboratory Animal Medicine (DLAM) and the Northeastern University-Institutional Animal 
Care and Use Committee (NU-IACUC). Breeders of heterozygous (+/b) and homozygous (b/b) 
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Belgrade rats (Fischer F344 background) were kindly provided by Dr. Michael Garrick (SUNY 
Buffalo) and maintained on a 12:12-hr light/dark cycle and given water and facility chow ad 
libitum. Prior to 59Fe gut iron absorption experiments, a variety of preliminary studies were 
performed on cohorts of Belgrade rats (ranging from 3-5 months old) during which the rats were 
treated with vehicle or various compounds for ≤ 15 weeks in iron-supplemented diet containing 
500 mg/kg iron (TD.02385, Harlan Teklad, Madison, WI). All rats were allowed to be drug-free 
and continued to receive iron-supplemented diet for at least one week before 59Fe gut absorption 
experiments were performed. 
 
Statistics 
 All data depicts the means or weighted mean ± SEM with a minimum of 3 biological 
replicates unless otherwise noted. Statistical analysis represents P values obtained from student t-
test or one- or two-way analysis of variance (ANOVA) with post-hoc TUKEY test where 
appropriate. NS, not significant; * P < 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001 unless 
otherwise noted. 
 
Transfection of Caco-2 cells and MEL cells against DMT1 
 Caco-2 cells were transfected as previously reported13 using lipofectamine LTX 
(Invitrogen 15338-100) and Plus reagent (Invitrogen 11514-015) with 10 µg/well of either non-
targeting control shRNA or four other shRNA constructs targeting human DMT1 (Qiagen 
KH05760N) 24 hours after seeding 2x105 cells/well in 6-well plates (~30% confluent). The 
transfection agents were removed, and the cells were allowed to recover for 24 hours before 
treatment with Caco-2 Complete media containing 0.8 g/L G418. Cells were incubated in G418 
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media for ~2 weeks to promote selection of transfected cells while complete cell death was 
observed with non-transfected cells. Non-targeting control construct = 5’-
GGAATCTCATTCGATGCATAC-3’; shDMT1 construct (Clone 4) = 5’-
AACCTATTCTGGCCAGTTTGT-3’. 
 MEL cells were transfected by electroporation (0.28 kV, 975 µF pulse) in 0.4 cm cuvette 
(Biorad 1652081) containing 400 µL of serum-free DMEM with 30 mM NaCl at 2x107 cells/mL 
with 50 µg of either non-targeting control shRNA (Sigma, 5’-
CAACAAGATGAAGAGCACCAA-3’ using a CMV-neo vector) or five shRNA constructs 
targeting mouse DMT1 (Sigma, Clone 1-5: TRCN0000332748, TRCN0000306610, 
TRCN0000079533, TRCN0000079535, and TRCN0000079536). After transfection, cells were 
transferred to T25 flasks containing 10 mL of MEL Complete media, and allowed to grow for 6 
days with re-seeding every 2 days at 10:1 dilution in fresh MEL Complete media. After this, cells 
were re-seeded at 1x105 cells/mL in MEL Complete media containing 1 g/L G418, and cells were 
selected over the course of 2 weeks by re-seeding at 10:1 dilution into fresh G418 media every ~2 
days until no cells were observed in T25 flasks originally containing non-electroporated wild type 
(DS19) MEL cells.  
 Mfrn1-deficient MEL cell lines were developed using CRISPR/Cas9 genome editing as 
previously described.31, 50, 51 Exons 2 and 4 of the Mfrn1 locus were targeted. The exon 2 targeting 
sequence was: 5’-GATGCTTGTATACCGGGCTT-3’; the exon 4 targeting sequence was: 5’-
GAAGAACTCATAAACGGACC-3’. The primers used for documenting intragenic deletion of 
the Mfrn1 mouse locus were the following: Exon 4 (Fwd) 5’-GTTTGCCTCTGCGGTGTGATC-




 Dmt1 mRNA levels were determined via qRT-PCR using SYBR Green (Agilent 600825) 
following manufacturer protocols after undergoing treatment as described below. For 
determination of Dmt1 mRNA levels in differentiated Caco-2 monolayers (21-28 days post 
seeding), mRNA was isolated using RNeasy Mini Kit (Qiagen 74104) according to manufacturer 
instructions. The threshold cycle (Ct) values of Dmt1 were normalized to internal control actin 
using primers against Dmt1 (Origene HP200584) and actin (Origene HP204660) using the Pfaffl 
Method and were then normalized to shControl levels.  
 For determination of relative Dmt1 mRNA levels in MEL clones, mRNA was isolated from 
MEL clones differentiated with 2% DMSO and 10 µM iron (III) citrate for 3 days using RNeasy 
Mini Kit (Qiagen 74104) according to manufacturer instructions. The Ct values of Dmt1 were 
normalized to internal control Hprt1 using primers against Dmt1 (Origene MP215650) and Hprt1 
(Origene MP206455) using the Pfaffl Method and were then normalized to shControl levels.  
 Fpn1 and Fth1 mRNA levels in shDMT1 Caco-2 monolayers upon treatment with 25 µM 
FeCl3 and increasing hinokitiol concentrations (0, 0.5, 1, 3, 5, 10, 25, and 50 µM) for four hours 
as described above were determined after isolation of mRNA as described above. The threshold 
cycle values were normalized to internal control actin using primers against Fpn1 (Origene 
HB210988) and Fth1 (Origene HP205786) using the Pfaffl Method and were then normalized to 
shDMT1 levels in the absence of hinokitiol. 
 Relative Mfrn1 mRNA levels were determined via qRT-PCR using TaqMan probes 




Western blotting conditions 
 Caco-2 monolayers, differentiated MEL cells, or J774 cells underwent treatment as 
described in rescue experiments before lysis with RIPA buffer (Thermo 89901) containing 
protease inhibitors (Thermo 88266). Protein concentrations were determined by a BCA kit 
(Thermo 23225) and diluted to 2 mg/mL in the same RIPA buffer. Relative protein levels were 
then determined through western blotting of 10 or 20 µg of protein lysate blocking for 2 hours at 
room temperature with 5% BSA and using primary antibodies consisting of either human anti-
DMT1 (1:3,000 dilution, Santa Cruz sc-30120), mouse anti-DMT1 (1:1,000 dilution, Santa Cruz 
sc-166884), human anti-FTL1 (1:1,000 dilution, Santa Cruz sc-74513), human anti-FPN1 HRP 
conjugate (1:10,000 dilution, Novus Biologicals NBP1-21502H), mouse anti-globin α HRP 
conjugate (not heated at 100 °C, 1:10,000 dilution, Lifespan Biosciences LS-C212172), human 
anti-TfR1 HRP conjugate (1:10,000 dilution, Abcam ab10250), human anti-IRP1 (1:1,000 
dilution, Santa Cruz sc-14216), human anti-IRP2 (1:1,000 dilution, Santa Cruz sc-33682), human 
anti-Hif1α HRP conjugate (1:1,000 dilution, Novus Biologicals NB100-105H), human anti-Hif2α 
HRP conjugate (1:1,000 dilution, Novus Biologicals NB100-122H), human anti-PCBP1 (1:1,000 
dilution, Santa Cruz sc-393076), or human anti-actin HRP conjugate (1:10,000 dilution, Cell 
Signaling 5125S) in 5% BSA overnight at 5 °C before rinsing thoroughly with TBST and 
incubation (if non-HRP conjugated) with secondary antibody consisting of either goat anti-rabbit 
IgG HRP conjugate (1:5,000 dilution – DMT1, Cell Signaling 7074, in 5% milk), goat anti-mouse 
IgG1 HRP conjugate (1:1,000 dilution – PCBP1, 1:5,000 dilution – IRP2, 1:3,000 dilution – 
DMT1, Santa Cruz sc-2060, in 5% BSA), donkey anti-goat IgG HRP conjugate (1:1,000 dilution 
– IRP1, Santa Cruz sc-2020, in 5% BSA), or goat anti-mouse IgG2a HRP conjugate (1:10,000 
dilution – FTL1, Santa Cruz sc-2061, in 5% BSA) at room temperature for two hours. Blots were 
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thoroughly rinsed with TBST and imaged after addition of Femto Chemluminescence solution 
according to manufacturer instructions (Thermo Fisher 34095).  
 
55Fe uptake and transport in differentiated Caco-2 monolayers 
 Media from differentiated Caco-2 monolayers (P25-50, 21-28 days post seeding) grown on 
PET inserts in 6-well plates was aspirated, and monolayers were rinsed with PBS. 2 mL of 
basolateral fluid (serum-free DMEM at pH = 7.4 in 10 mM HEPES buffer) was added to the 
basolateral side, and 1 mL of apical fluid (serum-free DMEM at pH = 5.5 in 10 mM MES buffer) 
containing 200 nM 55FeCl3 or the indicated concentration of FeCl3 and either DMSO vehicle, 
hinokitiol, C2deOHino, deferiprone, PIH, SIH, or deferoxamine mesylate (Sigma D9533) (500 
nM Hino/C2deOHino for DMT1-deficiency, 1 µM Hino/C2deOHino for FPN1-deficiency, or 
indicated concentration of small molecule from a 1000X stock in DMSO) was added to the apical 
side via addition on the wall of the membrane insert without disrupting the cell monolayer. The 
monolayers were then incubated for four hours at 37 °C unless otherwise noted. A 100 µL aliquot 
of the basolateral fluid was removed, diluted in scintillation cocktail, and radioactivity was 
determined on a liquid scintillation counter to quantify relative amounts of 55Fe transport. To 
determine intracellular 55Fe, the basolateral and apical media was removed, and the monolayer was 
rinsed with PBS (x2). The cells were then lysed with 500 µL of 200 mM NaOH with nutator 
mixing overnight, and radioactivity was determined on a liquid scintillation counter after diluting 
the cell lysate in scintillation cocktail. All values were normalized to shControl monolayers unless 
otherwise noted. Absolute iron levels were determined through calibration of 55Fe radioactivity 
levels with known standards and average mg of protein per membrane was determined by protein 
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lysis with RIPA buffer containing protease inhibitors and quantified through a BCA kit according 
to manufacturer instructions.  
 Determination of 55Fe transport as a function of pH used the protocol described above 
except for the use of apical fluid containing either 10 mM PIPES (pH=6.5) or 10 mM HEPES 
(pH=7.4) in DMEM.  
 Determination of unidirectional uptake and transport was determined as described above 
except for basolateral addition of 55FeCl3 (200 nM) and basolateral addition of DMSO or hinokitiol 
(500 nM). An aliquot of the apical fluid was then taken to determine the basolateral to apical 
transport. Intracellular 55Fe was determined as described above. 
 Determination of 55Fe transport as a function of the concentration of iron and/or hinokitiol 
was performed as described above except for the use of the indicated concentration of iron (20:1 
56Fe:55Fe for each concentration) or hinokitiol (from a 1000X stock in DMSO). Experiments for 
the translational and transcriptional regulated changes in endogenous proteins upon addition of 
increasing hinokitiol concentrations used 25 µM of non-radioactive FeCl3 and the indicated 
concentration of hinokitiol (from a 1000X stock in DMSO). 
 Determination of ferroportin levels upon increasing hinokitiol concentrations in the 
absence of iron used the procedure as described above containing 200 nM of non-radioactive 
FeCl3. 
 Determination of 55Fe transport after FPN1 knockdown was determined as described above 
using 200 nM 55FeCl3 after incubation of quercetin to knockdown FPN1





TEER determination in Caco-2 monolayers 
 To determine Caco-2 membrane integrity, transport studies were performed as described 
above, except for the use of non-radioactive iron instead of 55FeCl3. At the indicated time points, 
the transepithelial electrical resistance (TEER) was determined with an epithelial voltohmmeter 
and compared to the TEER of the membrane at the beginning of the experiment. 
 
WST-8 toxicity in cell lines 
 Determination of small molecule-mediated toxicity in Caco-2, MEL, and/or J774 cells was 
performed according to manufacturer instructions using a WST-8 kit (Cayman Chemical 
10010199) similar to previously reported53 using a 1000X stock of the indicated small molecule 
in DMSO to give the indicated final concentration. 
 
Table 3.1 Toxicity of small molecules to mammalian cells. 
 
Differentiation of MEL cells with DMSO 
 To perform differentiation experiments with MEL cells,30 the indicated MEL cells were 
diluted to 1x105 cells/mL in MEL Complete media containing 10 µM iron (III) citrate and 2% 
DMSO in the absence or presence of 1 µM hinokitiol or C2deOHino (added from 1000X stock in 
DMSO) in 12-well plates. Cells were then incubated at 37 °C for 72 hours unless otherwise noted. 
Control experiments were performed under identical conditions in the absence of DMSO, and it 
was found that no differentiation was observed by o-dianisidine staining as described below. 
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Staining of induced MEL cells with dianisidine 
 Hemoglobinized MEL cells were quantified three days after DMSO induction through o-
dianisidine staining similar to previously reported.31 Cells were centrifuged three days after 
induction and rinsed with PBS. The cells were then suspended in a solution containing 7.5 mM o-
dianisidine, 900 mM H2O2, and 150 mM acetic acid in water at ~1x10
6 cells/mL. Cells were then 
imaged on an AXIO Zoom V16 microscope to obtain color images. The number of stained cells 
were then quantified via ImageJ analysis and compared to the number of total cells in each image. 
To determine that hinokitiol requires DMSO induction for hemoglobinization, 2% DMSO was not 
added at the beginning of the experiment before a 72-hour incubation and o-dianisidine staining. 
 
55Fe uptake in MEL cells 
 MEL cells were induced for differentiation as described above and incubated at 37 °C for 
70 hours before addition of a saturated iron-transferrin (55Fe2Tf) solution (40 nM final 
concentration from a 10 µM 55Fe2Tf stock). The cells were incubated for an additional two hours. 
After completion, the cells were counted with a hemocytometer, the media was removed after 
centrifugation, the cells were rinsed with PBS (x3), and the cell suspension was diluted in 
scintillation cocktail and radioactivity was determined. Radioactive levels were normalized per 
cell (counted by hemocytometer) relative to wild type (DS19) levels. 
 
55Fe heme incorporation in MEL cells 
 MEL cells were induced for differentiation as described above and incubated at 37 °C for 
64 hours before addition of a saturated 55Fe2Tf solution (250 nM final concentration from a 10 µM 
55Fe2Tf stock). The cells were incubated for an additional eight hours. After completion, the cells 
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were counted with a hemocytometer, the media was removed after centrifugation, and the cells 
were rinsed with PBS (x3). The cells were then lysed with RIPA buffer, diluted with water, and 
heme was extracted using a 3:1 ethyl acetate:acetic acid solution. An aliquot of the organic extract 
was diluted in scintillation cocktail and radioactivity was determined. Radioactive levels were 
normalized per cell (counted by hemocytometer) relative to wild type (DS19) levels. 
 
Determination of hemoglobin levels 
 MEL cells were induced for differentiation as described above and incubated at 37 °C for 
72 hours. After completion, the cells were counted with a hemocytometer, the media was removed 
after centrifugation, and cells were rinsed with PBS (x2). The cells were then lysed through 
repeated freeze/thaw cycles with water, and hemoglobin levels per 106 cells were determined as 
previously described54 by determining the OD415 after centrifugation. 
 Globin levels by western blot were determined after differentiation as described above. 
After incubation for 72 hours, cells were lysed and globin levels were determined by western blot 
as described above. 
 
Knockdown of FPN1 in Caco-2 cells and J774 cells 
 To knockdown FPN1 levels in wild type Caco-2 cells, the differentiated epithelial 
monolayers were incubated with 150 µM quercetin (Sigma 337951) for 18 hours in Caco-2 
Complete media containing G418 similar to previously described.37 To knockdown FPN1 levels 
in shControl and shDMT1 Caco-2 monolayers, incubation was performed as above except with 
250 µM quercetin. After completion of the incubation, the apical and basolateral fluid was 
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aspirated and rinsed with PBS before 55Fe transport and uptake were determined as described 
above. 
 To knockdown FPN1 levels in wild type J774 cells, the cells were incubated with 2 µg/mL 
mouse hepcidin (Peptides International PLP-3773-PI) for 1 hour in J774 Complete media similar 
to previously described35 before 55Fe was loaded into J774 cells and 55Fe release was determined. 
 
55Fe release from J774 macrophages 
 J774 cells were grown in 12-well plates to ~80% confluency. The cells were then treated 
with vehicle or hepcidin in fresh J774 Complete media (1 mL) and incubated at 37 °C for 1 hour. 
After incubation, the media was aspirated, and then a 55Fe2Tf (50 nM) solution in J774 Complete 
media (1 mL) containing vehicle or hepcidin was added. The cells were incubated at 37 °C for 10 
minutes, and the media was removed. The cells were rinsed with PBS (x2), and then rinsed with 
J774 Complete media (1 mL) for 10 minutes at 37 °C. The media was aspirated, and J774 Complete 
media (1 mL) containing DMSO or small molecule (5 µM unless otherwise noted, 1000X dilution) 
was then added in the presence or absence of hepcidin. At the indicated times, aliquots (≤ 100 µL) 
of the media were removed, diluted in scintillation cocktail, and radioactivity was determined by 
liquid scintillation counting. After completion of the experiment, the media was removed, the cells 
were rinsed with PBS, and the cells were lysed with 500 µL of 200 mM NaOH at 37 °C for 2 hours 
with continuous shaking (50 rpm). The cell lysate was diluted in scintillation cocktail and 
intracellular 55Fe levels were determined by liquid scintillation counting. The % 55Fe release was 




59Fe gut absorption 
 To characterize the effects of hinokitiol on the gastrointestinal absorption of iron in healthy 
(+/+) and ffe/+ mice, food was withheld for 4 hours (8am to 12pm) prior to intragastric gavage. 
The mice were anesthetized with up to 2% isoflurane, and 59FeCl3 was administered using a 20-
gauge, 1.5-inch gavage needle. 59FeCl3 (200 µCi/kg body weight) was diluted in Tris-buffered 
saline containing 10 mM ascorbic acid in the presence or absence of 6 mM hinokitiol. Final volume 
administered was 1.5 mL/kg for each mouse, correcting for individual body weight. Blood was 
collected at 60, 120, and 240 min after administration to determine 59Fe levels. Mice were 
humanely sacrificed by isoflurane overdose after 6 hours and blood was collected by cardiac 
puncture. Radioactivity was quantified by gamma counting and calculated as the percentage of 
gavaged dose (± SEM). Experiments were performed with 4 genotyped-matched mice/day; 
preliminary analysis determined there were no gender effects on uptake of 59Fe after intragastric 
gavage; mixed genders were used in the experiments shown. 
 59Fe gastrointestinal absorption of iron in 3-5-month-old b/b rats was characterized similar 
to the procedure described above in the presence of either 6 mM hinokitiol or 6 mM C2deOHino. 
To compare with the rate of normal iron uptake, age-matched sibling control (+/+ or +/b) Belgrade 
rats were tested by the same procedure except that 59Fe was administered without small molecule. 
Blood (50 µL) was taken from the tail vein at 15, 30, 60, 120, 180, 240, and 360 minutes post 
administration. Radioactivity was quantified by gamma counting and calculated as the percentage 





Knockdown in morphant zebrafish 
 The morpholinos (MOs) were purchased from GeneTools, LLC (Philomath, OR). The 
sequences of the MO used were as follows: dmt1 MO: 5’-
GAGTGTGAAACGTGACGCACCCCTT-3’; mfrn1 MO: 5’-
TAAGTTGCATTACCTTGACTGAATC-3’. Zebrafish embryos at the 1-cell stage were injected 
with MOs as previously described.50, 55 o-dianisidine staining for hemoglobinized cells in embryos 
was as previously described.56 Quantification by flow cytometry using fluorescently labeled 
erythrocytes from the transgenic Tg(globinLCR:eGFP) line48 was performed as previously 
described.50, 52 Semi-quantitative RT-PCR of dmt1 mRNA in morphants was performed using 
custom designed probes as previously described.57 The sequences of the dmt1 primers are as 
follows: 5’-CTGAACCTGCGCTGGTCCC-3’ (Fwd); 5’-TCCGTTAGCGAAGTCGTGCATG-
3’ (Rev). The sequences of the control actb primers were as follows: 5’-
GTTGGTATGGGACAGAAAGACAG-3’ (Fwd); 5’-ACCAGAGGCATACAGGGACAG-3’ 
(Rev).  
 
Restored hemoglobinization in transporter-deficient zebrafish 
 Either mutant or morphant embryos were allowed to develop to >24 hours post fertilization 
(hpf), then dechorionated with pronase as previously described.58  The dechorionated embryos or 
morphants were then incubated in the presence of 1 µM hinokitiol (or vehicle) and 10 µM iron 
(III) citrate for an additional forty-eight hours. Vehicle treated embryos were exposed to 0.01 mM 
DMSO. C2deOHino (1 µM) with iron (III) citrate (10 µM) was used as a negative control. Control 
and either mutant or morphant embryos at ~72 hpf were either (a) directly stained by o-
dianisidine56 or (b) mechanically homogenized as previously described for flow cytometry.52, 55   
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MECHANISTIC STUDIES ON HINOKITIOL-MEDIATED RESTORATION OF PHYSIOLOGY 
 In Chapters 2 and 3, the potential for hinokitiol to promote the site- and direction-selective 
transport of iron into, within, and/or out of cells was demonstrated in both cells and animals 
missing three different iron transport proteins normally responsible for the movement of iron in 
different directions, cellular locations, and tissues. Remarkably, the same small molecule 
metallophore, which passively transports iron with minimal selectivity, restored gut iron 
absorption or hemoglobinization in many diverse protein deficiencies in rats, mice, and zebrafish.  
 This may be attributed to our underlying mechanistic hypothesis in which the dynamic 
endogenous networks of tunable active and passive ion transport proteins and their regulators 
promote the build-up of iron gradients upstream of the membranes that normally host these missing 
proteins, thus enabling an imperfect small molecule iron transporter to dissipate these gradients 
and move iron to its required location. The endogenous network can then utilize the iron in normal 
physiological processes. This chapter provides evidence for the capacity of hinokitiol to harness 
built-up iron gradients, and further confirms that a build-up of iron occurs in both DMT1-deficient 
endosomes and FPN1-deficient macrophages. Further, we discovered this molecular prosthetic 
functionally integrates into the endogenous iron-dependent regulatory networks to promote iron 
absorption while preventing its overload. This regulation is crucial for the realization of the 
therapeutic potential of using hinokitiol, or a derivative, to treat iron-related disorders in humans.  
 Portions of the work presented in this chapter was completed with the aid of colleagues Dr. 
Alex Cioffi (liposome studies), Anna SantaMaria (macrophage 55Fe uptake studies), and 
undergraduates Chris Nardone, James Fan, and Dillon Svoboda (western blotting). Portions of this 
chapter have been adapted from Grillo et al., Restored iron transport by a small molecule promotes 
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absorption and hemoglobinization in animals, Science, 2017, 356, 608-616 and Cioffi, A.G.; Hou, 
J.; Grillo, A.S.; Diaz, K.A.; Burke M.D., Restored physiology in protein-deficient yeast by a small 
molecule channel, J. Am. Chem. Soc. 2015, 137, 10096-10099. 
 
4.1 A BUILD-UP OF IRON IN IRON-TRANSPORT PROTEIN DEFICIENT CELLS 
 Having discovered a small molecule that can restore gut iron absorption and 
hemoglobinization in cells and animals,1 we next probed the underlying mechanistic hypothesis 
that drove our initial investigations. In the case of a deficiency of a passive iron-transport protein, 
the corresponding active iron-transport proteins typically remain functional. This may then 
promote the selective buildup of iron gradients upstream of the membranes that normally host the 
missing proteins (Figure 4.1). We hypothesized a small molecule iron transporter could leverage 
Figure 4.1 A build-up of iron gradients may selectively occur in iron-transport protein deficiencies. In the setting 
of a deficiency of an iron-transport protein, the other transport proteins in the endogenous network remain active. This 
may lead to the buildup of labile iron upstream of the membrane that normally hosts the missing protein. Hinokitiol 
may leverage these localized chemical gradients to promote the site- and direction-selective transport or iron. 
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these transmembrane gradients of the labile iron pool2 to restore the movement of iron into, within, 
and/or out of cells and thereby enable its use in endogenous iron-dependent physiological 
processes. We thus tested the capacity for hinokitiol to site- and direction-selectively mobilize iron 
by harnessing built-up iron gradients in transporter-deficient systems.1 
 We first visualized compartmentalized iron in DMT1-deficient MEL cells by using iron-
sensitive fluorescent dyes.3, 4 Based on our mechanistic framework, we predicted a deficiency of 
DMT1 in developing erythroid progenitors would lead to a site-selective build-up of iron in 
endosomes in accordance with low cytosolic and mitochondrial iron (Figure 4.2A). An 
OxyBURST Green-bovine serum albumin conjugate is recognized for endocytosis and is 
subsequently trapped. In the presence of H2O2, iron-mediated oxidation causes fluorescence 
emission to visualize endosomal iron (Figure 4.2B). The membrane permeable Calcein Green-AM 
Figure 4.2 Detection of intracellular labile iron with fluorescent dyes. (A) Iron is hypothesized to buildup in 
endosomes of DMT1-deficient erythroblasts. (B) OxyBurst Green conjugated to BSA is taken up via endocytosis, 
upon which oxidation by iron and H2O2 causes fluorescence emission. (C) Calcein green is used to visualize cytosolic 
iron. (D) RPA is used to visualize mitochondrial iron. (E) After binding to iron, fluorescence from the turn-off probes 
calcein green and RPA is quenched. 
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ester is hydrolyzed by unselective esterases in the cytosol to form the hydrophilic and fluorescent 
calcein green (Figure 4.2C). The iminodiacetic acid moieties bind cytosolic iron, upon which 
electron transfer quenches fluorescence causing the probe to “turn-off” (Figure 4.2E). The 
potentiometric turn-off probe RPA localizes in mitochondria and binds ferrous iron through 
phenanthroline ligands to quench rhodamine fluorescence (Figure 4.2D, E).  
 We loaded these fluorescent probes into DMT1-deficient MEL cells 72 hpi with 2% DMSO 
in the presence or absence of hinokitiol. Relatively low endosomal, high cytosolic, and high 
mitochondrial iron levels were observed in DMSO-induced control MEL cells by confocal 
microscopy (Figure 4.3A). We observed two-fold increases in iron-promoted OxyBURST Green 
fluorescence in DMT1-deficient MEL cells, along with reduced cytosolic and mitochondrial iron. 
Hinokitiol treatment decreased OxyBURST Green fluorescence 2.1-fold and concomitantly 
quenched calcein green and RPA fluorescence (Figure 4.3A-D). Similar results were obtained after 
FACS analysis of the induced cells, in which a decrease in the median fluorescence was observed 
in the hinokitiol-treated cell populations (Figure 4.4A-F). Collectively, these data support 
Figure 4.3 Endosomal build-up of labile iron in DMT1-deficient MEL cells. (A) Representative fluorescence 
images of differentiated shControl and DMT1-deficient MEL cells in the absence or presence of hinokitiol (1 µM) or 
C2deOHino (1 µM), using OxyBURST Green, calcein green, and RPA to detect relative endosomal, cytosolic, and 
mitochondrial levels, respectively. A buildup of labile iron was observed in endosomes of DMT1-deficient cells, 
which was released after hinokitiol treatment. (B-C) Quantification of cellular fluorescence in differentiated MEL 
cells treated with or without hinokitiol (1 µM) and C2deOHino (1 µM) to quantify relative levels of iron in (B) 
endosomes with OxyBURST Green, (C) cytosol with calcein green, and (D) mitochondria with RPA. 
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hinokitiol-mediated release of built-up pools of endosomal iron into the cytosol and subsequent 
mitochondrial uptake. 
 Literature precedent suggests FPN1-deficient flatiron mice exhibit macrophage iron 
loading as evident by increased levels of spleen and liver non-heme iron (Table 4.1).5-8 Consistent 
with this, calcein green and 55Fe studies similarly revealed a build-up of labile iron in FPN1-
Figure 4.4 FACS analysis of fluorescence of iron-sensitive dyes. (A and B) Flow cytometry of shDMT1 MEL cells 
stained with OxyBURST Green supports hinokitiol decreases endosomal iron levels. (C and D) Flow cytometry 
analysis of calcein green fluorescence in the cytosol supports hinokitiol treatment to shDMT1 MEL cells increases 
cytosolic labile iron levels. (E and F) Flow cytometry analysis of RPA fluorescence in the mitochondria supports 
hinokitiol treatment to shDMT1 MEL cells increases mitochondrial labile iron levels. 
Table 4.1 A build-up of iron in macrophages of FPN1-deficient mice. Flatiron mice that are genetically mutated 
in FPN1 exhibit inefficient iron recycling leading to a build-up of iron in reticuloendothelial macrophages as 
evidenced by the increased non-heme iron levels in the liver and spleen. Data is taken from Seo et al. 
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deficient J774 macrophages relative to wild-type cells (Figure 4.5A-C). Macrophages were treated 
with hepcidin to induce FPN1 degradation, and we tracked the uptake of extracellular iron. To 
quantify the levels of labile iron, we used the iron-sensitive turn-off probe calcein green. Minimal 
fluorescence quenching was observed in iron-treated wild-type J774 macrophages (Figure 4.5A, 
B). Significant quenching was observed in hepcidin-treated macrophages, consistent with a 
selective build-up of labile iron inside of FPN1-deficient cells. Further, increased levels of total 
cellular iron in FPN1-deficient J774 macrophages were observed using 55Fe as a radiotracer 
(Figure 4.5C). Finally, results presented in Chapter 3 demonstrated hinokitiol can leverage this 
gradient to release intracellular iron in FPN1-deficient J774 macrophages. 
 Hinokitiol direction-selectively promoted both iron influx to and efflux from J774 
macrophages depending on the presence of high extracellular or intracellular iron, respectively. 
Rates of hinokitiol-mediated iron (II) and iron (III) efflux from liposomes and iron (III) uptake 
into J774 macrophages was directly proportional to the magnitude of the transmembrane iron 
gradients (Figure 4.6A-E). Last, we loaded iron into J774 macrophages, rinsed the cells to remove 
Figure 4.5 A build-up of iron in FPN1-deficient J774 macrophages. (A) J774 macrophages treated with vehicle 
(wild type) or hepcidin (FPN1-deficient) were stained with calcein green. Iron (50 µM) was then added, and the 
relative levels of cytosolic labile iron were visualized via confocal microscopy. Significant fluorescence quenching 
was observed in FPN1-deficient macrophages, consistent with increased labile iron. (B) Quantification of calcein 
green fluorescence by ImageJ analysis. (C) Using 55Fe as radiotracer, a build-up of total cellular iron levels in FPN1-
deficient J774 macrophages was observed. 
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extracellular iron, and stained them with calcein green (Figure 4.7A). Hinokitiol addition at t = 5 
min rapidly increased calcein green fluorescence, whereas vehicle and C2deOHino treatment had 
no effect (Figure 4.7B, C). We then reversed the gradient in the same cells by external addition of 
FeCl3 (t = 12 min). DMSO or C2deOHino treatment of cells had no effect, whereas quenching of 
calcein green fluorescence was observed with hinokitiol treatment (Figure 4.7B, C). These results 
are consistent with initial hinokitiol-mediated release of iron from J774 macrophages when 
intracellular iron levels are high, followed by hinokitiol-mediated uptake of iron into these 
macrophages when this transmembrane gradient is reversed by addition of extracellular iron 
(Figure 4.7A). 
Figure 4.6 Rates of hinokitiol-mediated transport are dependent on the magnitude of the iron gradient. (A and 
B) Increased intraliposomal (A) ferrous and (B) ferric iron led to increased rates of iron efflux in the presence of 
hinokitiol (10 µM). No efflux was observed in the absence of hinokitiol. (C and D) The rates of iron release from 
hinokitiol-treated (10 µM) POPC liposomes increases as a function of the amount of (C) ferrous and (D) ferric iron 
inside of the liposomes. (E) Increased extracellular iron (III) levels increased rates of iron uptake into J774 
macrophages treated with hinokitiol (1 µM), as observed using 55Fe as a radiotracer. 
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4.2 YEAST INVOLVED IN ROBUSTNESS MECHANISMS 
 We then asked whether endogenous networks of other ion-transport proteins and 
regulators2 in iron transporter-deficient cells can collaborate with the small molecule hinokitiol to 
help promote restoration of site- and direction-selective iron transport while still maintaining iron 
homeostasis. In yeast, the intracellular movement and storage of iron is dependent on a proton 
gradient known as the proton motive force, which is generated by the ATP-dependent active ion-
transport proteins Pma1 and V-ATPase in the plasma and vacuolar membranes, respectively 
Figure 4.7 Hinokitiol direction-selectively transports iron down its concentration gradient. (A) Simplified 
schematic for hinokitiol-promoted direction-selective iron transport across membranes of J774 macrophages using 
artificial gradients. FeSO4 (200 µM) is first loaded into J774 macrophages, the extracellular fluid is replaced with a 
low iron media (<500 nM) after staining cells with calcein green, then hinokitiol (100 µM) is added at t = 5 min. 
Hinokitiol releases iron to the extracellular fluid. The gradient is then reversed by addition of extracellular FeCl3 (100 
µM) at t = 12 min. Hinokitiol alternatively promotes the uptake of iron into J774 macrophages, consistent with 
direction-selective transport depending on the direction of the pre-formed iron gradients. (B) Fluorescence imaging 
of cytosolic iron with calcein green using artificially created iron gradients in opposite directions in J774 macrophages. 
Cells were loaded with iron, then hinokitiol was added. An increase in fluorescence was observed, consistent with 
decreased intracellular labile iron. The gradient was then reversed in these same cells by addition of FeCl3 to the 
media. Fluorescence quenching was observed, consistent with iron uptake. (C) Representative ImageJ quantification 
of calcein green fluorescence in iron-loaded J774 cells with addition of DMSO, hinokitiol, or C2deOHino at t = 5 min 
and FeCl3 at t = 12 min. Scale bars = 20 µm. 
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(Figure 4.8A).9, 10 These proton pumps collaborate with passive ion transport proteins to achieve 
the intracellular movement of iron required for cell growth. Iron acquisition in yeast, normally via 
the transport complex Fet3Ftr1, is dependent on several collaborating proteins, including the 
copper importer Ctr1 and the Golgi Body chloride and copper importers Gef1 and Ccc2 (Figure 
4.8A).10 Vacuolar uptake of excess iron then occurs through the Fe2+ importer Ccc1 until it is 
required in metabolism. Deletion of any of these genes reduces iron uptake in yeast, leading to a 
no growth phenotype. Despite being a deficiency of a copper or chloride importer, hinokitiol 
treatment to ctr1Δctr3Δ, ccc2Δ, gef1Δ, and fet3Δftr1Δ restores growth in the presence of iron, but 
not in its absence (Figure 4.8B).10 Further, my colleague Page Daniels has demonstrated that this 
growth restoration is dependent on the concentration of iron in the media. This suggests that simply 
Figure 4.8 Restored growth in yeast by restoring function downstream from the protein deficiency. (A) Iron 
acquisition and homeostasis in yeast is highly regulated, with the majority of iron uptake going through the Fet3Ftr1 
transporting complex. For proper localization of Fet3Ftr1 to the plasma membrane, significant processing first occurs 
in the Golgi Body. The proton pumps Pma1 and V-ATPase create electrochemical gradients that are then used to 
promote the uptake of chloride into the Golgi Body through Gef1. Copper uptake occurs through Ctr1, then the copper 
is shuttled into the Golgi Body by Ccc2 using the favorable chloride electrochemical gradient. The copper is then 
loaded onto the ferroxidase Fet3 of apo-Fet3Ftr1. The active Fet3Ftr1 is then translocated to the plasma membrane. 
A deficiency of any one of these genes leads to an iron-deficiency phenotype, in which the yeast cannot grow. (B) 
Consistent with this, mutations of the copper transporters Ctr1, Ccc2, as well as the chloride transporter Gef1 leads to 
a no growth phenotype similar to the fet3Δftr1Δ yeast. Addition of hinokitiol restores growth to these mutant yeast 
strains. These results suggest that replacing the pathophysiologic cause of disease is sufficient to restore physiology, 
even if it is not directly replacing the function of the missing protein. 
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restoring the functional consequence, and not directly replacing the function of the missing protein, 
in protein deficiencies may be sufficient to restore normal physiology. This may have significant 
implications in many diseases, as many proteins and enzymes participate in the early stages of 
signaling cascades or metabolic pathways which cause a downstream effect. 
 We further hypothesized that hinokitiol-promoted rescue of fet3Δftr1Δ was dependent on 
the activity of V-ATPase and Pma1 by collaborating with these active proton pumps.11 Such a 
model predicts selective sensitivity of the small molecule-rescued mutants to chemical inhibition 
of these pumps. As a negative control, hinokitiol-treated wild type and hinokitiol-rescued 
fet3Δftr1Δ cells were equally sensitive to caspofungin, an off-pathway inhibitor of cell wall 
biosynthesis. In contrast, hinokitiol-rescued fet3Δftr1Δ cells were exceptionally sensitive to 
Figure 4.9 Functional collaboration of hinokitiol with proton pumps involved in iron uptake in yeast. (A) The 
Pma1 inhibitor ebselen and V-ATPase inhibitor bafilomycin were used to test if hinokitiol-rescued fet3Δftr1Δ yeast 
were exceptionally sensitive to inhibition of the proton pumps involved in iron uptake. (B) Wild type and fet3Δftr1Δ 
yeast grown in the presence of hinokitiol (10 µM) are equisensitive to an inhibitor of cell wall biosynthesis, 
caspofungin, which is off-pathway of iron uptake. Inhibition of the proton-motive force generating pumps, Pma1 with 
ebselen and V-ATPase with bafilomycin, lead to increased sensitivity of hinokitiol-rescued fet3Δftr1Δ yeast relative 
to hinokitiol-treated wild type yeast. This suggests that proteins play a role in hinokitiol-mediated restoration of yeast 
cell growth. (C) Quantification of EC50 values for small molecule inhibitors of yeast cell growth. 
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inhibition of V-ATPase with bafilomycin and Pma1 with ebselen, suggesting functional 
integration of hinokitiol into this network of active and passive ion transport proteins. A common 
channels and pumps architecture is responsible for the site- and direction-selective movement of 
ions in organisms from yeast to humans, suggesting that the same type of functional collaboration 
observed in fet3Δftr1Δ yeast might enable small molecule surrogates for missing protein ion 
transport proteins to impact on human disease. We therefore hypothesized similar mechanistic 
underpinnings enable the hinokitiol-mediated restoration of gut iron absorption and 
hemoglobinization in cells and animals missing DMT1, MFRN1, and FPN1. 
 
4.3 REGULATION OF IRON TRANSPORT IN HUMANS 
 Many human diseases, such as anemia of chronic inflammation, hemochromatosis, and 
neurological disorders, are characterized by a dysregulation of systemic iron supply. Iron 
homeostasis is typically maintained by dynamic networks of transporters and their regulators.2 No 
Figure 4.10 Iron homeostasis and human disease. (A) More than twenty-five diverse diseases are associated with 
the improper metabolism, transport, or regulation of iron. (B) As no regulatory mechanisms of iron excretion are 
known, the absorption of dietary non-heme iron is highly regulated to allow for its absorption while preventing iron 
overload. Non-heme iron is taken into duodenal enterocytes via the H+/Fe2+ symporter DMT1. Cytosolic iron can then 
be used in intracellular processes, bind to the iron-sensing regulator IRP1/2, stored in ferritin clusters mediated by the 
chaperone PCBP1, or taken into the blood via the efflux protein FPN1. 
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known mechanisms of regulating iron excretion exist, and thus the primary site of maintaining 
systemic iron levels resides in proximal duodenal villous enterocytes responsible for the absorption 
of dietary iron. In these cells, iron absorption is exquisitely controlled by iron-sensitive 
transcriptional, translational, and post-translational regulatory networks to prevent iron-promoted 
toxicity yet allow for its essential use.2, 12 
 Levels of apical H+/Fe2+ symporter divalent metal transporter 1 (DMT1), heavy (FTH1) 
and light (FTL1) chains of ferritin collectively responsible for sequestering excess iron, as well as 
Figure 4.11 Simplified schematics for translational and transcriptional regulation of iron-related proteins. (A) 
Translational regulation in duodenal enterocytes is mediated through iron response elements (IREs) located on the 5’ 
or 3’ ends of mRNA of several iron-related proteins. In the absence of iron, iron response proteins (IRP1 and IRP2) 
bind to the 5’- or 3’-IRE to block translation or stabilize mRNA, respectively. Upon iron binding, IRP1/2 dissociate 
from IRE (and IRP2 is degraded) and translation occurs (5’-IRE) or mRNA degrades (3’-IRE) to allow for iron-
sensitive regulation of proteins involved in iron uptake and transport. (B) Transcriptional regulation of FPN1 via 
HIF2α occurs to evade translational repression of FPN1. HIF2α activates Fpn1 transcription under iron-deplete 
conditions, however, in the presence of iron and O2, HIF2α is degraded, thus decreasing FPN1 protein levels. 
 141 
basolateral efflux protein ferroportin (FPN1) amongst other proteins are translationally controlled 
through short hairpin iron response elements (IREs) located at the 5’- and 3’- untranslated regions 
(UTRs) of the corresponding mRNA transcripts to block translation (5’-UTR, FTH1, FTL1, FPN1) 
or stabilize mRNA (3’-UTR DMT1) through the binding of iron response proteins (IRP1 and 
IRP2) under iron starvation.2, 13 Upon iron stimulation and binding, IRPs dissociate from the 
mRNAs, reversing their described effects. Holo-IRP1 undergoes an aconitase switch/iron-sulfur 
formation while IRP2 is ubiquitinated and degraded. Transcriptional regulation in duodenal 
enterocytes occurs through the hypoxic inducible factor HIF2α, which is degraded after O2 and 
iron-mediated proline hydroxylation. HIF2α activates transcription of iron-related proteins such as 
FPN1 to evade translational repression under iron depletion.2, 14 The peptide hepcidin produced by 
liver hepatocytes under plasma iron-repletion decreases dietary iron absorption through binding 
and proteasomal ubiquitinization/degradation of FPN1.2, 15 These networks maintain iron levels to 
permit its essential use yet prevent iron overload. 
 
4.4 FUNCTIONAL INTEGRATION OF HINOKITIOL INTO HOMEOSTATIC 
REGULATORY NETWORKS IN GUT EPITHELIA 
 Previous reports by Rouault and others demonstrate that in animals fed a low-iron diet, 
levels of the aforementioned iron transport proteins respond to changes in the cellular iron status 
through these homeostatic mechanisms.13, 14 Specifically, they reported increased levels of IRP2, 
DMT1, TfR1, and FPN1 as well as decreased levels of ferritin. They concluded these changes help 
promote the efficient absorption and utilization of the limited iron supply. Consistent with these 
reports,14 we initially observed an iron-deplete state in our shRNA-transfected DMT1-deficient 
Caco-2 monolayers (Figure 4.12A). As expected, IRP1 expression was unchanged, however, the 
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putatively low levels of labile iron did not allow for IRP2 degradation (Figure 4.12B, C). We also 
observed IRP-mediated decreases in the levels of ferritin (5’-IRE) by ELISA, ferritin light chain 
subunits (FTL1) by western blotting, as well as decreased levels of 55Fe in immunoprecipitated 
ferritin (Figure 4.12D, E). We similarly observed IRP-dependent increases in TfR1 (3’-IRE) 
protein (Figure 4.12F). FPN1 levels were also increased, while levels of HIF1α, HIF2α, and the 
iron chaperone PCBP12 were unchanged (Figure 4.12G-J). Collectively, the dynamic response to 
the low iron availability provides a favorable cellular environment for small-molecule mediated 
iron transport in a direction-selective manner. 
Figure 4.12 Endogenous proteins involved in iron uptake and transport. (A) Representative Western blot images 
of proteins involved in iron absorption and regulation indicate an iron-deficient state in shDMT1 Caco-2 monolayers 
to promote maximal iron absorption. (B-J) Western blot, ELISA, or 55Fe immunoprecipitation quantification of 
protein levels of iron-related proteins in shDMT1 Caco-2 monolayers indicate other proteins respond via 
transcriptional and translational feedback mechanisms to changes in cellular iron status. Importantly, (D) decreased 
ferritin, (E) 55Fe incorporation into ferritin, and (G) increased FPN1 levels were observed, presumably creating an 
environment favorable for small molecule-mediated iron transport. 
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 We thus hypothesized hinokitiol was functionally integrated into the endogenous network 
of iron transporters and regulators. If functionally integrated, normal iron homeostasis would be 
achieved through regulation of iron acquisition and utilization in zebrafish, mice, or other complex 
organisms. To discern between this and an iron uptake pathway independent of the endogenous 
system, we first tested the directionality of hinokitiol-promoted iron transport in DMT1-deficient 
Caco-2 monolayers. To the best of our knowledge, there are no known mechanisms for the 
basolateral to apical transport of iron in enterocytes. Consistent with this, basolateral addition of 
55Fe to normal Caco-2 monolayers led to negligible iron uptake or transport to the apical fluid 
(Figure 4.13A, B). Hinokitiol-mediated transport is similarly unidirectional, supporting functional 
integration. 
 In gut epithelia, excess cytosolic iron is normally stored in ferritin clusters or transported 
to the basolateral fluid through FPN1. Immunoprecipitation of ferritin after incubation with 55Fe 
led to the incorporation of 55Fe into ferritin in normal Caco-2 monolayers, while reduced 
incorporation was observed in DMT1-deficient Caco-2 monolayers (Figure 4.13C). Apical 
Figure 4.13 Hinokitiol-mediated transport is unidirectional and dependent on ferritin. (A) Hinokitiol-promoted 
uptake into shDMT1 Caco-2 monolayers is unidirectional. Apical addition of 55FeCl3 and hinokitiol (500 nM) led to 
significant levels of iron inside of cells, while basolateral addition of the same concentrations of 55FeCl3 and hinokitiol 
led to no uptake. (B) Unidirectional hinokitiol-mediated transport in shDMT1 Caco-2 monolayers was also observed 
with apical or basolateral addition of hinokitiol (500 nM) and 55Fe radiotracer. (C) Determination of 55Fe levels in 
immunoprecipitated ferritin in Caco-2 monolayers indicated apical hinokitiol treatment (500 nM) restored the 
incorporation of iron into ferritin. 
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treatment with this low dose of hinokitiol (500 nM) restored the incorporation of 55Fe into ferritin, 
possibly mediated by the high affinity chaperone PCBP1 (Figure 4.13C). Quercetin was recently 
demonstrated to down-regulate the expression of FPN1 through increased miRNA transcription.16 
Consistent with literature precedent, eighteen-hour incubation with quercetin followed by 55Fe 
treatment led to reduced FPN1 expression and 55Fe transport in Caco-2 monolayers without 
affecting its uptake (Figure 4.14A-D). Quercetin-mediated knockdown of FPN1 antagonized 
hinokitiol-mediated transepithelial iron transport without affecting apical uptake in these DMT1-
deficient monolayers, suggesting a continued reliance on FPN1 for basolateral iron efflux. 
Figure 4.14 Hinokitiol-mediated transport is dependent on FPN1. (A and B) Knockdown of FPN1 in shDMT1 
Caco-2 monolayers with quercetin (A) has no effect on hinokitiol-mediated uptake, however, (B) abrogates hinokitiol-
mediated transport. (C and D) Quercetin (250 µM) treatment for 18 hours to shDMT1 monolayers decreased FPN1 
levels by Western blotting analysis. 
Figure 4.15 Rates of hinokitiol-mediated transport level off. (A) Rates of Caco-2 transport with varying 
concentrations of iron 4 hours after treatment with hinokitiol (500 nM). The rates of transport level off with increasing 
iron. (B) Increased hinokitiol increases uptake into shDMT1 Caco-2 monolayers treated with 25 µM FeCl3; however, 
a bimodal effect is observed in transepithelial transport at 5 µM hinokitiol. (C) The rates of transepithelial transport 
of iron across differentiated shDMT1 Caco-2 monolayers over a wide range of hinokitiol concentrations increases 
with increasing iron. The rates of iron transport level off at high concentrations of iron, consistent with homeostatic 
regulation of iron uptake and transport to maintain normal iron homeostasis and prevent iron-related toxicity. 
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 Moreover, increased rates of transepithelial transport in DMT1-deficient monolayers were 
observed with increased concentrations of apical FeCl3, but these effects leveled off at higher 
concentrations of iron (Figure 4.15A). Further, a similar leveling of transmembrane transport was 
observed when the same monolayers were treated with a persistent iron gradient (25 µM FeCl3) 
and increasing concentrations of hinokitiol (Figure 4.15B). This phenomenon was evident over a 
wide range of hinokitiol and iron concentrations (Figure 4.15C), suggesting that hinokitiol-
mediated transport would not lead to aberrant iron accumulation and iron-associated toxicity when 
in the presence of a persistent iron gradient.  
Figure 4.16 The endogenous network is involved in hinokitiol-mediated Caco-2 transport. (A) Representative 
Western blot images of proteins involved in iron absorption and regulation after treatment with increasing hinokitiol 
and 25 µM FeCl3. Bimodal effects were similarly observed in protein levels involved in iron absorption and regulation. 
(B-G) Quantification of protein levels in shDMT1 Caco-2 monolayers treated with increasing concentrations of 
hinokitiol (0, 0.5, 1, 3, 5, 10, 25, and 50 µM) and 25 µM FeCl3 suggested that IRE-mediated translational homeostatic 
regulatory networks were responding to changes in the dynamic cellular iron status. Levels of IRP2 and TfR1 
decreased up to 5 µM hinokitiol, while ferritin levels and 55Fe incorporation into ferritin increased. These effects were 
modestly reversed upon treatment with higher doses of hinokitiol up to 50 µM, possibly due to competitive chelation 
of labile iron with high hinokitiol doses. 
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 We thus asked how the endogenous system responds to the hinokitiol-mediated changes in 
cellular iron status in the presence of a persistent iron gradient. Consistent with IRP-mediated 
translational regulation, decreased IRP2, increased ferritin subunits (5’-IREs) as well as 55Fe-
ferritin incorporation, and decreased TFR1 (3’-IRE) protein levels were observed as a function of 
hinokitiol concentrations up to 5 µM in the presence of a persistent iron gradient (Figure 4.16A-
G). As expected, no changes were observed in IRP1 protein levels while DMT1 levels remained 
low (Figure 4.16A-C). The transcription factors HIF1α and HIF2α similarly decreased along with 
decreased FPN1 mRNA and FPN1 protein levels (Figure 4.17A-D). As expected, IRE-
Figure 4.17 Endogenous proteins involved in transcriptional regulation of iron absorption in gut epithelia. (A-
D) Quantification of Western blots of proteins in shDMT1 Caco-2 monolayers treated with increasing concentrations 
of hinokitiol (0, 0.5, 1, 3, 5, 10, 25, and 50 µM) and 25 µM FeCl3 suggest that endogenous transcriptional regulatory 
networks are responded to changes in the dynamic cellular iron status. Decreased FPN1 protein, Fpn1 mRNA, and 
decreased levels of Hif1/2α were observed. (E) As expected, levels of the IRE-independent iron chaperone PCBP1 
did not change upon hinokitiol treatment. (F) As expected, levels of the Hif2α-independent Fth1 mRNA did not 
change upon hinokitiol treatment. (G) No changes in FPN1 in shDMT1 Caco-2 monolayers were observed when 
treated with hinokitiol in the absence of iron. 
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independent expression of the cytosolic iron chaperone PCBP1 and HIF2α-independent FTH1 
mRNA levels did not change, and no changes in FPN1 were observed upon the addition of 
hinokitiol in the absence of iron (Figure 4.17E-G).  
 A modest reversal of these effects was observed with higher concentrations of hinokitiol 
(Figure 4.16A-G and Figure 4.17A-G). Visualization of cytosolic iron levels with calcein green 
indicated that incubation of DMT1-deficient Caco-2 monolayers with increasing hinokitiol led to 
increased labile iron up to 5 µM (Figure 4.18A-C). Further increases in hinokitiol prevented 
fluorescence quenching, possibly because of competitive intracellular chelation of labile iron at 
high doses of this strongly binding metallophore (Figure 4.18A-C). While initially unexpected, 
these results are consistent with the high binding affinity of hinokitiol for both ferrous and ferric 
iron discussed in Chapter 2, as well as difficulties we faced throughout liposomal efflux assay 
development when using high concentrations of hinokitiol and low concentrations of the iron probe 
ferrozine. These results collectively support the conclusion that the endogenous homeostatic 
networks can collaborate with the small molecule hinokitiol to help promote iron transport while 
maintaining its homeostasis and preventing ferritoxicity. 
Figure 4.18 Visualization of labile iron levels in DMT1-deficient Caco-2 epithelia. (A)  Intermediate 
concentrations of hinokitiol (5 µM) led to significant calcein green quenching in shDMT1 monolayers treated with 
25 µM FeCl3 after 1 hour, consistent with increased labile iron. This effect was reversed at high doses of hinokitiol 
(50 µM), suggesting intracellular chelation of labile iron when hinokitiol concentrations are high. Scale bar = 20 µm. 
(B and C) ImageJ quantification of calcein green fluorescence in these monolayers treated with increasing 
concentrations of hinokitiol. While no changes were observed at t = 0 min, increases in labile iron were observed at 
intermediate hinokitiol concentrations. These effects were reversed with high hinokitiol concentrations. 
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 On the basis of this mechanistic framework, we hypothesized that hinokitiol would have 
relatively minimal effects in wild-type cells. We tested the capacity for the same concentrations of 
hinokitiol to perturb transepithelial iron transport, hemoglobinization, and iron release in normal 
Caco-2 monolayers, MEL cells, and J774 macrophages, respectively (Figure 4.19A-C). In contrast 
to the hinokitiol-promoted increases in transepithelial iron transport, hemoglobinization, and iron 
release observed in the corresponding protein-deficient systems, negligible effects were observed 
in hinokitiol-treated wild-type systems under identical conditions (Figure 4.19D-F). Additionally, 
minimal changes in the rate of 59Fe absorption in healthy mice treated with hinokitiol (1.5 mg/kg) 
via oral gavage were observed (Figure 4.19G, H). Collectively, these results are consistent with 
Figure 4.19 Hinokitiol has minor effects in healthy systems. (A) Transepithelial iron transport in shControl Caco-
2 monolayers treated with DMSO or hinokitiol (500 nM). (B) Relative shControl MEL cell populations positively 
stained with o-dianisidine after DMSO induction in the presence or absence of hinokitiol (1 µM). (C) Iron release 
from wild-type J774 macrophages in the presence or absence of hinokitiol (5 µM). (D) Changes in Caco-2 transport 
relative to DMSO control upon hinokitiol addition to DMT1-deficient and shControl monolayers. (E) Changes in o-
dianisidine staining relative to DMSO control upon hinokitiol addition to MFRN1-deficient and shControl MEL cells 
induced for differentiation. (F) Changes in iron release relative to DMSO control upon hinokitiol addition to FPN1-
deficient and wild-type J774 macrophages. (G) Hinokitiol (1.5 mg/kg) treatment via oral gavage to healthy (+/+) mice 
did not increase the absorption of 59Fe into the blood after two hours. (H) Time course of 59Fe absorption in healthy 
mice treated with vehicle or hinokitiol (1.5 mg/kg) via oral gavage. 
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hinokitiol restoring site- and direction-selective iron transport by harnessing iron gradients that 
selectively build up across lipid membranes missing specific iron-transport proteins. 
 
4.5 SUMMARY AND OUTLOOK 
 Thus, a small molecule can restore site- and direction-selective iron transport in different 
cells deficient in three distinct iron-transport proteins, and the same compound can promote dietary 
gut iron absorption or peripheral hemoglobinization in corresponding animal models. Mechanistic 
studies support the role of transmembrane ion gradients that build up in the setting of missing iron 
transporters, enabling hinokitiol to restore site- and direction-selective transmembrane iron 
transport. Further, endogenous protein-based homeostatic mechanisms interface with this 
imperfect small molecule to promote iron-related physiological processes without disrupting other 
cellular processes. 
 Like hinokitiol, many ion-transport proteins are imperfectly selective. However, the 
relative abundance of different ions contributes to increased selectivity in living systems. For 
example, protein chloride channels are largely unselective for chloride versus bromide and iodide, 
but the low natural abundance of the latter halogens favors chloride selectivity in vivo.17, 18 
Differential ion accessibility further enhances the in vivo selectivity observed for many imperfect 
ion-transport proteins.10, 19, 20 Like hinokitiol, DMT1 and FPN1 transport Co2+, Mn2+, Zn2+, and/or 
Cu2+.7, 21, 22 However, high affinity metalloproteins markedly decrease the labile pool of these other 
metals, leading to higher accessibility and thus selective binding and transport of iron in vivo. 10, 
19, 20 
 These findings also provide a conceptual framework and proof-of-concept demonstration 
to support the pursuit of small molecule surrogates for missing or dysfunctional iron-transport 
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proteins that underlie many human diseases. It has recently been recognized that acquired 
deficiencies of FPN1 underlie the anemia of chronic inflammation that frequently occurs in 
patients suffering from many common diseases, including rheumatoid arthritis, systemic lupus 
erythematosus, and inflammatory bowel disease (Figure 4.20).23-26 Further, this approach may 
have potential in promoting the rapid excretion of excess iron that builds up in tissues (e.g. liver 
or brain) in many diverse iron overload disorders. 
 These results also reveal frontier opportunities to probe biology using small molecules that 
autonomously perform protein-like functions. For example, our results demonstrate that in both 
cells and zebrafish, hinokitiol-mediated rescue of physiology can distinguish between defects in 
porphyrin biosynthesis and iron transport, which can be challenging to differentiate using genetic 
and biochemical techniques. This approach has been used to help uncover the role FAM210B plays 
Figure 4.20 Pathophysiology of anemia of chronic inflammation. Acquired FPN1 deficiencies play a critical role 
in the occurrence of anemia in patients suffering from autoimmune disorders such as IBD, ulcerative colitis, and 
rheumatoid arthritis. Induction of inflammation increases levels of IL-6, which stimulates the production of the 
systemic iron regulatory peptide hepcidin in hepatocytes. The circulating hepcidin then is recognized by FPN1 and 
promotes its proteasomal degradation. This decreases the absorption and recycling of iron, causing severe anemia. 
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in iron transport during erythropoiesis, where it is a facilitator for a protein-protein interaction 
between MFRN1 and ferrochelatase in the inner mitochondrial membrane. 
 Because networks of active and passive ion-transport proteins similarly underlie the 
directional movement of many other ions in most living systems, including humans, these findings 
may also have even broader scientific and therapeutic implications. Current efforts focus on 
translating these basic scientific findings into clinical practice with several laboratories focused on 
treating humans with microcytic anemia, FPN1 disease, and IRIDA with the ultimate goal of 
helping the millions of patients who suffer from anemia of chronic inflammation. 
 
4.6 METHODS 
Cell lines and growth conditions 
 Wild type (DEY1457) and isogenic fet3Δftr1Δ S. cerevisiae were obtained from D. 
Kosman.27 Wild type (W303) and isogenic gef1Δ and ccc2Δ yeast were obtained from R. 
Gaxiola.28 Wild type (MPY17) and ctr1Δctr3Δ yeast were obtained from D. Thiele.29 Yeast were 
maintained on standard YPD media containing 10 g/L yeast extract, 20 g/L peptone, and 20 g/L 
dextrose without (liquid media) or with (solid media) 20 g/L agar. Unless otherwise indicated, 
growth-restoration assays in yeast used a low iron SD media consisting of 1.91 g/L iron-free YNB-
FeCl3 (ForMedium CYN 1201), 0.79 g/L Complete Supplement Mixture (Sunrise Science 
Products 1001-010), 5 g/L ammonium sulfate (Sigma A4418), 20 g/L dextrose, 10 or 100 µM 
FeCl3 (Sigma 451649), and 10 or 100 µM hinokitiol (β-Thujaplicin, Sigma 469521) in 50 mM 
MES/Tris buffer at pH=7.0 without (liquid media) or with (solid media) 20 g/L agar. Dextrose, 
hinokitiol, and FeCl3 were added after autoclave sterilization from a filter-sterilized 40% w/v 
dextrose solution in water, from a freshly prepared sterile 10 mM hinokitiol stock in DMSO, and 
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from a freshly prepared 10 mM FeCl3 stock in sterile water, respectively. Non-fermentable growth 
restoration used the same synthetic medium except for the use of 30 g/L glycerol instead of 
dextrose.  
 Human Caco-2 cells (HTB-37) and mouse macrophages (J774A.1) were obtained from 
ATCC and cultured with DMEM (Gibco 10313-021) containing 10% HI FBS (Gibco 16000-036), 
4 mM glutamine (Lonza BE17-605E), 100 µg/mL PEN-STREP (Lonza DE17-602E), and 1% 
MEM NEAA (Fisher 11140-050). Transfected Caco-2 cell lines were maintained on this media 
containing 800 mg/L G418 (Santa Cruz sc-29065B). Friend mouse erythroleukemia cells (MEL, 
DS19 subclone) were obtained from Arthur Skoultchi (Albert Einstein College of Medicine, 
Bronx, NY) and cultured with DMEM containing 10% HI FBS, 2 mM glutamine, 100 µg/mL 
PEN-STREP, and 1% MEM NEAA. Transfected shControl and shDMT1 MEL cell lines were 
maintained on this media containing 1 g/L G418. 
 Caco-2 cells (passage 18-50) were grown in T75 flasks to ≥90% confluency before 
trypsinization with 0.25% trypsin-EDTA (Fisher 25200-056) and passaging at 10:1 dilution in 
Caco-2 media without (wild type) or with G418 (transfected). Monolayers were grown by seeding 
Caco-2 cells (passage 20-50) onto 0.4 µm PET cell culture inserts (Fisher 08-771) in 6-well 
companion plates (Fisher 08-771-24) at 2x105 cells/well and allowed to fully differentiate for 21-
28 days before experiments were performed with changing of media every 3-4 days. 
 MEL cells were grown in suspension in T25 flasks until ~1x106 cells/mL and re-seeding 
into a new T25 flask at 1x105 cells/mL in MEL Complete media with or without G418. Every 
month of culturing, new backstocks of MEL cells were used. 
 J774 cells (passage 20-80) were grown in T25 flasks to ≥90% confluency before scraping 
and re-seeding at 5:1 dilution in J774 Complete media. Media was changed every 1-2 days. 
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Animals and animal care 
 The studies performed were in strict accordance with the guidance and recommendations 
outlined in the Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health.  
 The protocols used for studies in healthy (+/+) and Flatiron (ffe/+) mice were approved 
by the Harvard Medical Animal Care and Use Committee. Breeding, diets, and genotyping of 
flatiron mice were performed as previously described (55).  
 
Statistics 
 All data depicts the means or weighted mean ± SEM with a minimum of 3 biological 
replicates unless otherwise noted. Statistical analysis represents P values obtained from student t-
test or one- or two-way analysis of variance (ANOVA) with post-hoc TUKEY test where 
appropriate. NS, not significant; * P < 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001 unless 
otherwise noted. 
 
Chemical inhibition of yeast cell growth with inhibitors of Pma1, V-ATPase 
 Chemical inhibition of hinokitiol-treated wild type and hinokitiol-rescued fet3Δftr1Δ yeast 
cell growth was performed as previously reported11 in low iron SD media containing 10 µM FeCl3 
and 10 µM hinokitiol. Increasing dosages of caspofungin (Sigma SML0425), ebselen (Sigma 
70530), or bafilomycin B1 (Santa Cruz sc-202072) (40X stocks in DMSO) were added to a yeast 
suspension (10-fold dilution from OD600 = 0.1) to give the indicated final dose. EC50 values were 




 Fpn1 and Fth1 mRNA levels in shDMT1 Caco-2 monolayers upon treatment with 25 µM 
FeCl3 and increasing hinokitiol concentrations (0, 0.5, 1, 3, 5, 10, 25, and 50 µM) for four hours 
as previously described were determined after isolation of mRNA as described above. The 
threshold cycle values were normalized to internal control actin using primers against Fpn1 
(Origene HB210988) and Fth1 (Origene HP205786) using the Pfaffl Method and were then 
normalized to shDMT1 levels in the absence of hinokitiol. 
 
Western blotting conditions 
 Caco-2 monolayers, differentiated or J774 cells underwent treatment as described in rescue 
experiments before lysis with RIPA buffer (Thermo 89901) containing protease inhibitors 
(Thermo 88266). Protein concentrations were determined by a BCA kit (Thermo 23225) and 
diluted to 2 mg/mL in the same RIPA buffer. Relative protein levels were then determined through 
western blotting of 10 or 20 µg of protein lysate blocking for 2 hours at room temperature with 
5% BSA and using primary antibodies consisting of either mouse anti-DMT1 (1:1,000 dilution, 
Santa Cruz sc-166884), human anti-FTL1 (1:1,000 dilution, Santa Cruz sc-74513), human anti-
FPN1 HRP conjugate (1:10,000 dilution, Novus Biologicals NBP1-21502H), mouse anti-globin α 
HRP conjugate (not heated at 100 °C, 1:10,000 dilution, Lifespan Biosciences LS-C212172), 
human anti-TfR1 HRP conjugate (1:10,000 dilution, Abcam ab10250), human anti-IRP1 (1:1,000 
dilution, Santa Cruz sc-14216), human anti-IRP2 (1:1,000 dilution, Santa Cruz sc-33682), human 
anti-Hif1α HRP conjugate (1:1,000 dilution, Novus Biologicals NB100-105H), human anti-Hif2α 
HRP conjugate (1:1,000 dilution, Novus Biologicals NB100-122H), human anti-PCBP1 (1:1,000 
dilution, Santa Cruz sc-393076), or human anti-actin HRP conjugate (1:10,000 dilution, Cell 
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Signaling 5125S) in 5% BSA overnight at 5 °C before rinsing thoroughly with TBST and 
incubation (if non-HRP conjugated) with secondary antibody consisting of either goat anti-rabbit 
IgG HRP conjugate (1:5,000 dilution – DMT1, Cell Signaling 7074, in 5% milk), goat anti-mouse 
IgG1 HRP conjugate (1:1,000 dilution – PCBP1, 1:5,000 dilution – IRP2, 1:3,000 dilution – 
DMT1, Santa Cruz sc-2060, in 5% BSA), donkey anti-goat IgG HRP conjugate (1:1,000 dilution 
– IRP1, Santa Cruz sc-2020, in 5% BSA), or goat anti-mouse IgG2a HRP conjugate (1:10,000 
dilution – FTL1, Santa Cruz sc-2061, in 5% BSA) at room temperature for two hours. Blots were 
thoroughly rinsed with TBST and imaged after addition of Femto Chemluminescence solution 
according to manufacturer instructions (Thermo Fisher 34095).  
 
Determination of ferritin levels by ELISA 
 Absolute ferritin protein levels in shControl and shDMT1 Caco-2 monolayer lysates were 
determined using a commercial sandwich ELISA kit (Abcam ab108837) according to 
manufacturer instructions. Protein lysate was isolated after treatment with 500 nM FeCl3 as 
described below. Caco-2 monolayers were treated with 25 µM FeCl3 and 0, 0.5, 1, 3, 5, 10, 25, or 
50 µM hinokitiol as described below. 
 
55Fe uptake and transport in differentiated Caco-2 monolayers 
 Media from differentiated Caco-2 monolayers (P25-50, 21-28 days post seeding) grown on 
PET inserts in 6-well plates was aspirated, and monolayers were rinsed with PBS. 2 mL of 
basolateral fluid (serum-free DMEM at pH = 7.4 in 10 mM HEPES buffer) was added to the 
basolateral side, and 1 mL of apical fluid (serum-free DMEM at pH = 5.5 in 10 mM MES buffer) 
containing 200 nM 55FeCl3 or the indicated concentration of FeCl3 and either DMSO vehicle, 
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hinokitiol or C2deOHino (500 nM Hino/C2deOHino for DMT1-deficiency, 1 µM 
Hino/C2deOHino for FPN1-deficiency, or indicated concentration of small molecule from a 
1000X stock in DMSO) was added to the apical side via addition on the wall of the membrane 
insert without disrupting the cell monolayer. The monolayers were then incubated for four hours 
at 37 °C unless otherwise noted. A 100 µL aliquot of the basolateral fluid was removed, diluted in 
scintillation cocktail, and radioactivity was determined on a liquid scintillation counter to quantify 
relative amounts of 55Fe transport. To determine intracellular 55Fe, the basolateral and apical media 
was removed, and the monolayer was rinsed with PBS (x2). The cells were then lysed with 500 
µL of 200 mM NaOH with nutator mixing overnight, and radioactivity was determined on a liquid 
scintillation counter after diluting the cell lysate in scintillation cocktail. All values were 
normalized to shControl monolayers unless otherwise noted. Absolute iron levels were determined 
through calibration of 55Fe radioactivity levels with known standards and average mg of protein 
per membrane was determined by protein lysis with RIPA buffer containing protease inhibitors 
and quantified through a BCA kit according to manufacturer instructions.   
 Determination of unidirectional uptake and transport was determined as described above 
except for basolateral addition of 55FeCl3 (200 nM) and basolateral addition of DMSO or hinokitiol 
(500 nM). An aliquot of the apical fluid was then taken to determine the basolateral to apical 
transport. Intracellular 55Fe was determined as described above. 
 Determination of 55Fe transport as a function of the concentration of iron and/or hinokitiol 
was performed as described above except for the use of the indicated concentration of iron (20:1 
56Fe:55Fe for each concentration) or hinokitiol (from a 1000X stock in DMSO). Experiments for 
the translational and transcriptional regulated changes in endogenous proteins upon addition of 
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increasing hinokitiol concentrations used 25 µM of non-radioactive FeCl3 and the indicated 
concentration of hinokitiol (from a 1000X stock in DMSO). 
 Determination of ferroportin levels upon increasing hinokitiol concentrations in the 
absence of iron used the procedure as described above containing 200 nM of non-radioactive 
FeCl3. 
 Determination of 55Fe transport after FPN1 knockdown was determined as described above 
using 200 nM 55FeCl3 after incubation of quercetin to knockdown FPN1
16 as described below. 
 
55Fe immunoprecipitation of ferritin in Caco-2 monolayers 
 Immunoprecipitation of ferritin was performed using human anti-FTL1 (Santa Cruz sc-
74513) and Protein G PLUS-Agarose beads (Santa Cruz sc-2002). Cell lysate was obtained from 
shControl and shDMT1 Caco-2 monolayers after apical treatment with DMSO or hinokitiol (500 
nM for fig. S14L and 0, 0.5, 1, 3, 5, 10, 25, or 50 µM for fig. S17B) and FeCl3 (200 nM of 
55Fe for 
fig. S14L and 25 µM of 20:1 56Fe:55Fe) for four hours as described above. Cell lysate was incubated 
with primary antibody (1:100 dilution) at room temperature for 1 hour, then with the secondary 
antibody (1:10 dilution) at room temperature for 1 hour with constant mixing. Repeated 
centrifugations and PBS rinses were performed, and the radioactive levels in the agarose pellet 
were determined by dilution in scintillation fluid. 
 
55Fe uptake into J774 macrophages 
 J774 cells were grown in 12-well plates to ~80% confluency. The cells were then treated 
with vehicle or hepcidin in serum-free DMEM media at pH=7.4 in 10 mM HEPES buffer (1 mL) 
containing 50 µM FeCl3 (100:1 
56Fe:55Fe). After four hours of incubation at 37 °C, the cells were 
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rinsed with PBS (x2), and lysed with 500 µL RIPA buffer containing protease inhibitors. The cell 
lysate was diluted in scintillation cocktail and intracellular 55Fe was determined by liquid 
scintillation counting and normalized to the total protein in each well. 
 Hinokitiol-promoted iron uptake as a function of extracellular iron was performed similar 
to described above in wild type J774 macrophages using 1 µM hinokitiol (from 1000X stock in 
DMSO) and the indicated final concentration of FeCl3 (20:1 
56Fe:55Fe). At the indicated time, cells 
were rinsed with PBS (x2), and lysed with 200 mM NaOH. The cell lysate was diluted in 
scintillation cocktail and intracellular 55Fe was determined by liquid scintillation counting and 
normalized to the total protein in each well. 
 
Staining of induced MEL cells with dianisidine 
 Hemoglobinized MEL cells were quantified three days after DMSO induction through o-
dianisidine staining similar to previously reported.30 Cells were centrifuged three days after 
induction and rinsed with PBS. The cells were then suspended in a solution containing 7.5 mM o-
dianisidine, 900 mM H2O2, and 150 mM acetic acid in water at ~1x10
6 cells/mL. Cells were then 
imaged on an AXIO Zoom V16 microscope to obtain color images. The number of stained cells 
were then quantified via ImageJ analysis and compared to the number of total cells in each image.  
 
Live cell fluorescence imaging of MEL cells 
 To visualize cytosolic and mitochondrial iron, confocal imaging of calcein green and RPA 
fluorescence was performed, respectively. MEL cells were induced for differentiation as described 
above. After 70 hours of incubation, iron (III) citrate (10 µM final concentration) was added. The 
cells were incubated for an additional 2 hours, and then were centrifuged and rinsed with PBS. 
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The cells were then re-suspended in PBS containing 1 µM calcein green-AM (Thermo Fisher 
C34852) and 1 µM RPA (Axxora SQX-RPA.1). The cells were then incubated at 37 °C for 15 
minutes. The cells were centrifuged, rinsed with PBS, and re-suspended in DMEM containing 10 
µM Fe2Tf. The cells were then imaged within 10 minutes on a LSM710 microscope. Relative 
calcein green and RPA fluorescence per cell was determined by ImageJ analysis using >100 cells 
per experiment. 
 To visualize endosomal iron levels, confocal imaging of an oxyburst green-BSA conjugate 
(Thermo Fisher O13291) was performed. MEL cells were induced for differentiation as described 
above. After 70 hours, iron (III) citrate (10 µM final concentration) and an oxyburst green-BSA 
conjugate (200 µg/mL) were added. The cells were incubated for an additional 2 hours, and then 
were centrifuged and rinsed with PBS. The cells were then re-suspended in DMEM-HEPES buffer, 
and H2O2 (50 mM final concentration) was added. The cells were incubated at room temperature, 
and the oxyburst green fluorescence was then determined 10 minutes after addition of H2O2 on a 
LSM710 microscope. Relative oxyburst green fluorescence per cell was determined by ImageJ 
analysis using >100 cells per experiment. 
 
Flow cytometry of MEL cells 
 To quantify median cellular calcein green and RPA fluorescence by flow cytometry, 
staining of cells was performed as described above except for the use of 0.1 µM calcein green-AM 
and 0.1 µM RPA. Calcein green and RPA fluorescence was then determined using a BD FACS 
Aria II Sorter at 37 °C counting ≥10,000 cells per experiment. Median fluorescence was then 
normalized to shDMT1 for each dye. 
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 To quantify median cellular oxyburst green fluorescence by flow cytometry, staining of 
cells was performed as described above except for the use of 500 µg/mL oxyburst green-BSA 
conjugate, the use of 5 mM H2O2, and cells were incubated for 20 minutes at 37 °C after addition 
of H2O2 before fluorescence analysis using a BD LSR II flow cytometer counting 20,000 cells per 
experiment. Median fluorescence was then normalized to shDMT1 for each dye. 
 
Temporal imaging of cytosolic iron levels in J774 macrophages 
 To assess for the capacity for hinokitiol to reversibly and autonomously transport iron 
across the plasma membrane through the creation of artificial iron gradients, J774 macrophages 
were grown in Ibidi dishes (Ibidi NC0723624) to ~80% confluency before incubation with J774 
Complete media containing 5 mM ascorbic acid and 200 µM FeSO4. The cells were incubated for 
1.5 hours, media was aspirated, and the cells were rinsed with PBS. The cells were then incubated 
with calcein green-AM (1 µM) in DMEM for 20 minutes at 37 °C. The media was aspirated and 
cells were rinsed (x2) with PBS before DMEM (pH=7.4 in 10 mM HEPES) and 1 mM probenecid 
(Sigma P8761) was added. Calcein green fluorescence was then imaged on a LSM880 microscope 
at 37 °C with 5% CO2 at the indicated time points for 30 minutes. Hinokitiol (100 µM final 
concentration), C2deOHino (100 µM final concentration), or DMSO (all from 1000X stocks in 50 
µL DMEM) were added at 5 minutes, and a solution of FeCl3 (100 µM final concentration, in 50 
µL DMEM) was added at 12 minutes. Fluorescence in each image at each time point was analyzed 
by ImageJ analysis then normalized to the fluorescence at t = 0 for each image using >100 cells 
per experiment. 
 Temporal live cell imaging of iron uptake in wild type and FPN1-deficient J774 cells was 
performed after staining of cells with calcein green as described above. The cells were then rinsed 
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with PBS (x2), and incubated in J774 Complete media containing 200 µM FeSO4, 5 mM ascorbic 
acid, and 5 mM probenecid in the presence or absence of hepcidin. Calcein green fluorescence was 
obtained at the indicated time points, and fluorescence in each image at each time point was 
quantified by ImageJ analysis then normalized to the fluorescence at t = 0 for each image using 
>100 cells per experiment. 
 
Temporal imaging of cytosolic iron with calcein green in Caco-2 monolayers 
 Temporal live cell imaging of labile iron levels in shDMT1 Caco-2 monolayers was 
performed after staining of Caco-2 monolayers with calcein green-AM (5 µM) in the apical and 
basolateral liquid for 30 minutes in pH=7.4 DMEM. After rinsing with PBS (x2 apically and 
basolaterally), monolayers were treated similar to Caco-2 transport experiments with a pH=7.4 
HEPES buffer in DMEM (basolateral) and an apical fluid (pH=5.5 MES buffer in DMEM) 
containing 25 µM FeCl3 and either 0, 0.5, 1, 3, 5, 10, 25, or 50 µM hinokitiol (from 1000x stocks 
in DMSO). Calcein green fluorescence was obtained at t = 0 min and t = 60 min, and the 
fluorescence in each image was quantified by ImageJ analysis. 
 
Temporal imaging of cytosolic iron with calcein green in Caco-2 monolayers 
 Temporal live cell imaging of labile iron levels in shDMT1 Caco-2 monolayers was 
performed after staining of Caco-2 monolayers with calcein green-AM (5 µM) in the apical and 
basolateral liquid for 30 minutes in pH=7.4 DMEM. After rinsing with PBS (x2 apically and 
basolaterally), monolayers were treated similar to Caco-2 transport experiments with a pH=7.4 
HEPES buffer in DMEM (basolateral) and an apical fluid (pH=5.5 MES buffer in DMEM) 
containing 25 µM FeCl3 and either 0, 0.5, 1, 3, 5, 10, 25, or 50 µM hinokitiol (from 1000x stocks 
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in DMSO). Calcein green fluorescence was obtained at t = 0 min and t = 60 min, and the 
fluorescence in each image was quantified by ImageJ analysis. 
 
59Fe gut absorption in mice 
 To characterize the effects of hinokitiol on the gastrointestinal absorption of iron in healthy 
(+/+) mice, food was withheld for 4 hours (8am to 12pm) prior to intragastric gavage. The mice 
were anesthetized with up to 2% isoflurane, and 59FeCl3 was administered using a 20-gauge, 1.5-
inch gavage needle. 59FeCl3 (200 µCi/kg body weight) was diluted in Tris-buffered saline 
containing 10 mM ascorbic acid in the presence or absence of 6 mM hinokitiol. Final volume 
administered was 1.5 mL/kg for each mouse, correcting for individual body weight. Blood was 
collected at 60, 120, and 240 min after administration to determine 59Fe levels. Mice were 
humanely sacrificed by isoflurane overdose after 6 hours and blood was collected by cardiac 
puncture. Radioactivity was quantified by gamma counting and calculated as the percentage of 
gavaged dose (± SEM). Experiments were performed with 4 genotyped-matched mice/day; 
preliminary analysis determined there were no gender effects on uptake of 59Fe after intragastric 
gavage; mixed genders were used in the experiments shown. 
 
4.7 REFERENCES 
1. Grillo, A. S.; SantaMaria, A. M.; Kafina, M. D.; Cioffi, A. G.; Huston, N. C.; Han, M.; Seo, 
Y. A.; Yien, Y. Y.; Nardone, C.; Menon, A. V.; Fan, J.; Svoboda, D. C.; Anderson, J. B.; 
Hong, J. D.; Nicolau, B. G.; Subedi, K.; Gewirth, A. A.; Wessling-Resnick, M.; Kim, J.; 
Paw, B. H.; Burke, M. D., Science 2017, 356, 608-616. 
2. Hentze, M. W.; Muckenthaler, M. U.; Galy, B.; Camaschella, C., Cell 2010, 142, 24-38. 
3. Espósito, B. P.; Breuer, W.; Cabantchik, Z. I., Biochem. Soc. Trans. 2002, 30, 729-732. 
4. Sohn, Y. S.; Ghoti, H.; Breuer, W.; Rachmilewitz, E.; Attar, S.; Weiss, G.; Cabantchik, Z. I., 
Haematologica 2012, 97, 670-678. 
5. Seo, Y. A.; Elkhader, J. A.; Wessling-Resnick, M., Biometals 2016, 29, 147-155. 
6. Seo, Y. A.; Elkhader, J. A.; Wessling-Resnick, M., Biometals 2015. 
 163 
7. Seo, Y. A.; Wessling-Resnick, M., FASEB J. 2015, 29, 2726-2733. 
8. Zohn, I. E.; De Domenico, I.; Pollock, A.; Ward, D. M.; Goodman, J. F.; Liang, X.; Sanchez, 
A. J.; Niswander, L.; Kaplan, J., Blood 2007, 109, 4174-4180. 
9. Bleackley, M. R.; MacGillivray, R. T. A., Biometals 2011, 24, 785-809. 
10. Cyert, M. S.; Philpott, C. C., Genetics 2013, 193, 677-713. 
11. Cioffi, A. G.; Hou, J.; Grillo, A. S.; Diaz, K. A.; Burke, M. D., J. Am. Chem. Soc. 2015, 137, 
10096-10099. 
12. Hentze, M. W.; Muckenthaler, M. U.; Andrews, N. C., Cell 2004, 117, 285-297. 
13. Wilkinson, N.; Pantopoulos, K., Front. Pharmacol. 2014, 5, 176. 
14. Zhang, D. L.; Hughes, R.M.; Ollivierre-Wilson, H.; Ghosh, M.C.; Rouault, T. A., Cell 
Metab. 2009, 9, 461-473. 
15. Ganz, T., Blood 2003, 102, 783-788. 
16. Lesjak, M.; Hoque, R.; Balesaria, S.; Skinner, V.; Debnam, E. S.; Srai, S. K. S.; Sharp, P. 
A., PLOS ONE 2014, 9, e102900. 
17. Gouaux, E.; Mackinnon, R., Science 2005, 310, 1461-1465. 
18. Miller, C., Nature 2006, 440, 484-489. 
19. Finney, L. A.; O'Halloran, T. V., Science 2003, 300, 931-936. 
20. Ba, L. A.; Doering, M.; Burkholz, T.; Jacob, C., Metallomics 2009, 1, 292-311. 
21. Andrews, N. C., Nat. Rev. Genet. 2000, 1, 208-217. 
22. McKie, A. T.; Marciani, P.; Rolfs, A.; Brennan, K.; Wehr, K.; Barrow, D.; Miret, S.; 
Bomford, A.; Peters, T. J.; Farzaneh, F.; Hediger, M. A.; Hentze, M. W.; Simpson, R. J., 
Mol. Cell 2000, 5, 299-309. 
23. Weiss, G.; Goodnough, L. T., N. Engl. J. Med. 2005, 352, 1011-1023. 
24. Rivera, S.; Ganz, T., Semin. Hematol. 2009, 46, 351-357. 
25. Nemeth, E.; Rivera, S.; Gabayan, V.; Keller, C.; Taudorf, S.; Pedersen, B. K.; Ganz, T., J. 
Clin. Invest. 2004, 113, 1271-1276. 
26. Gasche, C.; Reinisch, W.; Lochs, H.; Parsaei, B.; Bakos, S.; Wyatt, J.; Fueger, G. F.; Gangl, 
A., Dig. Dis. Sci. 1994, 39, 1930-1934. 
27. Kwok, E. Y.; Severance, S.; Kosman, D. J., Biochemistry 2006, 45, 6317-6327. 
28. Gaxiola, R. A.; Yuan, D. S.; Klausner, R. D.; Fink, G. R., Proc. Nat. Acad. Sci., U.S.A. 1998, 
95, 4046-4050. 
29. Lee, J.; Prohaska, J. R.; Thiele, D. J., Proc. Nat. Acad. Sci., U.S.A. 2001, 98, 6842-6847. 
30. Yien, Y. Y.; Robledo, R. F.; Schultz, I. J.; Takahashi-Makise, N.; Gwynn, B.; Bauer, D. E.; 
Dass, A.; Yi, G.; Li, L.; Hildick-Smith, G. J.; Cooney, J. D.; Pierce, E. L.; Mohler, K.; Dailey, 
T. A.; Miyata, N.; Kingsley, P. D.; Garone, C.; Hattangadi, S. M.; Huang, H.; Chen, W.; 
Keenan, E. M.; Shah, D. I.; Schlaeger, T. M.; DiMauro, S.; Orkin, S. H.; Cantor, A. B.; Palis, 
J.; Koehler, C. M.; Lodish, H. F.; Kaplan, J.; Ward, D. M.; Dailey, H. A.; Phillips, J. D.; 
Peters, L. L.; Paw, B. H., J. Clin. Invest. 2014, 124, 4294-4304. 
 
